var title_f15_17_15632="Approach to abdominal pain in female of childbearing age";
var content_f15_17_15632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Approach to abdominal pain in female of childbearing age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 547px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; HCG: human chorionic gonadotropin; OB/Gyn: obstetrics and gynecology; PID: pelvic inflammatory disease; RLQ: right lower quadrant; R/O: rule out; US: ultrasound; UTI: urinary tract infection.",
"     <br/>",
"     * Pelvic examination should NOT be performed in the presence of third-trimester vaginal bleeding.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15632=[""].join("\n");
var outline_f15_17_15632=null;
var title_f15_17_15633="Choosing an antiarrhythmic drug to prevent atrial fibrillation";
var content_f15_17_15633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64574%7ECARD%2F83173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64574%7ECARD%2F83173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Choosing an antiarrhythmic drug to prevent atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 357px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Within each box, the antiarrhythmic drugs are listed alphabetically. The vertical flow represents the order of preference for each condition.",
"    <div class=\"footnotes\">",
"     HTN: hypertension; CAD: coronary artery disease; HF: heart failure; LVH: left ventricular hypertrophy; NYHA: New York Heart Association class; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.",
"    </div>",
"    <div class=\"reference\">",
"     Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360. By permission of Oxford University Press. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Maintenance of sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 379px; background-image: url(data:image/gif;base64,R0lGODlhUAJ7AcQAAP///wAAAIiIiERERLu7uyIiIpmZmd3d3WZmZjMzM8zMzBEREe7u7lVVVXd3d6qqqkBAQM/Pz9/f35+fn39/f2BgYBAQEO/v77+/vwAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABQAnsBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY5TAZGSk5SVlpeYmZqbnJ2en6CTj6OkgwGlSaeoq6x2qq1Dr7CztGiytT23uLu8Wrq9N7/Aw8RMwsUxx8jLzD7KZAcFAQJFAQQu1jLPzdzdM7cCAQYi4eMm2efXTg4DKgLtOugo6PIv2974+SngAQki0uawqWvSgJqReulEIGxxT59Dh+AKFCDwYIA4ANICFFAAwBqBfgEWKEAg6UA4jQo+/yYIyZFkpHEDVgZAAOCAzAYAGkRKwIAEgQUhDRgoOcKBJAXvAMSMRBMBvAIGGFgM6dOaOJDiDmT76DKAVpkwMw6QtuBAiYYP03aLKABBg6EBMTroSODjtQE0sykQCcBBA7tKaY5A4G9Au48HGsADIIAngAQGRSygZmCB1MgKH4xIahgAYqf/DHzsWeKjwWmMCwBA0DSvOtQCVHceeq0A5o5qc+uOqHVBx6hdXX8UwZougKGSJqoqLgCoRqXUtEYL2HXmCOkKDwy4HXsmA87RvYLGOM7o5KojshlQ/RM7vWvroXtWtf2s7vsPI+akJm5ozwTCLZeXZntxJMJwqyGglf9mDsgWXmKLNUZaCec1dxkKCxgAXk1exeZZhiMo4NUICBoXn1IJ4NSRZiY6OJ8I9ZGAFn404qJfegbYFEkBARLXVCQmSYIAgsVNJZF80ukYAE46veQTUCDGKAIDzvG0YZLSJJDhR0yhpxB8qgHwADouaQWmfAhKqVCNbDYzoyNJxdPmnMW8ycgBC7CYg5109skIn2v5KWgtgHJT6KCIBnIoM4sm6ugejSIT6aOU1jEpMZdWqukbmQLT6aagphHKqKSWauqpqGYS6qqsntPqq7Cu8WmstNZKxKy25qqrnLv26usTuP4q7LAnBEvsscMai+yyuyrL7LO0Ogsto6lWa+3/tdhmq+223Hbr7bfghktqnbZK66Yj5vKRLj7rSoouubW2C++f88YqL6bv4htvq/eO0a8r5fKb7y4SRLAmABFIsGrBBydMKcO4IaxwIRCr4jAtFwQAwQQBTABBABesmvHGHX8c8qMjc+wxyIakXDLLtVRASQWtyjwJzZXaLAnOhugcCc+0RECJwawKPQnRlBotCdKFKB0J07R8HAkEsEqtMahWU51I1r1wHMkEsHrdMahig51I2cBYEIAFtKrNdqhuMxI3MBQEQAGtdd8dat6M8A2MBAFMDCvggm9KOCOHD4OBrYuz2jgjj08r+eTqimu5Jn5cDu4dmndeCQ+eZxvF/7/GZM4G6ankkSnqe46uuumycv76DqzjUHvtSOBeeuwA47G6La77Drsaut86O69m3H48pKfLLjztwEOx6AMbUWFNNHqmN7yoznffOhEWLVbaocqTYFF4A6FQQPY1xFmC+wJ9OOHB6r4fJka3yQD/CyXa4z05kmiAWayXPm2ArgR4EYGZklHAB1imWHUhX/BGMBavLDAFBvBHFdCRgLhErH4k8NA/8heD/QmheLEoQYM4op0CSs+FMPid+QRzQXsU0IReokH5KOiUASxwKgOYHwLmAqNIBPE3PCKRRkLSpLlwRiY04YxYyGKWjFQPHX6xTx9uhL/K9KQxHQGLZzICk/93TGJIZERRlxRwk+EoaS4qYYkWLUUh9v0kKIzZjleAyIA48sWKHBFHASxyjdFcRxI8sQslgoQSJBJyPvOTIQ8VmI2TbEQrO+mjVSYxQEwKckeBjOBqnjIOQaLRSTKaIIyGNA1rxIYBDICM+czxyljyR0VKrE07hpJHpRymQ+2YTTZsQ4ICzAUdBhDfB5kXQkpQAyrk6Qg1mgMAEDkQRWaJkzV90xnEgPFAp2gATvYSwbsIRnu9S88AR3AeL8bmGrWEDGASOAJjdkRFxSmOCRZkmi8BoEB9wcmSfJSgOX6PgpQgAECzSMkH9NM4IVSmPT1yivFAc6DVHMc1Uyk9BNL/pEkE0GdbZklQxrhmfDCixnCuBEw00UcADAgORJNpUD1wkZjvoJ4/EbPIGCXFk0CqT5J00sHhQFMpohFQTeVwCxAdcoAtLahJiYSAmAoJou0ZUYimIo4SqWcSqkFHVtdJv4OukpIEQA4ouZrU9NywHVbtEkVHGRrjAFWrZW3CLRKISQLUkpiDIeJf+VPANKn0FCw1STAPm1L/POakAV3q8zZzP2JSSZbGaVBGzWeQbzo1pRxa5zvDOc65ShWddCRBg67RwgpZJk6DpapjAQRRFOGSOP5gQFdfEQAC8cWtFEyRq6A3Q7QCFLcA0G1bM/O+XQbgPz3y0E9KqY7PSlYJ/3sVDEnuYsT5ZRChATgiQgz7osRuyLBKSiIHPYjC1IWwsgZxwAM7sqNCWlE+/wTKKZ8j1A5Joq1vfNFp88pUEwTnAHcEkfv4SNX0QlZM4wUKQEpUppNYRx5jcqEkz8oheArpjhN+RZk20w4H08WNWQKRWO/LUWDdYH1Y+Mn8lmlTF0hpIaqcA+lwmAMcbpgMO6QB9QxEBewNF4QrGNOEcNzRdCoBT+zTAZSLdcAzBDm1SOaek7FsViDnmA7tzV3ztgzmKifvy80FApNPuL3ocTkeMJTCj/2F5ojWQE1nEeURwrznMb95T3reoJnLcGUT8LgFeJZRnNm8RT+XOReLbv8y8ghdZ8pm6Yug9KRjPvnf68hkrpWJBDWaxBNNM4CNkcCJJYk8jzZb+X81UBKonTPqTJoa1QNd9aRt52YnPCM2B6CSARaKywXdE7QkUMyXhjMAIjLGMZjl0AO+mV+OMHQfmQvdtmBNA2Wf+BTN3gy0I7MgahN718HQtrUqTQ5SqhUlbIUono86VwKsZAAjOaMC2JqYfggFrCvgs6MJpQN6i9Le4c23kPb933538N33C0YYBD7oE8QJKsddTW4vgo5wJ7u0gc4JAiQ0mI0HJDYZD/gyKO7lHIjzn6YVQQNG7hjkKpeyKe8yF1iO7jRH08JDkjDH1YGcgCggS3M1Ekf/mtRVoWuo00BXubt4Mamjg0SUSs/Jf0EsDguPI+o63wLPw17gqe9i7BXf+Z91vPJeoJ24X3i7DeRO9rO7fXldoLsO8e6pu0/WC3r/Bt/9bve/533tZa8XwQ2v9kdzm+qEJ7PYER+HwE888pTHguWToe7OtZ3qndfc5fUVLYE1YvOH3xerUC9m0tvL9PRyPaxYTwjaH0Txr7K9IHRvPNnnHvaL4P0UKiaCi4GK+BJ7GNEsVjhBIN/4sHDZyk4GKumbjFLWhxkhsk/9WfgsAEAD1ffDn6jxI8L8uHBaAKC2KfWzH1HuR0T8d8G1V9VfU/c/RP5rgbZX9V9T/3cIAYgL/3MDKwW4KQeICAmIC34DKw24KQ+ICBGIC4kzOIGzMBe4CBXYC5EDKx24KR+ICCFIOSRYgq4Qeuu2RShoOb6zgqlyKy44KlnAe8JnQIyXeL2mZmemebyTZZnnBjTYey13BUHYaDdYeT0YBKgncEXog473g2DgLEs4g0lYY0cIB02ohDtIhEdwaHUHhSbQP0OQaHN3hSsQPiyAQ14oeCkUBGsocTxIAkDlbD2mTLngakbBFDMmYChAhhYHDzikJieiWwNhG/RUQwSGgxwiCXRIAg60h8axUotlZ2nnDCdgFB50An7YbozGhXI4IvZ2WzfwhmVohCPgQGbBRmQFTiqwif8+lwKCeD8zB05SQUMIUYNS91SeIVyGZof+RGJ/eIdtSAJU0hmj6ItwZwW3gB0wdxljoRTd5UccoWsW1g5dUUZjEWCxcWmMAUrXtWUOlD4WlVQrsRFSEQkZ8l/XqEYz4UkjZ42dFoun+EBuERho9Y2cUgLMKCJ9BCU58l+rdo2INYnVOEaoVANSaAKVgR3d0Q8yoRn1cRIJMI2SAI9Osh3ZKBNOJBH9gGmN1GLKqI94ZQ0xkU0FAEvylA14QWwiAk/iQxjYlBPjtAB+VQDBliHnBpJWGEIrcR7j+BFL9xfPRUG3AZPdFFXwY5SYcSKS8QBUwl2TUEC4qALLOJI/QRn/r9UO57YVAwkdLdlL2wSHnUhBcxGRNqkV1AAa2yEiLYFvlfSShZEAZvFy5ARswpaTqBWSnzhA/BgjIsVKPgJxJ5IUzbEj+HVUA6Ah7gZwOjl4IrAXD/CTquAh5kENPuUcLiIdsNUOhclfSxlxfnEih3iLhrePASAiUKVYxwFwXNlL2zGYPrRIpTiWi2iYcfKW0HEiBAAVYUKYmHmY5pCYF/dvyYGPLraXu0gTPnWSDGAbVJVxbJkTsckgLiKTMOdXpJRzebmT5FBV+VWTH7JctPWYezQXxqZZ/WUSGvQO51mdIsCUMIdZoymVpQmKtOVa36GVv8VckuiVpymdm/WF/7v2TVQybfCAm2v5n4oRnYrRnvhFl66UnftpnL4mkpJgEFLCYEoVdS6RAMG0I9WpjaTUjV3SmIaHcKJWEymWVDuBYFdVdEaSmV6xFzPBGSCKX+85CdSwEgM0nxQ6cEBlEAn2dYB4VS7BSxvSoYfBYggphCM0GAVxoC4pHxLZEjvxoRoRohrZSz93VSYqZ1XomEj4eHQ2jGXqiVrmhGxHpmKQkJQWh2nKTGwKhGFqiW+KpjkoplhohqNHm32ql3HKnWBYp0OohXcKqHnKp3Q6p1HopG1KhcTjamsqeYWqg4cqaJFqipS6p5nqp40KpyhAijQghrMJKTG4OYy6A6K6d/9mCgNouAJqiIwxBKlKVJGrSpTBqETJaCiMYqGR0IjH6KnCeEiMiAKPCEHlNYnAKJaIOh+iJas4QKpNyi69ipyhqKrQymutih3X2ovzkD6xqq146qzAuJtOYmEKdxH1gRVEapCR4K6Z6D/U+nm62IwYKRvRCBJ8QY0VuRrx+A42uaXb2JEkWj1fWnGm2Y9B4UlPhxIC6ZrT1K/mehHJQKvgJAnYuVkO9JUloJTSlBpgyVhhyareMJXNyox0UZKpgZICME8IwJK4WXIxSZc0aZc4yRfXlojDSknrZA3tlJXVFlmtCR5fmRQjO6ugSq7tdlfw2Zkuoh6qwZ6g6BWyyYb/JVut9dqXBvGXsgVWsMkYvxkjiKmYoQFxP8qsoUWeqJkdSWG2Q7tYsHlXq8gCTDg+zxqg19lQffG0Z2K0EYu303q19MqzyYlfsSUg0Kmg07m3Dwpyw6mdOouw9kkT+JkUKddbyeqfS9cO1lWxSYsY5Xpf6Bqj8gG1vYQcK+GuEee5gmt2lHShyAaN4aVJBMWhVyq7RxIjIlpXYLedP1CVsPsheARbRvoSXVkfSqq6NjiuWxgog/tqrfqnmBqo5/K8zWuplWo9hIqFpxp6Y0q9dpq9kLC9+VgIJktj1/u76Tu+nTqoinqp67uzj5q08cuptfe9iSq/0qu97fuEu4e//9ArrIBnsQHsvqkqvghciXFHwD0QDajhqJNqCgAcrCbgij2XC937CQTMJf0wtzHADn12wO+bvXnoHd6aqwhEQvo7v4IKugMgijJQECG8qZraBreAiv8klye8w5wFwSyMd6A7Wh/RsBMZRk5yjWrVbx0pjSRaxEthHUpyTmfbv4oCwOEohxrpjmoVRYfhjzhqqPUbwc4aS6xEDdEJGrDhGzIbkePmsmccTL+UGDSBJ6zmu4pYxfYrbiExajOZsSTgH357HJZhwQKaei2MSLR7HGGym5HYIWGblmckW4ssow7caUdmwDRcwCUAmWMbJxlUElKbmoQsrvC7ZaDLijC3uf+ZZZOYi57TVHMCxhoMOonSMYtUOcK4/MMm1RPkBKF+pUH2NCaqiZ+jjLZnCsR4VSJVSl8aAZW5axBMt1zMsRMckZ6y5sHnS2XmC8AoihoBRqMjtyMtNaRfjL1h8HzNJ8YMxL6ZLKeLCr5dwH25nBBgejqmwr2lEsb7+wXoJ8KNR765aMOBe8yaDAbz58+TN3BI+87LS9D6vAX7h8m+INAkS9FW69Cl/AUDKNEMXNDyytCsi9EJ7AULyNH0W8DhoCKA1Wrl6wAaFJ0BrcsPvQUTaNLMi9ILACIrrc2L2pw7Cqw8LdJC7QUbiNCw6ovFXKpxGhsWglPUfLAB/BMNwgD/USzIKYq+UZjB43IGI+i/fSEke8hjgajCCnyor7QACGAbbwzVzbtdIlcTIuFxdrzNJridOKyKPEyJKezDzeshJyEAuhlxJisLCJIRL4Fw+Ba5EsxUpyq9V+xpv6rFV5UU5JzUA73UYSINAjDLbH2oCGLLJWDL2XzBAI1d+9sYe2yddalMgMy5WHkh0YvSYTIUEdsPrDbYXnLNWYfVdD3Bx7nAKMDJwUm2x/FpisWMe0TWu5q/DJHHIY0Io41CdAcO3tnLjgvMcyHMgWwhll3R8Nzc5XvR0K3Ovz3APvFp0bGl4GxJ4+zF3S3ezE23zr3QiRDd02ve3z3SMV3a2BZ8/+T9ArcK3sCd30O931T80fWtzuuxEy60mSogrbf8qQTepvfMKRXuL1qdz0twwxQ7cifshRDe3wMe3yCNxyXu0dUQ2o24xe44sI5Bas1pmDCuSHEx3fx94/M84hNuzkiFAq1NDjYpbCSXkuTQxg/c2feN4vMNCLit0LeXbFJc3KAMiKRUHYDprx/2CzZ+4L79B02O4/I7JlsbG9ndIetJSiRHi882IdK65TsO5u2s3zL95CHkHAPgV+J8AOs9otEcS88RzW0+cRkeCjnu1Vye0XytV4cw2htuCMKHzmUA6TNcz71tI47OBvJMBplO55R+v5BX6WnQz2Qg6inOv6BOC/+M3tBpcNBkwOqlfoaYEeAIvtiF5+lsENFjgOuxXcGxjtSnEWkibuuWfuposNFjYOy7vtfLquyX/b+fLuxrUNJkIO2xvY5PzMVY3h//pZLdZcQUO8WF7t/EjgY1TQblnuwapxSlhRRwiV+uxJyyBBurq9g1jOqX7gZFbQb5/up1bpgx0nWc+chf8pctEtQ7N+gyGOd6agZdTQYN76cOWh/avbjoSUTvDkvEZLqX/M+HfuJeXtd2TLpcNU1YeiRFx+2zW/Abn9BwPtMLf0IIjzkM0dj0zW7NSuJO/vG7I+f0bto1L2mG3PEWTes+z/O8reg/X94c/+ZMb9TLLeEGXqH/SS/1+C30OS+pnD7nBg/0At7pWCDpYwD2S67zjY7o4M7vXW/zUbDpYsD24U307gUEsj71Kw8Dcx/hs871WEDqYsD3Ho/1aC8CmMgCrnj32HD4JbDg/dDgVP7gb/L4SY4Fri4Gk//39T7pU7IAxmgDhp/2wQ5h5uDhPgfikB9DNM8Fuh4GqX/1l5/1gsyQGZEAD0mlT12Q1g6w2siRjqFrSE5jDbDiQtLiut8TMH5fM24VNd4MyB4Gy8/6aur64WaWB4CWdJWgbVm07a6yNFuTNzlsOCuKDbFX8bqa+Qnk3T/kLTuZRp4/qS4F1C4G7+/87hz3r2ubUgqxgf21Tguc/zACAoYwAEBhGIEaFKUbuLFcwnGDyEayHmPpmwyIVQBBqA1XxpqMOXtCo9IptWq9YqeUACXr/YIB2264bP46z+q1Oc2upgWJEmPxAAYIAN9AoAgoADQM/AUOHgQ8ADi09JU0NAD8EQCdKCwEPrlBpT0ECJQgCBQ4AHj2zO2RBMkxuBy5tr5ubr7Z3uJKSQRI5Prq8v4KZ9UOG4cVD6cVgIY24OnxgQqoJAQmJZAMqBQ0Nh/sBJRWGuwpNVm5CSyoDFByBxxcFpELrhgw7LQ03B9pHgMM+AWDwGEECyIEkCwhwxcMFzaEky7iDIgUL2LMqDGgxY3KHnrE0rEjQJIhcf8RSalyJcuWLl/CTAdzJs2aJ2OYvGkr5xueGkdu9KnzjFCMQH8OVZi0YFGiS6Mczdj0KTGq/yQiHTrV6pWtyLiiwzrFkQsgt7yClYI2YVSjSdem5QQyrlKxUsj+WCWDbB40dHPBZToxq87Afx2y/ds2Cl5VTxr7PbxT8WCpbyWfnRt3cah7AAaEw+EjSQAU9/puCzDAVYBw5Spi7vnLLMrKX2irMZw5NhvdMmsCDy6ciO0ZCOYMiFSI9vHPzfKMYpAP1Kc9LWDzzv3EQWkqkGXgnmy3hIEC1fSAXxU+hj+Rl7Nrhx/0yTpuzmmIIFGfxX2FBBDgsAcOfZV3lXxfyVD/xwB6hbFeb8V58pooMwDhYAntdfXegQhueJEbiCjCyH2njADiIo2U4l90DDDjHwAFYtehF24YsAAiB1hXTTiKOEJNa4H4qBoApJXTxwAFgKPCON20Fgs3mSBGRRoNpOhCCioggAiWo5iXgCv8NGkef2B6ecQRr9GgoYxVrRnRJql189kK02jDTQtXpqBHaqu5CGNYbWa4Vyk9IokIKAho4wcgQxLSF3PIJYAjJJIsQAmSdRhwSSAORIJTcQOgmUMADFR46QIieAlAAgK0J8uqRzTjqVaAskkrQr5xaOsUaWhpHzSO9QEjASdc58N+3pRwQgmgknOlfbJKKcMNOYQT/0+Fq5xAWhHtabuEgRtJEEGaAETQi64yhDtuuecegysY7qYVRyp13LGKo4kWIkijhgxgoohkTToJOZrKNZ4nzYhCiinWpkKOLBeOukeqEH+r0QUBQDBBABNAEMAF7MZwccYbd/wxyMLAO+PJUMnQojO/SmPOj0NWUycLyAKQpDiOBSFzEX/uSiE7qr3DQjzziIJtOWCWls+Y/dByUwUpVbCyC1MTUbXVvqRc69ZRxlscRV2DEUFK4m5tNhFof72bZW2DDRZnburUsQoQwG03xnDXRhjcZAMmNt03aazCBHAXvjHfbru1OOB9R+t3SBYEYMHilFu+uHhv8/0442pV0f+YhW0MNcbipmve03Cr2+Q4ZeNBITqDLvCFntch7WIu3Lmn3nuHnm8etHex8rwX8ZHpdNDiyvvePG/AywY7zSoUGZpjRDqbp5yqseZaxc6DH7747n2xzez0nV98rqBH0VxykgDyaH/QFSDdqgpNcx3QM7Lev/8u7eR/Auzf+Ar4uV7t7AkPWIArKqIHf8SsLOm7HcuEZh++5GcPQ8NZHgD0gwHpwU/QQp5kAgO9BxkwhfFxwY0AQIAEdCo9nLCd+iToFNj5C1kk6lciTvSZFNFPOi0ikP5GqLLYmPB1Klziu2TQQvgxgADsOFWvRPAkIsEgZkEiwbCod8TI7cVO26v/Dh/EiCfUtIM1ISxi3ChIlyS+kYly/GIJnuifBYCiRqQiAcE45SII4uteADiVKRZAR/ZxjoSHgeNm5ujI4jyxEPGgQQ9I4Cz+9AWQzoFRiVKCI/KBsXFNRGLw5PbIUyKyjpN8IQ7wqME9UgpKClGEJvuQr0EMMlRu/N7gRmmM0d0QhbkAJulQacz9IbAZUgwAISt0jiSkAFiHqpkLxcRG6fGyIU3hFRGqpAZiloGRMeCOLh9zPBly7ZjqHFcjsakZRbbwhTE8AzjXF0wXKGiCWKinL9eJyhOuYW7aDKcTJwlFIzUijUfYASZkVgAgrYAERHLOkXS2pC45iQWyrIsw/61ko0mOQkcq4NE0qgHRdkyvOwi1qHUw6tCNAtSfB4rpPVPpIYLGwI55AA2OVvQq1CCgjw2YhPrcFylBKKdSozgApoS6v5r+8D5LNRSjnJMvRBFVfjxFKqUsxdRTOdWIMp0jTYsZypuuL5KjIosHBcQtBFySWHnR4AWboazPZDAIcX2qWVW5ghbALFHCkqtjjtWfuzJLaXsV61iZWFacSmmAkt1mQXHEyv6siBlvJVgJbsnDEOEsYNBRGmdjFFDwzMsOgbXqogbh2Rz2R7SUIG1Ds9nYFD7WnoDi5pyWFas9RREJonkmNeGEM5bWI0gBamNfTRArBDzDXtFIlMysMf+9bGwvTmRBrtJ8tlx23laOue2nrcYL1eZyxbzhDVsc2aVeyJ62vet17GTrSxOQvVe38DXlfPvr34JhRpz8/S+B/5tf8p6XKgcuMINn+rxSprfBEr7tgg+Z4KdUeMIalm8JIWyVDG84xB+eAj+9gKELv8u+KgagiFtMVhkcIaIl9i362LMWEDPWxTrWcBqO8MkavuHE6C3Mjoss4h4b1DFd7E6QFDBRR7TGiz5YMgyWXM5AYdjIWp4wklcw21wWkqgycB918ucYV/qDkAvU70lwvOU3ywfJP+4kEURoWCivURXxjIcnEUxkOAN6vnK2ISE725ec9fBf1MmzD1xJDTD/D/kmbg40pTnswiRP2Zo+U4Bx70NEx1xpB9V8liJnVelTr3PSZzU1qlt9SlULL8uunvWLSalgWuN6ibC2Katz7evw7bqCsv41sZsXbAAv5djFXjbKHnxrZkP7b84edrSrfTJ3HcA854Rcsq3tbfzCeAVHLYMD9Pm5Xn873Wsa9PvK8IySjFjd8pbRoEdhptL4yLpR7g72eECm4DL0pNYFDZZyZj3bhkTZ8164TX2cjyWA4qokIKMhXUBmibnip3oK6qIQ9RkuxmNaB6gtXyXN8JNPG2LVCC55rjOsP1prg/fp1lsHe58bicmLplUTynvO3ln8uD2edREjYNujiV06/xQc59fNQ/5dhHtE4T5H+aAp9gOTKoQbehIjwKCm9OoGwhE30lmSc9zmqaM9wsigYS+7nfa385wYbB/os+Fu94SnPO5333vbFxlvvgO+70p0e+ALf6u8o9vwiv+Iram9+Mens/GEhzzlz12G9XzH8iavPOejN04lNDAGDsL8tj28+c6jvrkLxJECxi36CZKe8Y5PPe1BWYIF0tCivYLrOaY8xSKV3vOTrz3xYScHZoIiYEqdXQpg6Uo9Zt70Zy8+9Vftgks8ALF51QEPOvnJeERf+HqvPvnBKyBXXIIAspVDskqxw0FOg4Hh7+j4y1/9HlcLFCxFmo/MU0kX/l5//P+Cqkmd/b1ZATLX6Rmg/SGg+SXeAlJfA3LU8EFgBCLen1Ug+UkgAWZg+W3g33Vg8X1g3YUg8Y3g7JUg6q3YCsYECabgC5ba10ggDFrbDMYXDeIglnVODvKgO62MDfYgsQEhigUhDw5hpBVhDx7hfiVhES4hmzUhDj6hn0Xh3bHgFbIYBVahFcLHpE3hFj6SDXohGAaeGLogGcKdGaIgGqKdGmohG06dG9YfHM5butTFusSFHdYAHoIL2uyh7tDhwomMxnCMx9DFIJKMIXoEIhaiyQQiw2HNCmgNXUSiCkyiR1RiAFziI86b2qwA28SFJ6oAKG6EKAYAKXKivOkN3kj/xioOhSum4sklzuFIxiwOhS3G4slhDm/sYlL0Yi4yHOpghjDqBDECo7zxTmwk41As4zHOG/NgBjQmjzNSYzXeHxZe4W9gY+towjYChzUak8IJ1DuVHDmCo3gNHq8JXgKa4znqWjoKmyjt3Ni4YxjCI7KhFdQJRj3WWjtZH93po0B8IT8O4GyYGxGyYxXM2D9OoBcsZKwRpAptAjkNjxQ8pA7yWnmcB4Woh7kJGUPSiJgkwNxdixR8JERGpAG5QT7R00Ei4f5ESCicU0lGwUmqo/nF5JDMZEeaZE4MZEqeW420UEi1xo5IFdZtUUoBX0WFw0U1yUuV4/5Qiahgye5x/8lT/pum/du9hUoxTIk3vYgSWCWTpEpW2sdW5kF3JCRQ+o4bDMCg5M8BUJXH2VLHNcp0xYBRSUpSeVVTNZQfmd3+gAoUNF+pfBWqZByr1ICrKOY5eeVeXFlYwpJ1HCZjtkqq/JRjsiVuFdRf8YwgBYvLEZaxyBxZaF+zEAEbLca0xAD3qcD/8Uy2EIG3pNS2RA0+sqaVVAtskgPNIcFsnuRPbuYN/kBq1QsN4GVd8strJVpoKcdoJUumkFxUGtHByKTCkEjDKM3DXFosIF1wxuPCIMwouB/DzBUrfGfEcCd4Duf4LMNzRRdyShPYXZfNaNc3NGVsloNyUWcb7Yc79P/f0bBD0kSnPVCP0+yD182jfw4NgMKDPAxoPTANPuiDgZYGe7YnsN1jQHJEeNJjhmqopXnoOjogiYKo64goPn4oh8LbiTqPOAoOQC6ojLpo6sCoD9IO8VwkSIaOjrokFdZo29woQ8aA7JiTfFrYWtKYDc1A7cRgkArphs6o8bzekTKhkgogkGXpk0Lp1gwpSnaGFxHcz4zGPWQPGnGPQnjPlG7Ck1lPmVLPmW5dmu7blQlnl2LkFZgPFazHjmJpQ44ZcjynAmjVc1iK/ZSZddhWMrjPoBYqcvpUoo4Ci+IprfCWkkDBAoUeTjxQFlEXk14pL93Zc2TQqCJnWwkACL3/yDUBKnOZqkKUamkaKqqqqgj9aaVaamW5EAzVmCbQUJ/+KJiqqNGBwg4ZHRAdKoss2qou6gwQ68JU0rFCav0oa5+w6p3iKkqqVRT9XhX1n5OdxnwmpZUlKS91WmqQkX3eCfWgKZ98Gps+Btf1VhndTFiWRruqEbNOabaeCzf9WB48HwP5gFNlkqeyFl6qWcXZ3k22Y4nSKL9em67Czx983//tVcFKEyfxEBH8WIzu6+GpqIlCbHnp6mU5msDy0XT2UC0pCtMVGpf2p0CO6MOObL92pgooUwA6U8FBk8E6AjZwkabt0sfuI6UaA7bWbMwqIMMmRsjSbNLmaooarewRWq3MQi24SW3VdqjTNuzVrpuUKm2LTm2zea3NZm0TeCM3VkTa3lfZ6sqXuq0Jgm3cVh7c0m3qsa2K3e3e8m3f+u3fAm7gCu7gEm7hGu7hIm7iKu7iMm7jYkYIAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation. Drugs are listed alphabetically and not in order of suggested use. The seriousness of heart disease progresses from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present.",
"    <div class=\"footnotes\">",
"     LVH: left ventricular hypertrophy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57:223. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15633=[""].join("\n");
var outline_f15_17_15633=null;
var title_f15_17_15634="Cap polyposis Endosc III";
var content_f15_17_15634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cap polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15634=[""].join("\n");
var outline_f15_17_15634=null;
var title_f15_17_15635="Cryptococcal papular skin lesions";
var content_f15_17_15635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcal papular skin lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of www.doctorfungus.org. Copyright &copy;2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15635=[""].join("\n");
var outline_f15_17_15635=null;
var title_f15_17_15636="Meprobamate: Patient drug information";
var content_f15_17_15636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Meprobamate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/43/19125?source=see_link\">",
"     see \"Meprobamate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Mepro",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702470",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to meprobamate, carisoprodol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11500 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15636=[""].join("\n");
var outline_f15_17_15636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193085\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018355\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018354\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018359\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018360\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018362\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018357\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018358\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018363\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018364\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/43/19125?source=related_link\">",
"      Meprobamate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_17_15637="Maternal floor infarction";
var content_f15_17_15637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Maternal floor infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Band of fibrinoid materal along maternal floor of placenta causing \"strangulation\" and necrosis of the villi",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15637=[""].join("\n");
var outline_f15_17_15637=null;
var title_f15_17_15638="Diffuse alveolar damage DAH";
var content_f15_17_15638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse alveolar damage with alveolar hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of diffuse alveolar damage, as can occur in the acute respiratory distress syndrome. The alveolar septa are edematous but without acute inflammation. Hyaline membranes are lining the alveolar spaces (arrow), and alveolar hemorrhage is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15638=[""].join("\n");
var outline_f15_17_15638=null;
var title_f15_17_15639="Hepatitis B vaccine: Pediatric drug information";
var content_f15_17_15639=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hepatitis B vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"    see \"Hepatitis B vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/38/10849?source=see_link\">",
"    see \"Hepatitis B vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Engerix-B&reg;;",
"     </li>",
"     <li>",
"      Recombivax HB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Engerix-B&reg;;",
"     </li>",
"     <li>",
"      Recombivax HB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although hepatitis B vaccine products differ by concentration (mcg/mL), when dosed in terms of volume (mL), the equivalent dose is the same between products (ie, 0.5 mL of Recombivax-HB&reg; is equivalent to 0.5 mL of Engerix-B&reg;). Combination vaccines (eg, also containing DTaP, HIB) should not be used for the \"birth\" dose but may be used to complete the  immunization series after the infant is 6 weeks of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     Recombivax-HB&reg;, Engerix-B&reg; (Pediatric/Adolescent formulation):  I.M.: 0.5 mL per dose for 3 total doses; ideally first dose given at birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CDC (ACIP) Recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Neonates born to HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag-",
"      <b>",
"       positive",
"      </b>",
"      mothers:",
"     </i>",
"     Administer first dose within the first 12 hours of life, even if premature and regardless of birth weight (hepatitis immune globulin should also be administered at the same time/different site);",
"     <b>",
"      Note:",
"     </b>",
"     Due to possible decreased immunogenicity, premature neonates &lt;2 kg should receive 4 total doses at 0, 1, 2-3, and 6-7 months of chronological age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Neonates born to HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag-",
"      <b>",
"       negative",
"      </b>",
"      mothers:",
"     </i>",
"     First dose should be given at hospital discharge, or at 1-2 months of age;",
"     <b>",
"      Note:",
"     </b>",
"     Premature neonates &lt;2 kg may have the initial dose deferred up to 30 days of chronological age or at hospital discharge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Neonates born to mothers with unknown HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag status at birth:",
"     </i>",
"     Administer first dose within 12 hours of birth even if premature and regardless of birth weight, second dose following 1-2 months later; if HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag test is positive, the neonate should receive hepatitis immune globulin as soon as possible (no later than age 1 week).",
"     <b>",
"      Note:",
"     </b>",
"     Due to possible decreased immunogenicity, premature neonates &lt;2 kg, who received an initial dose within 12 hours of birth, should receive 4 total doses at 0, 1, 2-3, and 6-7 months of chronological age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer's labeling: Neonates with recent exposure to the virus or certain travelers to high-risk areas: Engerix-B&reg;: 0.5 mL per dose for 4 doses given at 0, 1, 2, and 12 months",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"      see \"Hepatitis B vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although hepatitis B vaccine products differ by concentration (mcg/mL), when dosed in terms of volume (mL), the equivalent dose is the same between products (ie, 0.5 mL of Recombivax-HB&reg;  is equivalent to 0.5 mL of Engerix-B&reg;). Combination vaccines may be used to complete the immunization series after the infant is 6 weeks of age. Please see combination vaccine monographs for dose and schedule details. Vaccines from different manufacturers are interchangeable during an immunization series with the exception of an adolescent (11-15 years) 2-dose Recombivax-HB&reg; regimen (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CDC (ACIP) Recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: Recombivax-HB&reg;, Engerix-B&reg; (Pediatric/Adolescent formulation): I.M.: 0.5 mL per dose for 3 total doses; ideally first dose is given at birth, the second dose is given at 1-2 months of age, and a final third dose at 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For infants born to HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-",
"     <b>",
"      positive",
"     </b>",
"     mothers, anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     and HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag levels should be checked at 9-18 months of age (ie, next well child visit after series completion). If anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     and HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag are negative, reimmunize with 3 doses 2 months apart and reassess. Due to possible decreased immunogenicity, former premature neonates &lt;2 kg should receive 4 total doses at 0, 1, 2-3, and 6-7 months of chronological age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Infants born of HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag-",
"      <b>",
"       positive",
"      </b>",
"      mothers:",
"     </i>",
"     First dose should be given within the first 12 hours of life, even if premature and regardless of birth weight (hepatitis immune globulin should also be administered at the same time/different site); the second dose is administered at 1-2 months of age and the third dose at 6 months of age; anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     and HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag levels should be checked at 9-18 months of age (ie, next well child visit after series completion). If anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     and HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag are negative, reimmunize with 3 doses 2 months apart and reassess.",
"     <b>",
"      Note:",
"     </b>",
"     Due to possible decreased immunogenicity, premature neonates &lt;2 kg should receive 4 total doses at 0, 1, 2-3, and 6-7 months of chronological age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Infants born of HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag-",
"      <b>",
"       negative",
"      </b>",
"      mothers:",
"     </i>",
"     First dose should be given at hospital discharge, or at 1-2 months of age; another dose is given 1-2 months later and a final dose at 6 months of age; 4 total doses of vaccine may be given if a &ldquo;birth dose&rdquo; is administered and a combination vaccine is used to complete the series.",
"     <b>",
"      Note:",
"     </b>",
"     Premature neonates &lt;2 kg may have the initial dose deferred up to 30 days of chronological age or at hospital discharge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Infants born of mothers whose HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag status is unknown at birth:",
"     </i>",
"     First dose given within 12 hours of birth even if premature and  regardless of birth weight, second dose following 1-2 months later; the third dose at 6 months of age; if the mother's blood HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag test is positive, the infant should receive hepatitis immune globulin as soon as possible (no later than age 1 week).",
"     <b>",
"      Note:",
"     </b>",
"     Due to possible decreased immunogenicity, premature neonates &lt;2 kg who received an initial dose within 12 hours of birth, should receive 4 total doses at 0, 1, 2-3, and 6-7 months of chronological age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;11 years, Adolescents, and Adults &le;19 years: Recombivax-HB&reg;, Engerix-B&reg; (Pediatric/Adolescent formulation):  I.M.: 0.5 mL per dose for 3 total doses; first dose given on the elected date, second dose given 4 weeks later, third dose given 12-16 weeks later and at least 16 weeks after the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate regimen: Adolescents 11-15 years: Recombivax HB&reg; (Adult formulation): I.M.: 1 mL per dose for 2 doses; first dose given on the elected date, second dose given 4-6 months later if patient still &le;15 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults &ge;20 years (Adult formulation): I.M.: 1 mL per dose for 3 total doses; first dose given on the elected date, second dose given 1-2 months later, third dose given 4-6 months later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When used for immediate prophylactic intervention (eg, administration to persons who are wounded in bombings or similar mass casualty events), vaccination should begin within 24 hours and no later than 7 days following the event.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children 1 month to 10 years with recent exposure to the virus or certain travelers to high-risk areas: Engerix-B&reg; (Pediatric/Adolescent formulation): I.M.: 0.5 mL per dose for 4 doses given at 0, 1, 2, and 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-10 years: Engerix-B&reg; (Pediatric/Adolescent formulation): I.M.: 0.5 mL per dose for 3 doses given 12 months apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;11 years and Adults with recent exposure to the virus or certain travelers to high-risk areas: Engerix-B&reg;: (Adult formulation): I.M.: 1 mL per dose for 4 doses given at 0, 1, 2, and 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents 11-15 years: Recombivax HB&reg; (Adult formulation): I.M.: 1 mL per dose initially and repeated 4-6 months later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Hemodialysis patients often respond poorly to hepatitis B vaccination; higher vaccine doses or increased number of doses may be required. The anti-HBs (antibody to hepatitis B surface antigen) response of such persons should be tested after they are vaccinated, and those who have not responded should be revaccinated with 1-3 additional doses. Patients with chronic renal disease should be vaccinated as early as possible, ideally before they require hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic renal impairment: Administer dose at 0, 1-2, and 4-6 months; repeat dose depending upon annual assessment of hepatitis B surface antigen (anti-HB) level; if anti-HB &lt;10 milli-international units/mL administer an additional dose (MMWR, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;20 years: Dialysis and nondialysis patients; limited data available: I.M.: 20",
"     <b>",
"      mcg",
"     </b>",
"     /dose; no specific ACIP recommendations; dosing based on a multicenter trial of 78 pediatric patients (age:1-18 years) using Recombivax-HB&reg; (Dialysis formulation) and showed protective levels of antibody occurring in 75% to 97% of pediatric hemodialysis patients using higher dose (CDC, 2005a; Watkins, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;20 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Nondialysis patients: 10",
"     <b>",
"      mcg",
"     </b>",
"     /dose (Recombivax-HB&reg;); 20",
"     <b>",
"      mcg",
"     </b>",
"     /dose (Engerix-B&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dialysis patients: 40",
"     <b>",
"      mcg",
"     </b>",
"     /dose [Recombivax-HB&reg; (Dialysis formulation) or Engerix-B&reg; (Adult formulation)]",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [adult, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Engerix-B&reg;: Hepatitis B surface antigen 20 mcg/mL (1 mL) [contains aluminum, yeast protein, may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Engerix-B&reg;: Hepatitis B surface antigen 20 mcg/mL (1 mL) [contains aluminum, yeast protein; vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recombivax HB&reg;: Hepatitis B surface antigen 10 mcg/mL (1 mL) [contains aluminum, natural rubber/natural latex in packaging, yeast protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [dialysis formulation, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recombivax HB&reg;: Hepatitis B surface antigen 40 mcg/mL (1 mL) [contains aluminum, natural rubber/natural latex in packaging, yeast protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [pediatric/adolescent, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Engerix-B&reg;: Hepatitis B surface antigen 10 mcg/0.5 mL (0.5 mL) [contains aluminum, yeast protein, may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recombivax HB&reg;: Hepatitis B surface antigen 5 mcg/0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in packaging, yeast protein]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well; administer I.M. in either the anterolateral aspect of the thigh in infants and young children; in adults, deltoid muscle is the preferred site; not for gluteal administration.",
"     <b>",
"      Not for I.V. or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. The following stability information has also been reported for Engerix-B&reg;: May be stored at room temperature for up to 72 hours (Cohen, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization against infection caused by all known subtypes of hepatitis B virus (FDA approved in all ages).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following (CDC, 2005; CDC, 2006; CDC, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; All infants at birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; All infants and children (postbirth dose; refer to recommended vaccination schedule)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; All unvaccinated adults requesting protection from HBV infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; All unvaccinated adults at risk for HBV infection such as those with:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Behavioral risks: Sexually active persons with &gt;1 partner in a 6-month period; persons seeking evaluation or treatment for a sexually transmitted disease; men who have sex with men; injection drug users",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Occupational risks: Healthcare and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Medical risks: Persons with end-stage renal disease (including predialysis, hemodialysis, peritoneal dialysis, and home dialysis); persons with HIV infection; persons with chronic liver disease. Adults (19-59 years of age) with diabetes mellitus type 1 or type 2 should be vaccinated as soon as possible following diagnosis. Adults &ge;60 years with diabetes mellitus may also be vaccinated at the discretion of their treating clinician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Other risks: Household contacts and sex partners of persons with chronic HBV infection; residents and staff of facilities for developmentally disabled persons; international travelers to regions with high or intermediate levels of endemic HBV infection",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In addition, the ACIP recommends vaccination for any persons who are wounded in bombings or similar mass casualty events who have penetrating injuries or nonintact skin exposure, or who have contact with mucous membranes (exception - superficial contact with intact skin), and who cannot confirm receipt of a hepatitis B vaccination (CDC, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Engerix-B&reg; adult may be confused with Engerix-B&reg; pediatric/adolescent",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Recombivax HB&reg; may be confused with Comvax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, chills, dizziness, fatigue, fever (&ge;37.5&deg;C/100&deg;F),  headache, insomnia, irritability, lightheadedness, malaise, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, petechiae, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, constipation, cramps, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Ecchymosis, erythema, induration, pain, nodule formation, soreness, swelling, tenderness, warmth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Achiness, arthralgia, back pain, myalgia, neck pain, neck stiffness, paresthesia, shoulder pain, tingling, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Earache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, lymphadenopathy, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, alopecia, anaphylaxis, apnea, Bell's palsy, bronchospasm, encephalitis, erythema nodosum, erythema multiforme, febrile seizure, Guillain-Barr&eacute; syndrome, herpes zoster, hypoesthesia, keratitis, liver enzymes increased, lupus-like syndrome, migraine, multiple sclerosis, muscle weakness, neuropathy, optic neuritis, palpitation, paralysis, paresis, polyarteritis nodosa, purpura, seizure, serum-sickness like syndrome (may be delayed days to weeks), Stevens-Johnson syndrome, SLE, syncope, tachycardia, thrombocytopenia, tinnitus, transverse myelitis, uveitis, vasculitis, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hepatitis vaccine, yeast, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with caution in patients with multiple sclerosis; rare exacerbations of symptoms have been observed. The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo-/radiation therapy, or other immunosuppressive therapy including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with coagulation disorders including thrombocytopenia, due to an increased risk for bleeding following I.M. administration; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered; use with caution in patients with decreased cardiopulmonary function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Infants born to HBsAg negative mothers and weighing &lt;2 kg at birth may have the initial dose deferred up to 30 days of chronological age or until hospital discharge. If the mother's HBsAg status at delivery is unknown or positive, hepatitis B vaccine and hepatitis B immune globulin should be administered within 12 hours of life and the first dose of the vaccine should not be counted as part of the vaccine series. Combination vaccines (eg, also containing DTaP, HIB) should not be used as a \"birth\" dose. Use with caution in patients with latex sensitivity, packaging may contain natural latex rubber.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactic reactions should be available during vaccine use. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F178977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. The ACIP recommends HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag testing for all pregnant women. Based on limited data, there is no apparent risk to the fetus when the hepatitis B vaccine is administered during pregnancy. Pregnancy itself is not a contraindication to vaccination; vaccination should be considered if otherwise indicated (CDC, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag and antibodies to HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag (anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     ) should be tested in infants born to mothers positive for HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag when they are 9-18 months of age; annual anti-HB in dialysis patients. Vaccination at the time of HBsAg testing: For persons in whom vaccination is recommended, the first dose of hepatitis B vaccine can be given after blood is drawn to test for HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag. Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinant hepatitis B vaccine is a noninfectious subunit viral vaccine. The vaccine is derived from hepatitis B surface antigen (HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag) produced through recombinant DNA techniques from yeast cells. The portion of the hepatitis B gene which codes for HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag is cloned into yeast which is then cultured to produce hepatitis B vaccine. Promotes immunity to hepatitis B virus by inducing the production of specific antibodies to the virus.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10278561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With use of hepatitic B vaccine, hepatitis D should also be prevented since delta virus replicates only in presence of HBV infection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-16):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/16371945/pubmed\" id=\"16371945\" target=\"_blank\">",
"        16371945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 54(RR-16):1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/17159833/pubmed\" id=\"17159833\" target=\"_blank\">",
"        17159833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Vaccinating Kidney Dialysis Patients and Patients With Chronic Kidney Disease, Summarized From Recommentations of the Advisory Committee on Immunization Practices (ACIP).\" Available at",
"      <a href=\"file://www.cdc.gov/diabetes/pubs/pdf/CKD_vaccination.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/diabetes/pubs/pdf/CKD_vaccination.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1991, 40(RR-13):23.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of Hepatitis B Vaccination for Adults With Diabetes Mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(50):1709-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/22189894/pubmed\" id=\"22189894\" target=\"_blank\">",
"        22189894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman LE, Sullivent EE, Grohskopf LA, et al, \"Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events &minus; United States, 2008: Recommendations of the Centers for Disease Control and Prevention (CDC),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-6):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/18668022/pubmed\" id=\"18668022\" target=\"_blank\">",
"        18668022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mast EE, Margolis HS, Fiore AE, et al, \"A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-16):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/16371945/pubmed\" id=\"16371945\" target=\"_blank\">",
"        16371945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saari TN and American Academy of Pediatrics Committee on Infectious Diseases, \"Immunization of Preterm and Low Birth Weight Infants. American Academy of Pediatrics Committee on Infectious Diseases,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(1 Pt 1):193-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/12837889/pubmed\" id=\"12837889\" target=\"_blank\">",
"        12837889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watkins SL, Alexander SR, Brewer ED, et al, \"Response to Recombinant Hepatitis B Vaccine in Children and Adolescents With Chronic Renal Failure,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 40(2):365-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/17/15639/abstract-text/12148110/pubmed\" id=\"12148110\" target=\"_blank\">",
"        12148110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12938 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-BCBD45DDC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15639=[""].join("\n");
var outline_f15_17_15639=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178984\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178985\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059212\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442600\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059206\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178967\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059216\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059208\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059215\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179005\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179004\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059218\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059205\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059204\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299442\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178962\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178964\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178977\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059211\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059203\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10278561\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12938|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=related_link\">",
"      Hepatitis B vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/38/10849?source=related_link\">",
"      Hepatitis B vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_17_15640="Respiratory syncytial virus infection: Prevention";
var content_f15_17_15640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Respiratory syncytial virus infection: Prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Frederick E Barr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Barney S Graham, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15640/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15640/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/17/15640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H104280778\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory syncytial virus (RSV) causes acute respiratory tract illness in persons of all ages. Almost all children are infected by two years of age, and reinfection is common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical manifestations vary with age, health status, and whether the infection is primary or secondary.",
"   </p>",
"   <p>",
"    The prevention of respiratory syncytial virus infection will be discussed here. The epidemiology, microbiology, clinical manifestations, diagnosis, and treatment of RSV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=see_link\">",
"     \"Respiratory syncytial virus infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278842\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of RSV infection entails decreasing exposure to RSV and decreasing the risk of acquisition if exposure occurs. Strategies to decrease exposure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the risk of acquisition include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of exposure to tobacco smoke",
"     </li>",
"     <li>",
"      Restricting participation in child care during RSV season for high-risk infants (if possible)",
"     </li>",
"     <li>",
"      Hand washing in all settings, particularly when high-risk infants are at risk for exposure to respiratory infections from older siblings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278849\">",
"    <span class=\"h1\">",
"     NOSOCOMIAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;RSV is highly contagious and can cause serious nosocomial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/3\">",
"     3",
"    </a>",
"    ]. The intensity of the precautions should be determined by the setting; prevention of nosocomial infection is most important for infants with congenital heart or lung disease, bone marrow and lung transplant recipients, and the frail elderly with multiple underlying conditions.",
"   </p>",
"   <p>",
"    Rapid diagnosis, hand washing, and appropriate use of gloves are probably the most important infection control measures, but contact precautions, including surgical mask and eye protection for health care providers, should be used when there is a chance of exposure to aerosols of infectious respiratory secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/4-12\">",
"     4-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolation of patients in private rooms or in rooms with other RSV-infected patients (cohorting patients), and limited transport of patients from their rooms also is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/6,11,13\">",
"     6,11,13",
"    </a>",
"    ]. During outbreaks, personnel caring for RSV-infected patients should be restricted from caring for uninfected patients as often as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/6,11,13\">",
"     6,11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Health care personnel should have continuing education on the symptoms, epidemiology, diagnosis, and transmission of RSV. Health care personnel and visitors with upper respiratory tract infections should be restricted from contact with high-risk patients as much as is practical, especially during the peak RSV transmission months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278856\">",
"    <span class=\"h1\">",
"     IMMUNOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from epidemiologic studies suggested that infants with high titers of maternally acquired RSV-neutralizing antibody develop less severe RSV disease, even though antibody does not prevent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/15\">",
"     15",
"    </a>",
"    ]. This finding, and pilot studies indicating that monthly injections of intravenous immunoglobulin were safe and effective in decreasing the severity of subsequent RSV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], led to the development of immunoprophylactic agents for RSV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282122\">",
"    <span class=\"h2\">",
"     Immunoprophylactic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278863\">",
"    <span class=\"h3\">",
"     Palivizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     Palivizumab",
"    </a>",
"    (Synagis&reg;), is a humanized monoclonal antibody against the RSV F glycoprotein (which is highly conserved among various isolates). It is licensed for use in selected infants and children younger than 24 months with BPD, preterm birth (&le;35 weeks), or hemodynamically significant congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Even before the discontinuation of RSVIG, palivizumab was preferred because of its ease of administration and lack of interference with immune response to MMR and varicella vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282159\">",
"    <span class=\"h3\">",
"     Motavizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another more potent RSV-neutralizing antibody (MEDI-524, motavizumab, [Numax&trade;]) was derived from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It appears to be more effective than palivizumab in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/18\">",
"     18",
"    </a>",
"    ]. A multinational phase 3 randomized trial compared motavizumab and palivizumab in 6635 preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/20\">",
"     20",
"    </a>",
"    ]. Both groups had low rates of hospitalization for RSV (1.4 and 1.9 percent, respectively) and medically attended lower respiratory tract infection (2.0 versus 3.9 percent). The overall rate of adverse effects was similar between groups, but cutaneous adverse effects were more frequent among motavizumab recipients (7 versus 5 percent). Similar findings were noted in a multinational trial comparing the safety and tolerability of motavizumab and palivizumab in children with hemodynamically significant congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motavizumab has not been licensed by the United States Food and Drug Administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282342\">",
"    <span class=\"h3\">",
"     RSVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory syncytial virus immune globulin (RespiGam&reg;, RSVIG), which is no longer available, was a polyclonal hyperimmune globulin prepared from donors with high serum titers of RSV neutralizing antibody. In controlled trials, RSVIG reduced RSV-associated hospitalizations among high-risk infants by 41 to 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, its use was associated with increased morbidity and mortality in infants with congenital heart disease, and it was never labeled for use in these infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In addition, as a blood product, RSVIG had the potential to interfere with the immune response to certain live virus vaccines (eg,",
"    <span class=\"nowrap\">",
"     measles/mumps/rubella",
"    </span>",
"    and varicella) and to be contaminated adventitious agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278870\">",
"    <span class=\"h2\">",
"     Target groups for palivizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) recommends that immunoprophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    be considered for certain groups of children who are at risk for severe RSV infection. These include infants and young children with BPD, prematurity, and hemodynamically significant congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these conditions, factors that may influence the decision to administer immunoprophylaxis include the presence of other conditions that predispose to respiratory illness (eg, neurologic disease), distance to and availability of hospital care for severe respiratory illness, logistical difficulties of monthly administration, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,25,26\">",
"     1,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282416\">",
"    <span class=\"h3\">",
"     Bronchopulmonary dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    be administered to infants and children younger than two years of age with BPD who have required medical therapy for their pulmonary disease within six months of the anticipated RSV season [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282423\">",
"    <span class=\"h3\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    be administered to infants and children younger than two years of age who have hemodynamically significant cyanotic and acyanotic congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. Decisions should be made on the basis of degree of cardiovascular compromise (",
"    <a class=\"graphic graphic_table graphicRef73126 \" href=\"UTD.htm?31/55/32635\">",
"     table 1",
"    </a>",
"    ). Infants in this category who require cardiac bypass during RSV season should receive a postoperative dose of palivizumab as soon as they are medically stable because the mean serum palivizumab concentration has been observed to decrease by more than 50 percent after cardiac bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,28,29\">",
"     1,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282430\">",
"    <span class=\"h3\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    be administered to infants younger than 12 months of age who were born at &le;28 weeks, 6 days of gestation and to infants younger than six months of age who were born between 29 weeks, 0 days and 31 weeks, 6 days of gestation, particularly if they have risk factors for RSV, such as day care attendance or school-age siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks, benefits, and cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    for infants between 32 and 35 weeks must be carefully considered [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2009, the AAP Committee on Infectious Diseases (COID) revised its recommendations for palivizumab prophylaxis in this gestational age group to focus on infants at the greatest risk of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. The COID suggests that prophylaxis may be warranted for infants born at 32 weeks, 0 days' through 34 weeks, 6 days' gestation who are younger than three months of age at the start of RSV season or who are born during RSV season",
"    <strong>",
"     AND",
"    </strong>",
"    have at least one of the following two risk factors: infant attends child care or infant has a sibling &lt;5 years of age. Prophylaxis is only administered until the infant reaches 90 days of age. (See",
"    <a class=\"local\" href=\"#H104278877\">",
"     'Dose and schedule'",
"    </a>",
"    below.) The revised recommendations were designed to balance benefit and cost but are somewhat controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The original recommendations were based upon clinical trial data and the revised recommendations upon clinical judgment, in an effort to balance benefit and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. Some editorialists suggest that the decision to deliver doses beyond 90 days of age be made on a case-by-case basis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565537500\">",
"    <span class=\"h4\">",
"     Congenital abnormalities of the airway or neuromuscular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants younger than 12 months of age who were born before 35 weeks of gestation and who have a neuromuscular condition that impairs handling of respiratory secretions or a congenital abnormality of the airway may benefit from RSV immunoprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104282503\">",
"    <span class=\"h3\">",
"     Immunocompromised",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of RSV immunoprophylaxis has not been evaluated in immunocompromised children in controlled trials. Nonetheless, children with severe immunodeficiencies (eg, severe combined immunodeficiency or severe acquired immunodeficiency, children younger than two years who have undergone lung transplantation or hematopoietic stem cell transplantation) may benefit from immunoprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278877\">",
"    <span class=\"h2\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    is 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intramuscularly (IM) once per month for a maximum of five doses. The first dose is administered before the RSV season begins (usually in November, but may vary by geographic region) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H3#H3\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Seasonality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once an infant born at &lt;32 weeks' gestation (&le;31 weeks 6 days) qualifies for initiation of prophylaxis at the beginning of the RSV season, all five doses should be administered, even if the infant becomes old enough that prophylaxis is no longer indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As an example, an infant born at 29 weeks who is without BPD or congenital heart disease and turns six months old in January should still receive immunoprophylaxis in February and March. Fewer than five doses may be administered to an infant who qualifies for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    and is born during the RSV season [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. As a general rule, an infant born in February would receive only two doses (February and March), but may receive more if the local RSV season extends into April or May. The hospital laboratory or health department may have data to help determine when the local RSV season has ended.",
"   </p>",
"   <p>",
"    Infants born at &ge;32 weeks' through 34 weeks, 6 days' gestation who qualify for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    should not receive palivizumab after 90 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. The maximum number of doses varies depending upon the month of birth (three doses for infants born in October through January, two doses for those born in September or February, one dose for those born August or March, and zero doses for those born in April through July). The American Academy of Pediatrics Committee on Infectious Diseases (COID) decreased the maximum number of recommended doses from five to three in this gestational age group in 2009, in an effort to balance benefit and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. However, the recommendation is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The original recommendations were based upon clinical trial data and the revised recommendations upon clinical judgment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. Some editorialists suggest that the decision to deliver doses beyond 90 days of age be made on a case-by-case basis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     Palivizumab",
"    </a>",
"    Outcomes Registry, including nearly 20,000 infants who received palivizumab between 2000 and 2004, indicate that approximately 80 percent of palivizumab recipients received all five doses and between 65 and 70 percent of palivizumab recipients received the second through fifth doses within 35 days of the previous dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No association was detected between receiving all five doses and RSV hospitalization. However, infants who received the second through fifth doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    within 35 days of the previous dose had a lower risk of hospitalization than those who did not (odds ratio 0.7, 95% CI 0.54 to 0.91) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunoprophylaxis should continue even if the infant experiences breakthrough infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"     1",
"    </a>",
"    ]. This is because some infants may have two separate episodes of RSV infection in a single season, probably because more than one strain of RSV may cocirculate in a community. In the event of a natural infection at the beginning of the RSV infection, infants who have already begun immunoprophylaxis should continue to receive it as scheduled; infants who have not received any doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    should receive their first dose after the acute phase of the illness has resolved (so that an allergic reaction, should one occur, can be distinguished from the viral illness). There is no evidence to suggest that palivizumab will alter the course of, interfere with recovery from, or blunt the antibody response to the natural infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278884\">",
"    <span class=\"h2\">",
"     Home administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    in the home setting may increase adherence to the schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Administration in the home setting was associated with a decreased rate of RSV-associated hospitalization in the 2000-2004 Palivizumab Outcomes Registry (0.4 versus 1.2 percent when administered in the outpatient setting) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278891\">",
"    <span class=\"h2\">",
"     Efficacy and effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    for preventing severe RSV infection in infants and children with prematurity, BPD, and congenital heart disease has been demonstrated in randomized controlled trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the IMpact-RSV Trial, 1502 patients with BPD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prematurity (&lt;35 weeks) were randomly assigned to monthly treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"       palivizumab",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/36\">",
"       36",
"      </a>",
"      ]. Palivizumab was associated with significantly fewer RSV-associated hospitalizations (4.8 versus 10.6 percent with placebo, a 55 percent reduction).",
"     </li>",
"     <li>",
"      In another trial, 1287 children with hemodynamically significant congenital heart disease were randomly assigned to monthly treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"       palivizumab",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/28\">",
"       28",
"      </a>",
"      ]. Palivizumab was associated with fewer RSV-associated hospitalizations (5.3 versus 9.3 percent, a 45 percent reduction), fewer hospital days requiring oxygen (178 versus 658, a 73 percent reduction) and fewer total hospital days (367 versus 876, a 56 percent reduction). The mortality rates were similar in both groups (3.3 versus 4.3 percent). No deaths or adverse events were attributed to palivizumab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postlicensure surveillance indicates the RSV-associated hospitalization rates among high-risk infants who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    are similar to or lower than the RSV-associated hospitalization rates described above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/32,37-42\">",
"     32,37-42",
"    </a>",
"    ]. Data from the Palivizumab Outcomes Registry indicate an RSV hospitalization rate of 1.3 percent among infants who received palivizumab during 2000 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether prevention of RSV LRTI with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    affects the incidence of subsequent episodes of recurrent wheezing was evaluated in a cohort of 421 premature infants without chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/43\">",
"     43",
"    </a>",
"    ]. Of these, 191 received palivizumab prophylaxis and were not hospitalized for RSV, and 230 did not receive palivizumab (76 were hospitalized for RSV, and 154 were not). The incidence of clinician-diagnosed recurrent wheezing between 19 and 43 months of age was decreased in the palivizumab group (8 versus 16 percent). This preliminary finding suggests that prevention of RSV LRTI may reduce the risk of recurrent wheezing in premature infants without chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278898\">",
"    <span class=\"h2\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of severe hypersensitivity reactions (&lt;1 per 100,000 recipients) have been described after an initial dose, as well as after reexposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/37\">",
"     37",
"    </a>",
"    ]. In two studies evaluating the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    during two consecutive seasons, no serious adverse events were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Only 1 of 118 children had a significant increase in antipalivizumab antibody titer, and the antibody response declined with continued dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The development of RSV resistant to palivizumab is another potential adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], although in a study of 458 palivizumab-treated infants, no escape mutants were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"     Palivizumab",
"    </a>",
"    does not interfere with routine childhood immunizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104278905\">",
"    <span class=\"h1\">",
"     VACCINE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple challenges to the development of a successful RSV vaccine. Immature immunity and possible suppression of an immune response by maternal antibody are issues in the target population of young infants. The vaccine must be protective against antigenically divergent strains. In addition, it must not potentiate disease in recipients who subsequently become infected with wild-type virus, as occurred in trials with a formalin-inactivated vaccine developed in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/50-54\">",
"     50-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Live attenuated RSV vaccines are being developed and tested. Although several biologically attenuated candidate vaccines have induced an antibody response in young infants, they have been insufficiently attenuated for use in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/55\">",
"     55",
"    </a>",
"    ]. Recombination technology has been used to produce an attenuated strain that was well tolerated by one- to two-month-old infants in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/56\">",
"     56",
"    </a>",
"    ]. However, only 44 percent of subjects had a detectable antibody response.",
"   </p>",
"   <p>",
"    Subunit vaccines have been developed from RSV F and G glycoproteins. Trials conducted in adults, the elderly, pregnant women, and children &ge;12 months of age have been successful in demonstrating some rise in antibody titers but have not had a significant effect on clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15640/abstract/57\">",
"     57",
"    </a>",
"    ]. The utility of this approach in young infants is limited because of safety concerns.",
"   </p>",
"   <p>",
"    A variety of gene-based vaccine vectors and novel adjuvants for candidate RSV vaccine are in preclinical development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/19/27958?source=see_link\">",
"       \"Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104280568\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of respiratory syncytial virus (RSV) infection entails decreasing exposure to RSV and decreasing the risk of acquisition if exposure occurs. (See",
"      <a class=\"local\" href=\"#H104278842\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of nosocomial infections should include rapid diagnosis, handwashing, and appropriate contact precautions (including masks and eye protection) for health care workers. (See",
"      <a class=\"local\" href=\"#H104278849\">",
"       'Nosocomial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest immunoprophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"       palivizumab",
"      </a>",
"      for (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants and children younger than two years who have bronchopulmonary dysplasia that required medical therapy within six months of the anticipated RSV season",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemodynamically significant congenital heart disease (",
"      <a class=\"graphic graphic_table graphicRef73126 \" href=\"UTD.htm?31/55/32635\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H104282416\">",
"       'Bronchopulmonary dysplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H104282423\">",
"       'Congenital heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants younger than one year who were born at &le;28 weeks of gestation (See",
"      <a class=\"local\" href=\"#H104282430\">",
"       'Prematurity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants younger than six months who were born between 29 and 32 weeks of gestation (See",
"      <a class=\"local\" href=\"#H104282430\">",
"       'Prematurity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40371?source=see_link\">",
"       Palivizumab",
"      </a>",
"      also may be indicated for infants younger than three months of age who were born between 32 and 35 weeks of gestation, those born at less than 35 weeks of gestation with neuromuscular disease or congenital abnormalities of the airways, and immunocompromised children. (See",
"      <a class=\"local\" href=\"#H104282430\">",
"       'Prematurity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/1\">",
"      Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/2\">",
"      American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/3\">",
"      Steyerberg EW, de Groot R, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr 2000; 89:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/4\">",
"      Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child 1981; 135:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/5\">",
"      Murphy D, Todd JK, Chao RK, et al. The use of gowns and masks to control respiratory illness in pediatric hospital personnel. J Pediatr 1981; 99:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/6\">",
"      Krasinski K, LaCouture R, Holzman RS, et al. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission. J Pediatr 1990; 116:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/7\">",
"      Agah R, Cherry JD, Garakian AJ, Chapin M. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Routine isolation procedure vs routine procedure supplemented by use of masks and goggles. Am J Dis Child 1987; 141:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/8\">",
"      Gala CL, Hall CB, Schnabel KC, et al. The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection. JAMA 1986; 256:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/9\">",
"      Leclair JM, Freeman J, Sullivan BF, et al. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med 1987; 317:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/10\">",
"      Thorburn K, Kerr S, Taylor N, van Saene HK. RSV outbreak in a paediatric intensive care unit. J Hosp Infect 2004; 57:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/11\">",
"      Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/12\">",
"      Harris JA, Huskins WC, Langley JM, et al. Health care epidemiology perspective on the October 2006 recommendations of the Subcommittee on Diagnosis and Management of Bronchiolitis. Pediatrics 2007; 120:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/13\">",
"      Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) 1989; 68:269.",
"     </a>",
"    </li>",
"    <li>",
"     Hall CB, Walsh EE. Respiratory syncytial virus and human metapneumovirus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2462.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/15\">",
"      Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/16\">",
"      Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993; 37:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/17\">",
"      Groothuis JR, Levin MJ, Rodriguez W, et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother 1991; 35:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/18\">",
"      Mej&iacute;as A, Ch&aacute;vez-Bueno S, R&iacute;os AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49:4700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/19\">",
"      Venkatesh MP, Weisman LE. Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev Vaccines 2006; 5:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/20\">",
"      Carbonell-Estrany X, Sim&otilde;es EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:e35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/21\">",
"      Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/22\">",
"      Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997; 99:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/23\">",
"      Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/24\">",
"      Simoes EA, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998; 133:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/25\">",
"      Harkensee C, Brodlie M, Embleton ND, Mckean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect 2006; 52:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/26\">",
"      Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/27\">",
"      Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009; 94:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/28\">",
"      Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/29\">",
"      Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/30\">",
"      Meissner HC, Bocchini JA Jr, Brady MT, et al. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics 2009; 124:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/31\">",
"      Krilov LR, Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatrics 2009; 124:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/32\">",
"      Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/33\">",
"      Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004; 23:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/34\">",
"      Hand IL, Noble L, Geiss D, Shotkin A. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J 2008; 27:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/35\">",
"      Frogel M, Nerwen C, Boron M, et al. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Infect Dis J 2008; 27:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/36\">",
"      Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/37\">",
"      Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/38\">",
"      Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000; 19:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/39\">",
"      Oh PI, Lanct��t KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002; 21:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/40\">",
"      Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a \"real life\" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006; 41:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/41\">",
"      Medrano L&oacute;pez C, Garc&iacute;a-Guereta L, CIVIC Study Group. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J 2010; 29:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/42\">",
"      Mitchell I, Paes BA, Li A, et al. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 2011; 30:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/43\">",
"      Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/44\">",
"      Meissner HC, Long SS. Respiratory syncytial virus infection and recurrent wheezing: a complex relationship. J Pediatr 2007; 151:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/45\">",
"      Null D Jr, Pollara B, Dennehy PH, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005; 24:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/46\">",
"      Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/47\">",
"      Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005; 79:3962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/48\">",
"      Adams O, Bonzel L, Kovacevic A, et al. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010; 51:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/49\">",
"      DeVincenzo JP, Hall CB, Kimberlin DW, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004; 190:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/50\">",
"      Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/51\">",
"      Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/52\">",
"      Graham BS, Henderson GS, Tang YW, et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/53\">",
"      Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988; 26:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/54\">",
"      Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/55\">",
"      Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/56\">",
"      Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15640/abstract/57\">",
"      Polack FP, Karron RA. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 2004; 23:S65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15389 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15640=[""].join("\n");
var outline_f15_17_15640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H104280568\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104280778\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104278842\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104278849\">",
"      NOSOCOMIAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104278856\">",
"      IMMUNOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104282122\">",
"      Immunoprophylactic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104278863\">",
"      - Palivizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104282159\">",
"      - Motavizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104282342\">",
"      - RSVIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104278870\">",
"      Target groups for palivizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104282416\">",
"      - Bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104282423\">",
"      - Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104282430\">",
"      - Prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H565537500\">",
"      Congenital abnormalities of the airway or neuromuscular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104282503\">",
"      - Immunocompromised",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104278877\">",
"      Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104278884\">",
"      Home administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104278891\">",
"      Efficacy and effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104278898\">",
"      Adverse events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104278905\">",
"      VACCINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104280568\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/55/32635\" title=\"table 1\">",
"      RSV prophylaxis and CHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/19/27958?source=related_link\">",
"      Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=related_link\">",
"      Respiratory syncytial virus infection: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_17_15641="An overview of angioedema: Clinical features, diagnosis, and management";
var content_f15_17_15641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   An overview of angioedema: Clinical features, diagnosis, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/17/15641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15641/contributors\">",
"     Clifton O Bingham, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/17/15641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15641/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/17/15641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/17/15641/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/17/15641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema is self-limited, localized subcutaneous (or submucosal) swelling, which results from extravasation of fluid into interstitial tissues. Angioedema may occur in isolation, accompanied by urticaria, or as a component of anaphylaxis.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, differential diagnosis, and management of angioedema will be reviewed here. The pathogenesis and causes of angioedema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema typically affects areas with loose connective tissue, such as the face, lips, mouth, and throat, larynx, uvula, extremities, and genitalia. Bowel wall angioedema presents as colicky abdominal pain.",
"   </p>",
"   <p>",
"    Angioedema can be distinguished clinically from other forms of edema by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset in minutes to hours",
"     </li>",
"     <li>",
"      Asymmetric distribution",
"     </li>",
"     <li>",
"      Tendency",
"      <strong>",
"       not",
"      </strong>",
"      to involve gravitationally dependent areas",
"     </li>",
"     <li>",
"      Involvement of face, lips, larynx, and bowels",
"     </li>",
"     <li>",
"      Association of some forms of angioedema with other signs and symptoms of allergic reactions or anaphylaxis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Types of angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of angioedema can be distinguished: mast cell-mediated angioedema and bradykinin-mediated angioedema. However, for many of the known triggers of angioedema, the mechanism is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mast cell-mediated angioedema, such as allergic reactions to foods or insect stings, there are often (not always) other signs and symptoms of mast cell mediator release. These signs and symptoms include urticaria, flushing, generalized pruritus, bronchospasm, throat tightness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension. Mast cell-mediated angioedema usually begins within minutes of exposure to the allergen, builds over a few hours, and resolves in 24 to 48 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H5#H5\">",
"       \"An overview of angioedema: Pathogenesis and causes\", section on 'Mast cell-mediated etiologies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradykinin-induced angioedema is",
"      <strong>",
"       not",
"      </strong>",
"      associated with urticaria, bronchospasm, or other symptoms of allergic reactions. It has a somewhat more prolonged time course, usually developing over 24 to 36 hours and resolving within two to four days [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/1\">",
"       1",
"      </a>",
"      ]. In this type of angioedema, the relationship between the trigger and the onset of symptoms is often not apparent. As an example, in ACE inhibitor-induced angioedema, swelling may appear within a week of starting or increasing the medications, or after years of use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H10#H10\">",
"       \"An overview of angioedema: Pathogenesis and causes\", section on 'Bradykinin-mediated etiologies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anatomic sites",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Larynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal edema can develop rapidly (over minutes) or more slowly over several hours. Early symptoms include hoarse voice, throat tightness, and difficulty swallowing. Assessment and treatment are discussed below (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Angioedema in or near the airway'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Skin and mucous membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema affects the subcutaneous and submucosal tissues (",
"    <a class=\"graphic graphic_picture graphicRef78006 \" href=\"UTD.htm?14/51/15154\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57090 \" href=\"UTD.htm?34/19/35121\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68820 \" href=\"UTD.htm?37/21/38225\">",
"     picture 3",
"    </a>",
"    ). Pruritus is absent, unless the angioedema is associated with urticarial lesions, which are intensely pruritic (",
"    <a class=\"graphic graphic_picture graphicRef66159 \" href=\"UTD.htm?38/54/39791\">",
"     picture 4",
"    </a>",
"    ). The skin is either normal in color or mildly erythematous. Mild pain and warmth may be present, but are much less prominent than the pain and warmth of cellulitis. Some patients describe the discomfort of angioedema as burning in nature. Angioedema resolves without leaving residual markings on the skin, unless there has been trauma induced by rubbing or scratching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Bowel wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema affecting the bowel wall presents as colicky abdominal pain, sometimes accompanied by nausea, vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea. Bowel wall edema can often be visualized by abdominal CT or ultrasound. Bowel wall angioedema is seen in patients on ACE inhibitors and in those with hereditary or acquired C1 inhibitor deficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors should be suspected in an older adult (particularly women) taking these medications, in whom the problem is newly-developed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/2-6\">",
"       2-6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5546601\">",
"       'Imaging for suspected bowel wall edema'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Acquired C1 inhibitor deficiency also typically presents in older patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=see_link\">",
"       \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary angioedema should be considered in an adolescent or adult, particularly if there is a family history of recurrent, episodic swelling. A more detailed discussion of the evaluation of abdominal pain in patients with hereditary angioedema is found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link&amp;anchor=H15#H15\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Gastrointestinal attacks'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Life-threatening situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema is usually a benign condition, although it can be life-threatening in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angioedema of the larynx, upper airway, or tongue (of any mechanism) can progress to airway obstruction and asphyxiation.",
"     </li>",
"     <li>",
"      Angioedema may be a presenting symptom of anaphylaxis (a serious allergic reaction that is rapid in onset and may cause death). The diagnosis and treatment of anaphylaxis are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with angioedema affecting the airway, airway protection must be given priority over a comprehensive diagnostic evaluation. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Angioedema in or near the airway'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should be directed at identifying possible causes, as well as determining if the patient has had previous episodes of angioedema. Causes are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be questioned about any unusual exposures (eg, insect stings), activities (eg, exercise), foods or other ingestions in the 24 hours before the onset of symptoms.",
"     </li>",
"     <li>",
"      A review of the patient's medications is important, with particular attention to the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </li>",
"     <li>",
"      ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)",
"     </li>",
"     <li>",
"      Calcium channel blockers",
"     </li>",
"     <li>",
"      Estrogens",
"     </li>",
"     <li>",
"      Fibrinolytic agents",
"     </li>",
"     <li>",
"      Any new medications or significant increases in doses of medications",
"     </li>",
"     <li>",
"      Patients with previous episodes of angioedema (cutaneous swelling or abdominal pain) should be asked about activities and exposures surrounding those episodes, to see if any pattern is apparent. Individuals with ACEI-induced angioedema may have several episodes of swelling before the drug is recognized as the culprit and discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients with recurrent orofacial angioedema after dental work or episodes of unexplained abdominal pain may have hereditary or acquired C1 inhibitor deficiency.",
"     </li>",
"     <li>",
"      Patients should be asked about family members with similar episodes of cutaneous or laryngeal angioedema or with recurrent abdominal pain, to identify families with hereditary angioedema (HAE). However, about 25 percent of patients with HAE have a new mutation and so do not have a positive family history. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of other signs and symptoms of an allergic reaction (or more precisely, of mast cell activation) is helpful in narrowing the list of possible causes, as mentioned previously. These signs and symptoms include urticaria, flushing, generalized pruritus, bronchospasm, throat tightness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension. If one or more of these other signs or symptoms is present, the history should be directed toward mast cell-mediated etiologies, such as allergic reactions to foods, drugs, and stinging insects (",
"    <a class=\"graphic graphic_table graphicRef58834 \" href=\"UTD.htm?11/8/11403\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H5#H5\">",
"     \"An overview of angioedema: Pathogenesis and causes\", section on 'Mast cell-mediated etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If signs and symptoms of mast cell activation are",
"    <strong>",
"     absent",
"    </strong>",
"    , then bradykinin-mediated angioedema, such as that caused by ACE inhibitors and the rare disorders hereditary or acquired C1 inhibitor deficiency, should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of angioedema: Pathogenesis and causes\", section on 'Bradykinin-mediated etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory tests that are indicated in a patient presenting with angioedema are influenced by the presence of other signs and symptoms and by the suspected cause, as described below. However, we suggest that the following laboratories be considered in all patients with new onset angioedema: complete blood count with differential, basic chemistry panel with liver function tests, CRP, ESR, and C4 and C3 levels.",
"   </p>",
"   <p>",
"    Depressed C4 levels should prompt further evaluation for complement mediated angioedema, and low levels C3 and C4 levels suggest an immune complex mediated process, such as systemic lupus erythematosus. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Angioedema with prominent urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the evaluation of urticaria (with or without angioedema) suggest that the following tests be obtained: a complete blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/9\">",
"     9",
"    </a>",
"    ]. This evaluation is reviewed separately. A specific cause can sometimes be identified in patients with new onset",
"    <span class=\"nowrap\">",
"     urticaria/angioedema.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Urticaria/angioedema",
"    </span>",
"    is considered chronic when it has been present on most days of the week for a period of six weeks or more. The evaluation of chronic",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    differs from that of new onset symptoms, since a specific external trigger or allergy is",
"    <strong>",
"     not",
"    </strong>",
"    found in most patients and laboratory studies are most often normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Angioedema with anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum total tryptase level drawn shortly after the onset of anaphylaxis may be useful in confirming that the episode was a mast cell-mediated event. Serum tryptase is a mast cell-specific protease that is released upon mast cell activation. Any elevation in serum tryptase suggests an anaphylactic event. However, a normal level does not exclude anaphylaxis because tryptase elevations are variable and transient. Tryptase elevations are most consistently found in patients with hypotension during anaphylaxis. Instructions for proper sample collection are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef72041 \" href=\"UTD.htm?21/8/21644\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Angioedema due to a suspect allergen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases in which an allergic reaction to an identifiable substance is suspected, there may be commercially-available tests for IgE antibodies to the substance in question. Allergen-specific IgE immunoassays are available for a variety of foods, insect venoms, inhaled allergens, and latex. These tests vary in sensitivity and specificity, but a positive result can be helpful. IgE immunoassays are not altered by recent allergic reactions, so they can be obtained at any time. Allergy skin testing provides similar information and is more sensitive in many cases, but it requires referral to an allergy specialist and should be deferred until the patient has fully recovered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of in vitro allergy tests\", section on 'Immunoassays'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Patients taking an ACE inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors have advised screening for underlying defects in C1 inhibitor with a serum C4 level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/10\">",
"     10",
"    </a>",
"    ], although the likelihood of finding such a disorder in a patient with no other suggestive history is low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=see_link&amp;anchor=H20395298#H20395298\">",
"     \"ACE inhibitor-induced angioedema\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Isolated angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening tests for C1 inhibitor deficiency should be obtained in patients with isolated mucosal or cutaneous angioedema (ie, without urticaria or other evidence of mast cell involvement) or bowel wall angioedema on imaging of the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/11\">",
"     11",
"    </a>",
"    ]. The recommended tests are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C4 level",
"     </li>",
"     <li>",
"      C1 inhibitor (antigenic level)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of C1 inhibitor deficiency are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5546601\">",
"    <span class=\"h2\">",
"     Imaging for suspected bowel wall edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel wall edema may be imaged by ultrasound or abdominal CT. Multidetector CT (MDCT) has been suggested as particularly helpful for diagnosis of ACE inhibitor-induced angioedema. Most reported cases of ACE inhibitor-induced intestinal angioedema involved the small bowel, with abdominal CT demonstrating circumferential thickening of the small bowel wall with ascites or subobstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/3,5,12\">",
"     3,5,12",
"    </a>",
"    ]. The thickened area of bowel wall may have a stratified appearance, and mesenteric lymphadenopathy has not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/12\">",
"     12",
"    </a>",
"    ]. Recognition of this complication of ACE inhibitor therapy can spare the patient unnecessary surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of angioedema is made clinically, based on a suggestive history and physical findings. Laboratories may be helpful in confirming an underlying allergy or a complement disorder. However, laboratories are normal in many cases of angioedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     The utility of extensive empiric testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive testing beyond the laboratory tests already mentioned is of relatively low yield. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Laboratory tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The utility of extensive testing was evaluated in a large series of 776 patients with recurrent angioedema, without major urticaria, who presented to a referral center over a 10 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/13\">",
"     13",
"    </a>",
"    ]. In the majority of these patients, neither the patient nor the referring clinician could detect an association between the episodes of angioedema and an obvious trigger. All patients underwent a careful history and physical examination, sinus and dental radiographs, complete blood count, serum protein electrophoresis, complement studies, erythrocyte sedimentation rate, C-reactive protein, hepatic enzymes, renal function, thyroid function and anti-tissue antibodies, stool examination for ova and parasites, urinalysis, pharyngeal cultures, and urine cultures. Further studies, including allergy testing or medication withdrawal and challenge, were performed only if allergy was suggested by the clinical history. A condition or trigger was considered causative only if the angioedema improved after",
"    <span class=\"nowrap\">",
"     treatment/discontinuation.",
"    </span>",
"   </p>",
"   <p>",
"    The following potentially causative conditions were identified (",
"    <a class=\"graphic graphic_figure graphicRef71000 \" href=\"UTD.htm?0/33/528\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary or acquired angioedema due to C1 inhibitor deficiency was identified in 23 and 2 percent, respectively.",
"     </li>",
"     <li>",
"      ACE inhibitors were implicated in 11 percent, with a median duration of treatment of one year before symptoms began.",
"     </li>",
"     <li>",
"      A specific causative factor (a food, drug, insect bite, environmental allergen, or physical stimulus) was identified in 16 percent.",
"     </li>",
"     <li>",
"      Other disorders, most commonly chronic infection or autoimmune disease, were identified in 7 percent. Within this group, chronic infections were identified in 27 patients, 19 of whom had resolution of the angioedema following treatment of the infection.",
"     </li>",
"     <li>",
"      Three percent did not have angioedema, but rather other types of peripheral or generalized edema. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No trigger could be identified in 38 percent, and these patients were deemed to have idiopathic angioedema. Thus, if the initial approach suggested above, (ie, obtaining complete blood count with differential, basic chemistry panel with liver function tests, CRP, ESR, and C4 and C3 levels and stopping any ACE inhibitors) were applied to this referral group, patients with hereditary or acquired angioedema and those with ACE inhibitor-related angioedema would have been reliably detected. A detailed clinical history and review of systems would likely have identified many of the remaining patients (those with a specific causative factor or an underlying infection or autoimmune disease) as requiring further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Idiopathic angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic angioedema is the term applied to recurrent episodes of angioedema without urticaria, for which no explanation can be found after a thorough evaluation (as previously described) to exclude allergic disorders, drug reactions, and defects in complement pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several conditions that may be mistaken for angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/10,14\">",
"     10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Disorders resembling cutaneous edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous edema mimicking angioedema can result from contact dermatitis, cellulitis, autoimmune diseases, superior vena cava syndrome, and other disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Contact dermatitis",
"      </strong>",
"      &mdash; Contact dermatitis is a common mimic of facial angioedema and can cause dramatic swelling of the facial and periorbital skin when it develops in response to cosmetics or topical pharmaceuticals (",
"      <a class=\"graphic graphic_picture graphicRef72864 \" href=\"UTD.htm?11/54/12131\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef52903 \" href=\"UTD.htm?28/21/29011\">",
"       picture 6",
"      </a>",
"      ). Microvesiculation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deep erythema of the skin can help distinguish contact dermatitis from complement-mediated angioedema. Poison ivy can cause severe facial swelling, although linear patterns of vesiculations are often present.",
"      <br/>",
"      <br/>",
"      Patients with contact dermatitis often report prominent pain, pruritus, and burning of the skin. Resolution of contact dermatitis may be followed by peeling, which does not occur in angioedema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"       \"Overview of dermatitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link\">",
"       \"Contact dermatitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cellulitis and erysipelas",
"      </strong>",
"      &mdash; Cellulitis and erysipelas are infections of various layers of the dermis, which present as areas of skin erythema, edema and warmth in the absence of an underlying suppurative focus. Cellulitis involves the deeper dermis and subcutaneous fat and has relatively smooth, flat borders. In contrast, erysipelas involves the upper dermis and superficial lymphatics and is characteristically raised above the level of surrounding skin, with a clear line of demarcation between involved and uninvolved tissue (",
"      <a class=\"graphic graphic_picture graphicRef56797 \" href=\"UTD.htm?36/50/37667\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef78928 \" href=\"UTD.htm?3/36/3649\">",
"       picture 8",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Compared with angioedema, cellulitis and erysipelas are deeply erythematous, painful, and may be accompanied by fever. The involved areas of skin are more clearly demarcated than angioedematous skin. Resolution may be followed by peeling, whereas angioedema resolves without peeling.",
"     </li>",
"     <li>",
"      <strong>",
"       Facial lymphedema",
"      </strong>",
"      &mdash; Facial lymphedema can be associated with rosacea, although there are other characteristic skin changes in rosacea. Patients may also experience prominent flushing and warmth of the face, and the combination of flushing, heat, and swelling is interpreted by some patients as a possible allergic reaction. However, lymphedema does not develop or resolve rapidly, in contrast to angioedema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Autoimmune conditions",
"      </strong>",
"      &mdash; Edema of the face, periorbital areas, and sometimes the hands can be seen in systemic lupus, polymyositis, dermatomyositis, and Sj&ouml;gren&rsquo;s syndrome. Early stages of both scleredema and systemic sclerosis can present as swelling. Scleredema often involves the posterior neck, and systemic sclerosis often affects the hands and is accompanied by Raynaud's phenomenon [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/15\">",
"       15",
"      </a>",
"      ]. These disorders can be distinguished from angioedema by their persistence, and by the presence of associated systemic rheumatologic findings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eyelid edema",
"      </strong>",
"      &mdash; Blepharochalasis is an uncommon disorder in which recurrent and episodic eyelid edema leads to atrophic eyelid skin with fine wrinkling and bronze discoloration (",
"      <a class=\"graphic graphic_picture graphicRef71807 \" href=\"UTD.htm?0/4/78\">",
"       picture 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/9,16,17\">",
"       9,16,17",
"      </a>",
"      ]. This is seen predominantly in children and young adults. The etiology is unknown, although IgA deposits have been described in the periorbital tissues, suggesting an immunological pathogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Parasitic infections",
"      </strong>",
"      &mdash; In areas of the world where parasitic infections are prevalent, certain infections can cause periorbital edema that is persistent rather than episodic. Specific infections that can present with this finding include trichinosis and American trypanosomiasis (ie, Romana's sign) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=see_link\">",
"       \"Trichinellosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathology and pathogenesis of Chagas disease\", section on 'Acute phase'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypothyroidism",
"      </strong>",
"      &mdash; Severe hypothyroidism can cause a puffiness of the face and lips that can be mistaken for angioedema, but is not transient. Nonpitting edema (myxedema) may be generalized. Myxedema results from infiltration of the skin by glycosaminoglycans with associated water retention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"       \"Clinical manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Superior vena cava syndrome and tumors",
"      </strong>",
"      &mdash; Occasionally, edema of the face, neck, or upper extremities, accompanied by venous engorgement, is observed with superior vena cava syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"       \"Malignancy-related superior vena cava syndrome\"",
"      </a>",
"      .) Tumors of the head and neck, lymphoma, and superior (pulmonary) sulcus (Pancoast) tumors can also cause localized edema. With these entities, protracted or progressive swelling would be expected, in contrast to the transient swelling of angioedema.",
"     </li>",
"     <li>",
"      <strong>",
"       Cheilitis granulomatosa (Miescher's cheilitis) and Melkersson-Rosenthal syndrome",
"      </strong>",
"      &mdash; These are rare disorders of recurrent angioedema involving the lips and face that lead to eventual permanent enlargement of the affected areas (",
"      <a class=\"graphic graphic_picture graphicRef67657 \" href=\"UTD.htm?3/5/3156\">",
"       picture 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef78861 \" href=\"UTD.htm?12/28/12739\">",
"       picture 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Idiopathic edema",
"      </strong>",
"      &mdash; Idiopathic edema (as opposed to idiopathic",
"      <strong>",
"       angio",
"      </strong>",
"      edema) is a syndrome of persistent and recurrent fluid retention, typically occurring in young, menstruating women in the absence of cardiac, hepatic, or renal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20981?source=see_link\">",
"       \"Idiopathic edema\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Disorders resembling laryngeal edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of laryngeal edema includes tonsillitis, peritonsillar abscess, and pharyngeal foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/10\">",
"     10",
"    </a>",
"    ]. Historical information should differentiate these entities from angioedema, as infectious causes should have accompanying fever and other signs of illness. The diagnosis of a pharyngeal foreign body can be difficult, however, particularly in the preverbal infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other causes of bowel wall edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thickening of the wall of the small bowel can be seen in multiple disorders, including mesenteric infarction, vasculitis, intramural hemorrhage, inflammatory bowel disease, acute ileitis (Yersinia, Campylobacter infections), peritoneal carcinomatosis, inflammatory conditions adjacent to the bowel wall, and other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/12,22-24\">",
"     12,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of angioedema depends upon the acuity, severity, and proposed mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Angioedema in or near the airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with angioedema near or involving the tongue, uvula, soft palate, or larynx must be immediately assessed for signs of airway compromise. The airway should be managed by the most experienced person available, as intubation in the presence of laryngeal angioedema can be difficult due to distortion of the normal anatomy. Angioedema sometimes spreads to adjacent areas, and frequent monitoring of airway patency is critical throughout treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Angioedema in anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis should be treated with intramuscular epinephrine, intravenous fluids, and oxygen. Rapid overview tables are provided for treatment of anaphylaxis in adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ). The treatment of anaphylaxis is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients who have experienced anaphylaxis should be equipped with an anaphylaxis emergency action plan, one or more epinephrine autoinjectors, a plan for arranging further evaluation, and printed information about anaphylaxis and its treatment. These materials can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H39#H39\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Discharge care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Acute allergic angioedema (less severe than anaphylaxis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines and glucocorticoids are the main therapies for isolated angioedema that appears to be allergic (ie, mast-cell mediated) but is NOT part of a larger anaphylactic reaction. In contrast, anaphylaxis should be treated with intramuscular epinephrine because antihistamines are not sufficient. Angioedema that is accelerating and could affect the airway would also be appropriately treated with intramuscular epinephrine, although this is unlikely to help if the angioedema is bradykinin-mediated (as in hereditary angioedema).",
"   </p>",
"   <p>",
"    Suggested treatment includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H1 and H2 antihistamines at standard doses",
"     </li>",
"     <li>",
"      Glucocorticoids (the dosing in acute angioedema has not been specifically studied):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      , 60 to 80 mg initially, replaced with oral preparations and tapered over five to seven days, in adults requiring hospitalization for severe angioedema",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      (20 to 40 mg daily) in adults or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      in children, tapered over five to seven days in patients discharged to home",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of antihistamines for angioedema is extrapolated from the treatment of acute",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    as the data on isolated allergic angioedema are scant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link&amp;anchor=H10818973#H10818973\">",
"     \"New onset urticaria\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     C1-inhibitor deficiency (hereditary angioedema)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute attacks of hereditary and acquired C1 inhibitor disorders is outlined here and discussed in detail separately.",
"   </p>",
"   <p>",
"    The treatment of laryngeal attacks, which are the leading cause of mortality in patients with hereditary angioedema, must always begin with immediate and meticulous attention to airway patency, regardless of the therapies available. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Angioedema in or near the airway'",
"    </a>",
"    above.) Those with respiratory distress or stridor may require intubation, because even the first line therapies take approximately 30 minutes or more to begin working.",
"   </p>",
"   <p>",
"    Briefly, treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Purified",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"       C1 inhibitor concentrate",
"      </a>",
"      (Cinryze&reg;, Berinert&reg;)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       Ecallantide",
"      </a>",
"      (Kalbitor&reg;) (a kallikrein inhibitor available in the United States)",
"     </li>",
"     <li>",
"      Fresh frozen plasma (used in the US) or solvent-detergent treated plasma (used in the European Union [EU])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another option is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    (Firazyr&reg;), a bradykinin B2 receptor antagonist.",
"   </p>",
"   <p>",
"    The dosing and administration of each of these therapies is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Medication options'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     ACE inhibitor-induced angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ACEI-induced angioedema primarily involves discontinuation of the drug and monitoring for resolution. The airway must be protected if swelling involves the mouth or throat, as several deaths have been attributed to asphyxiation from massive tongue swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of other medications for severe or refractory symptoms (including bradykinin receptor antagonists, C1-inhibitor concentrate, fresh frozen plasma, antihistamines, glucocorticoids, and epinephrine) is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=see_link&amp;anchor=H9838067#H9838067\">",
"     \"ACE inhibitor-induced angioedema\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Future use of related medications, particularly angiotensin II receptor blockers (ARBs) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=see_link&amp;anchor=H20395068#H20395068\">",
"     \"ACE inhibitor-induced angioedema\", section on 'Future use of other related drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Recurrent, idiopathic angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of nonsedating antihistamines, administered twice daily, is suggested as an initial intervention to prevent recurrence in patients with idiopathic recurrent angioedema without urticaria.",
"   </p>",
"   <p>",
"    In the largest series available, 294 patients with idiopathic recurrent angioedema without urticaria were treated with nonsedating antihistamines initially (ie, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    10 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    5 mg twice daily) for at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/13\">",
"     13",
"    </a>",
"    ]. With this intervention, 86 percent experienced significant improvement or resolution of the angioedema. In those that did not improve significantly (40 patients), the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    (25 mg three times daily) did",
"    <strong>",
"     not",
"    </strong>",
"    result in additional symptom control. Responsiveness to antihistamines suggests that mast-cell or basophil-mediated processes were underlying the symptoms of these patients, despite the lack of identifiable triggers.",
"   </p>",
"   <p>",
"    Other experts describe less success in preventing recurrence with antihistamines, even with high doses (ie, up to 200 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) and no response in up to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/10,26\">",
"     10,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For adult patients with idiopathic angioedema who have infrequent attacks (ie, a few attacks per year) and do not wish to take regular medications for prevention, we (the authors and editors of UpToDate) have found the following to be helpful. We instruct patients to take 40 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and 25 to 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , all at once, at the first sign of swelling, with no further doses. Some patients have identifiable sensations in the skin just before the onset of angioedema, and the medications should be taken when these sensations appear. This approach has not been formally studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4094018\">",
"    <span class=\"h3\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    (bradykinin B2 receptor antagonist), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (B cell depleting anti-CD20 monoclonal antibody) have been reported in severe and refractory cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/17/15641/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe or recurrent angioedema or",
"    <span class=\"nowrap\">",
"     angioedema/urticaria,",
"    </span>",
"    for which no cause is readily apparent, should be referred to a specialist for further evaluation. An allergy specialist is most appropriate if an allergic cause or C1 inhibitor deficiency is suspected. Dermatology specialists also manage mast cell-mediated",
"    <span class=\"nowrap\">",
"     urticaria/angioedema.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate",
"    offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"       \"Patient information: Angioedema (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angioedema typically affects the skin and mucosal tissues of the face, lips, mouth, and throat, larynx, extremities, and genitalia, often in an asymmetric pattern (",
"      <a class=\"graphic graphic_picture graphicRef78006 \" href=\"UTD.htm?14/51/15154\">",
"       picture 1",
"      </a>",
"      ). Angioedema can also affect the bowel wall and present as colicky abdominal pain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two types of angioedema can be distinguished: mast cell-mediated angioedema (eg, allergic reactions) and bradykinin-mediated angioedema (eg, ACE inhibitor induced angioedema, hereditary angioedema). However, there are other causes of angioedema for which the mechanism unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"       \"An overview of angioedema: Pathogenesis and causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angioedema may be life-threatening if it causes airway obstruction or when it represents a component of anaphylaxis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Life-threatening situations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the clinical history or physical exam reveals a possible external cause or concomitant condition, then these findings should guide further testing. If there is no information to suggest an external cause and the patient has isolated angioedema (without pruritus or urticaria), then a C4 and a C1 inhibitor antigenic level should be obtained. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate assessment and ongoing protection of the airway is critical in any patient with angioedema near or affecting the larynx, mouth, soft palate, or tongue. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Angioedema in or near the airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of angioedema depends upon the acuity, severity, and the mechanism believed responsible (mast cell or bradykinin-mediated). Mast cell-mediated angioedema responds to epinephrine (if severe), glucocorticoids, and antihistamines. In contrast, bradykinin-mediated angioedema responds to C1-inhibitor concentrate, fresh frozen plasma, and other agents that interfere with the production or action of bradykinin. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/1\">",
"      Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/2\">",
"      Dobbels P, Van Overbeke L, Vanbeckevoort D, Hiele M. Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? Acta Gastroenterol Belg 2009; 72:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/3\">",
"      Chase MP, Fiarman GS, Scholz FJ, MacDermott RP. Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor. J Clin Gastroenterol 2000; 31:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/4\">",
"      Jacobs RL, Hoberman LJ, Goldstein HM. Angioedema of the small bowel caused by an angiotensin-converting enzyme inhibitor. Am J Gastroenterol 1994; 89:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/5\">",
"      Arakawa M, Murata Y, Rikimaru Y, Sasaki Y. Drug-induced isolated visceral angioneurotic edema. Intern Med 2005; 44:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/6\">",
"      Shahzad G, Korsten MA, Blatt C, Motwani P. Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. Mt Sinai J Med 2006; 73:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/7\">",
"      Gabb GM, Ryan P, Wing LM, Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996; 26:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/8\">",
"      Greaves MW, Sabroe RA. ABC of allergies. Allergy and the skin. I--Urticaria. BMJ 1998; 316:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/9\">",
"      Kaneoya K, Momota Y, Hatamochi A, et al. Elastin gene expression in blepharochalasis. J Dermatol 2005; 32:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/10\">",
"      Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005; 53:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/11\">",
"      Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 2004; 114:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/12\">",
"      Vallurupalli K, Coakley KJ. MDCT features of angiotensin-converting enzyme inhibitor-induced visceral angioedema. AJR Am J Roentgenol 2011; 196:W405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/13\">",
"      Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/14\">",
"      Charlesworth EN. Differential diagnosis of angioedema. Allergy Asthma Proc 2002; 23:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/15\">",
"      Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/16\">",
"      Wang G, Li C, Gao T. Blepharochalasis: a rare condition misdiagnosed as recurrent angioedema. Arch Dermatol 2009; 145:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/17\">",
"      Koursh DM, Modjtahedi SP, Selva D, Leibovitch I. The blepharochalasis syndrome. Surv Ophthalmol 2009; 54:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/18\">",
"      D&oacute;zsa A, K&aacute;rolyi ZS, Degrell P. Bilateral blepharochalasis. J Eur Acad Dermatol Venereol 2005; 19:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/19\">",
"      Van Dellen RG, Maddox DE, Dutta EJ. Masqueraders of angioedema and urticaria. Ann Allergy Asthma Immunol 2002; 88:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/20\">",
"      Kakimoto C, Sparks C, White AA. Melkersson-Rosenthal syndrome: a form of pseudoangioedema. Ann Allergy Asthma Immunol 2007; 99:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/21\">",
"      van der Waal RI, Schulten EA, van de Scheur MR, et al. Cheilitis granulomatosa. J Eur Acad Dermatol Venereol 2001; 15:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/22\">",
"      Ledermann HP, B&ouml;rner N, Strunk H, et al. Bowel wall thickening on transabdominal sonography. AJR Am J Roentgenol 2000; 174:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/23\">",
"      Macari M, Megibow AJ, Balthazar EJ. A pattern approach to the abnormal small bowel: observations at MDCT and CT enterography. AJR Am J Roentgenol 2007; 188:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/24\">",
"      De Backer AI, De Schepper AM, Vandevenne JE, et al. CT of angioedema of the small bowel. AJR Am J Roentgenol 2001; 176:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/25\">",
"      Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001; 46:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/26\">",
"      Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/27\">",
"      Gonz&aacute;lez P, Soriano V, Caballero T, Niveiro E. Idiopatic angioedema treated with dapsone. Allergol Immunopathol (Madr) 2005; 33:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/28\">",
"      Del Corso I, Puxeddu I, Sardano E, et al. Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant. Ann Allergy Asthma Immunol 2012; 108:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/17/15641/abstract/29\">",
"      Ghazan-Shahi S, Ellis AK. Severe steroid-dependent idiopathic angioedema with response to rituximab. Ann Allergy Asthma Immunol 2011; 107:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8105 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15641=[""].join("\n");
var outline_f15_17_15641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Types of angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anatomic sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Larynx",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Skin and mucous membranes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Bowel wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Life-threatening situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Angioedema with prominent urticaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Angioedema with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Angioedema due to a suspect allergen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Patients taking an ACE inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Isolated angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5546601\">",
"      Imaging for suspected bowel wall edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      The utility of extensive empiric testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Idiopathic angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Disorders resembling cutaneous edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Disorders resembling laryngeal edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other causes of bowel wall edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Angioedema in or near the airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Angioedema in anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Acute allergic angioedema (less severe than anaphylaxis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      C1-inhibitor deficiency (hereditary angioedema)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Recurrent, idiopathic angioedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4094018\">",
"      - Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8105|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/33/528\" title=\"figure 1\">",
"      Etiologies of angioedema in referral populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8105|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/51/15154\" title=\"picture 1\">",
"      Angioedema lip 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/19/35121\" title=\"picture 2\">",
"      Angioedema lip 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/21/38225\" title=\"picture 3\">",
"      Angioedema tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/54/39791\" title=\"picture 4\">",
"      Angioedema and hives face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12131\" title=\"picture 5\">",
"      Contact derm eyelids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/21/29011\" title=\"picture 6\">",
"      Contact derm face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/50/37667\" title=\"picture 7\">",
"      Erysipelas thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/36/3649\" title=\"picture 8\">",
"      Erysipelas buttock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/4/78\" title=\"picture 9\">",
"      Blepharochalasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/5/3156\" title=\"picture 10\">",
"      Granulomatous cheilitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/28/12739\" title=\"picture 11\">",
"      Granulomatous cheilitis 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8105|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/8/11403\" title=\"table 1\">",
"      Mast cell mediated angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/8/21644\" title=\"table 2\">",
"      Tryptase and histamine collection instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16813\" title=\"table 3\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 4\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=related_link\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20981?source=related_link\">",
"      Idiopathic edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=related_link\">",
"      Pathology and pathogenesis of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=related_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_17_15642="Epidermal basement membrane zone";
var content_f15_17_15642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67891%7EDERM%2F86896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67891%7EDERM%2F86896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    The epidermal basement membrane zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrastructural view of the epidermal basement membrane zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 536px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIYAaYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5d/aqjhPjfTDLJKm7T0XCDggSyE5r6ir5+/aDvrWDxjZQTwxvM2nqysThv9ZJwPyoQHz8wtwyyGaXy2OFRQdqj1ojjZLeW0sZS5LeYJm4DD0+ldTLHpl9Av2WBbO46SqzjEg/pWdcabZMwTT0lilRCDubgD29aYGVa6pdw2SwsqySOxSMKevqTUunaskVvG16ZijMy7Rx83pRJF5NvGwjjlbcfMkQbTiqoacR+YYw0JUlVYfKD659aANKCZLiQtI00TxZI8z1qXTr2ZA5Mlw0m8nDHANZ1hdBJJLWYxMkUfMhbhyR0/CtSCeJIlNoDIJYwzO6ZUY7CgC1/bl7NZoJZpiJH2lS/KD0OOlX9P17+z/LBBmjfK7yNw+vuaxoYfMh3Lb+U0n3mY8Z9/Slt7VbaGXzsbYSWVjnZk9l9aAOsttYtpiqz4SExMksDcZbs4qj9subVDdRKC8cZBEfIYHp9KzY7SUzpcTFWRos4PUelVneQNvkVoSMMVOV3+w9aBHXC6mu9JtJScvCQWCtht2enuKv6clxIkw+UJJLmWKWTov8AsH1rnvDchjmktLyTbuy8bOoIiJ7mu40eG0lu4mvQxtY9u2VeA0v0pgdI93BFYNbWNrcSuq5EjsG+uPpWtBo1q2mxwzkb3QZKr8u40aXDavaGSC5jWXft3YHy/hW1uSMxLJJETGMlW+UgetAGVG95pgiBCtbqMFlOCT6kUybxNDNbO2m3sQYcMZFJwB1x71Lql/b3EvkIzRDGBMBke/FcHq6NpUkcdxIRIH328yDarr2BoA62/kmaF5UurmW3m2gNcONo/CnXkCx3kcxumjjwFV3bcGGO3pXNTa3ba1pkkMsSySpgSQI5GT6gVNqlw81kiXPl2kUOxYXc8Bv7re9AC6s8+77QZ4Rb8MqohRpCDg789BWzplxJI90bqE/Z4cMqBcFeO1cf4iv71bK6mu7eOSfb8sayABVHRvf6VNpHidrnRVs5beV5dmftIbAUf7XrQB1a6nNbxPDdCG5tZY2cTOpyD2X2wKgTwrE9rFLpsi+X5e8KZD8xNcTZeJdSimksolW4/eeYG28bf7o966bwxdai97cuY3RZJA6QE/Mq96AOy0zUWRDaXi7Vt1Ck468dc96fcpblo7iJo0BO7cp5Y+1R6hpctzcJNcTMdvyqnT5COc+9U7/SbZbKCzaVsW5LxyAc4x0oAtWfieFnlhaRGnU/6oHBC+vNSRX0t6CWgTyEyxbbk4HY+9clL4Xt7fVNKvIfnjdsyzFvmk9BXbJaRxxAx5FumS0S/wAR+tAHO6lpFvqBMMPmxLKpZ0ibax3dzW7pnhmysliKKWKosfPOAKdplsk+rzag0DK2zywS3IA7EVuK5DMIyo/vZpAMSGKOPMSRpjjIGKoa3qy6bZPPIchflG3khj0qv4mvza6c72ADzTOqq33lY+lOs7KS5h8y+aNycHy9nQj196AOc13TL3WIrS5lnEC+YCyg4DegI7V6/XIXFtA6lZUyr/K/ofeuvoYwooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfM/wC08kL+NLEXErRj+zkwwAyD5stfTFfM37T1tLN41s3QqFGmRjBP3j5svAFAHkQjhmgMiSZmTG/eODj+tdDpy2ks0IkkV7mUbCrnCr6ciuWuILuys5oTGHDkMqMuNwPqafZSXFmzq8aqzY92z/simB1VxYWqzxPbytM6FlkjUZGfcelU0SW2kRjAkm848sqdp+gqPTbt1cDYY92WE4kwx+o9a1ZYFvColuLtVQ4Mp6/QegoEZF7oFnfwu9qEt2WX/UseRn0algsr3Tb6HG7yIwAIgRjB6nNdTDoKXSO0DeVvT5REchD23j3qabQbq1sY1vZoJJQv7srxx7+1MDl47W4nmKozyI79X596tQystiizpI0b7wFbBBYdOO1bn/CMapFhrNVV9yAvvyqk9wKuWPhWSaaadn3SQPlmZu/c47UAc/FrNlbvEn+jgiICUgff/wBnHY1r2sVvrksbqkclvGCqofvD6H1qS28KW2qXkn2u1WxZpsK2/JI9R2GadL4QudNuSbCSRYo5DJMd+Tt7dPWgCgfD/k3ltdZZoZQwXzRjcegVv8a04tLfyLVZlmV1bO2NiQSO2faks3NlEUv3lWLI2pIMgEnsTTJ0k066eYyyrbR53gZJBboR7GgDQXdLO0tg5W6BMcsOcox7HNWtR0rxHFbRyf2ixT+Ioc8+hz2qlbm3gAlLja5UllGPLHuPWunhxqVs0d1MrW0JzF5L7S5/2hQBXstVnh1VXuXFtG0Qj2hdysfX2NVLzVDrBWyvbbZZwkyHeASfQKexpt3L5t7FFJL5cbpsVlA2nHIGfWsHXI0ubDzll3XBb5YvMwAw4H4mgC1H9nfUYTBm48wEQwwH54mXufWm3l2b02+m31xvkQmVUkXBc++O4rC0oXGkxyaiibbyIgZY8J68Uy+vf3MqzwCGWVfOEyPlWOe1AHWanMklrbXFzsjhQi3dHX5kP941at0kspAcqyeXs2MAwI9wK5Cw1RpNKu59UJkMibE8teXPbI/rW3oqzyT29zZSJHMECbJpMbx3x70Adhp9rapeCSaEO5KkTqhAi9FFaMc/2bV7lo2jupQwAZP4l7gn2rHvft0xs57RzCYCWkij/j7EnPU1fSa0spEhaaSAzpgICNxJ53UAdbHeRXZKIzHLBXU8Ffao9V05bmylSGeWF34yvP8AkVh20DWcgmhujLbyIWZ2XLEiltteuIL0xapAqxbQYZY0PzDPQ0AZur6Vq2m2UEdrJ5sEbBiiDO33rSXXXXQy93ayGMIUcRn7p9q2b+5jvLKeG2lj3OvyFT3+vpWFqhgFxaWbYLrGZSofIDY6H2NAG34YvrFLUYu1lJGQZDtbaPX6VbubkXjmK1kQiT/WiM5baehrkp5bC80S0to3hinnVl+XgJzyM+9JaQNYokNjMd6EISTkfQGgDs4rKCxsjFK5eFjxu42ewrFg1aNrub7EWkEbgOEkGPw9awpbPVVuZ7+6+1SwwH92ivk7j/s9xSS6lFpUM91HFG1wNqMVTG0nqQO9AHXLJd3rlXQtbvlTxjjtXfV5TFrl1MrtEvlrsDGSZcD6AdjXq1JggooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvln9qsXA8e6XIpxbJp8RfBwwPmy8ivqavmL9qCGOXx7pgZgZDpqbFPQfvZOT7UAeQXF5qEEQYy/bASMDqdv1qxca0t89pcyRIjBhGRgB8DqaWSGSwiG7BjAw7cZI+lETQO0rSrE6yMPIWRMEEetMCz9ohRYjYlJPKdsKf4c/3vU1vWiG4Np9rdvtjZaRo2wir2Hua55pkZ512LG+5VOxch/pU1nM7K5Vh5ecYZflU+goA7XTIb37W/kOZbXaX3Z2lgOo9zVrzZEuFUqIYn/dbbjoR1zurjNP167gslhuLZd6ylgC3IHtiuptdYur63ju5o45IQRlGGT+XamI1LXVJLi2vrC4hCRQujRMsnK+5PpV2y1dEhvobQrtm4klIyNmOq/jXOSR38Nw4EifZnJ3mROMdqn0q0mkt9iB1EyHd8vyqAetAHQ211BqLTWM5e3lCRoXmXhx2I9K01AsZDZ2peK5dwqlnDK34fSuVeLUreyuEnt/s8Majy5m5Mo7Y9Ksw3L5DMr2rxp5ruyhmkOOMGgDsbmz0zUWNndQpcJIQrsh4Ujv7Grtz4RtA4USyMdgUqejDtXmcuri2Nxcs0kjzRqbcp8gBB5zXTaP8QpY2SDUklMKgZmXDEt6EelAFjVfALyW0kdtOI1b5sY+97VyF/pWpaROTFG0pWPygMbVfPX616dpvjfR9WaW3srvMicsrrgj/ABqhrviLTDJbJEvnB5CpVPUdiPegDy211Ga0vGgNrJFFGN0aABgG74Jp39p21xGsd1CGuhMGKqmNv4966XxFp0GoRkwWLCSP94khYBF/2MfxVxbeSs8WoXS4ij48oHAdqAE1e+sZpDdQPIXDlWhJPzD1xWBcS3moWksGwgCUAdgFPYV0SQW81zJPbTo8yKX2MoPl+3uKaZ7C4ske3V3uS6q6kYVj3I9KQGPeGSylSJAzlBkMvynH901an1Py5II4wqQp+8Az824jue9Wb3DSyyXNukkeeM9UXseKdDpourO1nMXLFh23SHt9KANfTfEjybrS+aVwqgxlWwF9efX2ra1eXSltftSwtLfKFRJ0cnr0NcfPbRb5PJGxowu50OSG7g1aaMQSo0MzSwyEOf7rYHQgdKYHYaZrzy7oona4SKMoUX5Qzjvn0plt4slTU9stuzxmICMOf4845PTFYyaotpCpjtVgaQDd5Z5jB9fWm/bhFcQRs8c0J/1mF/i9PrQB0TTajdG4+eSGDcPlUgCId+fSuT16R7fULiO21TzFPDHdgBf9k0TfaxHctcXTW0cpOSxzlO2AKytYghkaHypg4aEKjkYwaAOn8PzyvYlUgkMRDEPJzgjowPpWja3mqvpgjt5RbtA25JTzv74PrmsCxuGgS1sAzJKDkoSSpbHAz71uyw3F3YWa3cbKq5S4jjYFV5+97GgBq63rDv5811Ksyod6q3yqfULVm01KCKBIb2OXUDH0kR8ZY8jj1BqxaeEoQHL3Jh3qJIZwc/KK1JIdMgtoF3Gd0bzNiJjePWgBLO8k8uSS+hWBwm3NycLLn+H617tXhhgfVrmxKKIdHRyZIH+Yknvk17nSYI5G98VXtr8Q4PDrabamxfTpNSe+N4wdI42VGHlCIgnc6/x9MnqADUb4oeHJ9EvdQ0qe5vTDp8mpQxmzuIhdRIBkxs0eGALKGK5255AxSav4e1y6+JUetQRab/ZQ0efSyXunE2ZHR9+wRFcAxhcb+jZ7YOafh9qMug+EtOlurRDpfh640e5dSzZkkghjDIMDKgxsecHGOPRDNy3+IehnR9Pvrr+0LeS9UmO1Om3TTuVRWcpF5e90UMMyBdvvVl/Hnh37RYwQ3st3NfW63dulnaTXJeJiVD/u0bAyDnOMd8VyN54K8QXv9h393b2X9padZPprW9pr95ZxyxnyyJRNFGrg5jOYyrDkHdla3PBXg+50HWLa6ZLKG2j0lbHyLeaWXbJ57yHDSZZlw/3ick54FADofin4Sn8jyb69k+0Flt9ul3R+0Mpwyxfuv3jDPIXJHpWhP488Ow6Zp1/9tlmh1AO1rHb2k000gT758pEMg29Gyo2ng4rG8O+DNR0238DxzzWjHQ/tH2nY7Hf5kbqNmV55YZzisJPhpqlpHptzC0Nze2zajG8EWsXenKY7i8a4QiaBd2QMAoVKknr8oJAOt174gaHYaOt1aXhvJbixe+tltbaa5zGBxI4iUlEzwWbaOozwaND8Xxz2dxc39x50kFlZXM1nYabcSywGdSf4d5kBIOAq5UKd2eo5y18D65otpcpoNtovmX+lR6dNHPe3Gy1KPO26NmR3lB885DFTlc55wGyeBPE1ta6odJ1O1trm5tdKtwY7h4mdbYMJk8wITHuDYV1BPsKANjVPiho1qmkyWUN/ex3mptpk6pYXImtXWFpDuh8ovu4XCEAkMWGQprWk8eeHYtVTTpL6VLkyRQtm0mEcUsgBSOSTZsjc5GEYhuRxzXDad8PvEdjJJqEX9mvfJr0Wrw2s+qXNwrRrZm3aN7mRGkLfMSCVI4AwBwJ7n4d6jJrF7I9raXVnf6gmoy+br1/GkLZRmT7MgEcu1kJViUz8uV+XkA6n4l+KZ/C+m6cbKMm71C9jtI5DZT3axA5LMY4fmchVOFBBJ78Gsy38aXn9qeH7FLyw1BrzVpNOvXTT5rQwlLRptoSSRiGyFOTkYbbjIJro/Fui3GsTaA9s8Siw1OO9l8wkZRUdSFwDzlh1x9a5JvAWsDX1v4byyiC+ILrVlbLMyxyWRgX5SuCwfkjOMd+1AHTWvjvQLiW7iae9tZrW0e+ljvdOubV/IT7zqssalwOM7c9R61nj4p+EiBtvL8s0P2hEGlXZeSHn96i+Vloxg5cAqO5rjrH4ceK5rjz9YvLWW5Gi32nSTyavdXZnnnWMCQI6BIUyhyqDjjluMdrB4VvY9YtLppbYxQ6A2lMNzZMpZDkcfd+U89fagC5q3jzw5pXkG71Ess1st6Gt7eWcJbnpM5jVhHGf77YHB54NR3fxC8M2urT6dNqEn2iCSGKZktJniiaVUaPfKqGNQwkTBLAc4zkGuFj+F2qWdhYJGtvfTNollpV3H/bl7p8SvBGyFh5A/fI24/K4UjB5+Y42ZvAGof2F4tsIJLCP+1ZrN7YB5NkawwW8bBsgkcwtjluCMnOaANKz+Jekm98RQalDfWMej3xsjO1lcPHL8sWCHEe3ezS7VjBLN8rLkMK6fw/rth4gtJbjTHmZIZWgkWe3kt5I5AASrJIqsDgg8jvXD6t4Q1yRvFdnBZaHqOlazfR6iovLueCRXVIEKYjQlceTuWRWyDj5TXSeANH1bRdMu4tau2nea6aaCFryW8+yxFVAiE8oDyDIZssBjdjtQB09FFFABXzr+0bYyXHjXTZkBYJYopUDt5knJ9q+iq8o+KNot94qihlkjWJbJHaN1yZB5kmQD2x1poD5+uIgmnMYUSZiTvcfeXHqPSm2Nh9qtTJIsZK4IVh8zN6j2rodV0e3SFhpGDGZCzuJOcZ5UUSaZdQQm2SzlMEqh4maTHzex7CmIxrfT7X7VJ9vcpGw3jB289vpTLvTVe58t53SAAMhAyuT16Va1PTbuG1ijjUll4laQ7hyeBnvVOS+ls7eaxmAgdirD+LHr+dIC2NKnsHjR4PtkE3IdF+ZeOOak0zS3llmjhneIoufLLEBz6Z9am0fWZJJUjtjGyfejYZ3ggcgj0rbLW89tbTQJJK8sgeNU5Vf7xNMDJ0nU9R0N4ozC88RUnEwLAE+voBXY6P4ysrsxWl4ggkk+TzI1Cxt659BXP6Vc3VpPcb2e80/zWjifAYse4PtUGo20WozXhkjEIkCpB8u1lPpj3oA72+u7GSBrHySsECM/nuchu4A9azX1Kzt0tp2gCzvAAquMRjPcn1rirYXdzcBJ9QYi3TkdQSONq+pq7pd7NFDNb6hEbucNiNZflyh9PcUAdFeWmi3VhcxwyeXMqEypI/EhPdfauXh8Kx39qk9lJcJGmWcg88dsdTWXqN9dT3piRW2REp5gXBA/wDrU3T9a1i0t3ZRPHHI20Mp+8R3oAbqmiXOlbWjlljlzlSw2sc1cs7OS1vW82dHlTDbt2CcjrWHcXer6jcyzziVoywCF14PvmrENtqEMRB3LNESEJXcW9aQG+Jr21WLDLEIVJVN29Wz/ED2NYmros0C3K23kb3+Ubt31JFRpeXe61A2yxICVUpjB9T60461PqkJt5LYKU5aRMDj39BTAzpF2XQkiRUKrtHlnBcHr9amjkaO7n+xK3lMnAcDLHHOKmu8JaKwtJJGC5VwMeSf6g1Tj1VbW5s3aORiEwrNyFakMmTVkGmtYKPsl/Iw+cjIdQehz0rY0+6nluAbaGHasZWQvncx/vD2qvIsF5bzTOsP2uRQEZOR7jHY1uaa8EFvaPcwSRC0Uo0ZAJckcGmIdBd6dBpM6pZtb78fvT82X7/QVUeaRdKmlexW2YEE7Dtye34GrsBsdUtoPLjRZDISN/Hy+w70wxXTMDJbzb1GZZZh8pQHgbaAMo3txdtcyNEYGMQ3ZG0tj0qTS7yEQCO4YpJJ8w8xcA+p+tdDfadfTONyQpbthkKD5SB1ye1Ymq2raVaG5az+1SygmIKcqRnvQBYlszcXNvBZ/wClqJAchcjnsfageGLmG6ZrvazPIVVVb5VA9PSuj8E6qZ45bH7EkF0ig7oxgYI+7n1rs00prq2H9oOohP8ACgwSfc0AcHLpT3kCJPtZy3LKfugdMn1rI2alpizQgcqS23rle26vS9V0nTLKCS8aR4odoUx7sDA7/WqV5cQajZW5tNMleCVDuZj84x3z3HtQBxtzBqeq2cP2O5P7hQSpc4U9waYG1CzSJJkYQhCxlD8g9q6STw/f3BLaXsjhnAd42yMgVBcaVfrbEwPtnyI33L8gUelAGcdaMSRx3VyHjlGEFvkk+oPpX07Xyrq2mixltJriPbL5mFWE8H149a+qqTAKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxn41xWU/iOz8+a4huoLQSK0QwCpdxyfwr2avL/AInW1nceIYheySIfsalSvQ4d8g+vXpTQHmT6TFssXeeSaa5XzFaFRyM45HY1bu7aeG2extbhtq7llil4KqRn8KrW1uPtV+9jFcBcYimLcMPTHapU02e0eaW4e4kgktciZvnJJ6gn0FMQ9P8ASLHTokeGFTkLvXI2qP4vWucv9NDBr4W8NxLL8jlcggDoa249PsrpJ0+0kTmMC2w/yKPRh1zWdc6g2i6yI71o1tAiruj+b5iMZoA5e7028s7uKSzTy4liMkbk4KtnnNPtdYuYgklzJtkR87QMbs9TgV1un6vpp05bRoz55LRgScrt6lye30qtY6HY3Uc0UMuTuBimZ1Utu6YJ7UAUP7Rivnt40ngRnbeQo8sxkeo6VpyaxA42gwXixyH7VIfldUPTB6ZrE1Hwve28ZluokCiQjzQcgHtk1RubO9TfbOoWJ1zI5GFwO5oA0ryytD9olhZ4lCHysPuJB/ix60yK7gMVv5168r4UecODEe1Z4uLxnjjtpkYR48oqdp29xzSie5ZGuYEjigmcxsXXcAR/WkBdvdQmjvDP5aXUKt5bSodnnt7gfzpLHxdaQag1tq2kyRQyAhI87gp9azrfUGiMIRoZXd9jhEwB65Fblve6Vf2Si+tgPs58pXLAMW/ug+nuaYHPXuu21yyK8rfZt23ykOAvPXmll1smdY42QxeZvEhOSRjHJ9K3JtB0prUHyzGFkztYbioPQt6is+60a3hjWOBleQ54xkewPoKBksU1xcmJ0jEaq+116ll9celbP/CMfbdMa8sIXdpG2eTEQuwjvzUOnWNrBaSpdKWvQ21WLkIgx0B71Lp2oT6fbtHaTwyNnzFUnaW9eaBEkFtqOn6VM2oWwitQcukvJf0AasbXRaXkkFxBCkJki2+Xt3AN65FbV7qWpa/cWcdlbC4+zKd0Wf3crf3WqbTPC8V8QkZMF62SLYZ2xeoNAHGDStZtHiVrfYrHAYrnf757VTup7qzjMd5M4ldjtlUnKex9a9d0yxutJz9pP2i1lQw7fvqrd2Fcfr8dqzrINrLJJ5LGM5ZB6kdjQBheGSIBHDcMJi5HksTiTP09K7RZplljEsksZ35uJI23BVHRDnrXJLpstpbo6ozW0RwH25kbng+tWo7u5uWlMmZMMCUK44Ix19aAPSLO70RI5YpJwGlImLTH5BngYrQ03RbbypfNMcqFm8oKRwpHavJvtdsNOmhdv36yAIj9AoptnrM8MUsVnPJ8x4DnkY7gelAHXyWkunataahbWh+zRsyyANny8dyK6pfE0ELRTTGaRnj+6FwF9zXnM3j24nsoYJYUjigIaSZF+8enPvT7HWI762uYrmNw5P7wg9s8fSgD06OS212JopZo1lTsF5I7A1ENQis4f7MgjEV8mSAwOEz0I9a8x1bVVW9iaxmYRyqIw5bHzDqPpWxBe6hfSRWkBaUS5SRy2CgH91qAO+03V2NylpPLi7XLrhDtZQOef6VPcXNzqKJ5FuDDHINyE4Z19QK5PRdVsLHb9qlLPGphPzbt7dxmu50/U7GZkaGVEYgbXD8MPTPrQBnt4cAuFmnnEtyXLW7FfuZHAIr12vOJdasjcSRTXEcbsdsYYYPHU5r0ekwQUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXIeN7C21CdIJspO8QEUw6ocnmuvrmvE6n7bA8UKSzbQqlmwEyTz700B5fJ9t0rUk0+6VWheTKXDLteQjjJHpT7a1nhtpYbASCSCVygkOVkB5Ix3FdbrVot9dW8bLLJNbyKTngkHqAfSq+mQzHT5muoSl3bTMQAf4c/KSfSmI5Pw5c6VM8g1Kzihc5Mnmj7vPY1U+J2h27aXHqVlGqQxjDhFBUjt+NdDq2hwW8jajKUlmfPmQBflbPcVm6a8snh5La7yTctJ8kq5VVHQe1AHlcsaXAA0t9sG5XmyMt9COtamjaLHqOLotGgkdjKJThMDoBjpXJ6ct9Y+ILmGREiGS7uDneueAfau+8K2j6pJDunNvCdytGke4SE9CfQUAT6j4f1SWwkRozNaqnmOVlOzaO4HsKxb3TbvVLi3kgnWSxnjDZ+6No/gb1rv7See4+02NrHF5b/ALkwI5ViRwWOexqs+iatbn7GEggt7cZhuVGdmeq4/rQB51qGg3otgkluwcyYikyBnHt1xWK0t6FW2BEflFpViZeMj+L3r3Gbw+t5Ckt5IFlZNpkc8gkYyv8AhXJT+AZVMcUjzTmEOzTHHzp6Z7YoA82vbOZbe31BJBEZF8wxKOc96pAF7lUZVVSpwHPDkjr9a6CSwhtre4nKSTWqTYRw2eP9oVjXVrHPCkiFTFHMdjHnbnsBSGTaZdXlsLd4Zi3knacjP4+9bYmgvbqVDcopuDkpGvzse5rlLi21A2bw2ofzAxPzAhtvr9KteH54ItRtJL5ArIpWPJ+ZW9T60Ad1ZTLd3kFrJCpSPPlSQemP48+lWl0KFNLtvlWVkndwqncHXuAfSsDTr2S/2p5rxhmYMIyAM9jjrireh3E+mRTRXcePKbaSjkMwY+namI1r9JtHczaQrxRbllZE7/7JroZJLS/nS6tClrcvFmWUN8wcDOzHqelc/rk721zGU2Lbwxlldhk4PTf61k6nqVyqPLYPb5CCaSEjIY92H+FAHWC9g3TaoHnt5FiAjtpMgb+hO3vXP6p9l0qB9UuYfJlucKqrH8pf3rn7vxPPcvIollIdV25BBQ/4VR1e8vbqygtNRBMchyXQ5Bbs3tQBv6S1rrUEcrSyrdCQxHyjhsY6AelWpZjY2S2oAgJDKHf5i3PBPvUHhdo7CK3nEKz3C5DuxAOPYVKVtpLS5vNrzXEsvmpE/IQDrz2oAqzPpr3u5rX5E2i4kfGGA7+taloLKy1QzXaQ+Q8eIXbA5PTH4Vl6k9jBmW8toVW4UPFtOckdj7UpgttQQairKXjASSMvnb6FRQBd1G3svMJyUtUYZiMYO/6VRv7G1CR3dirW80uVWJ2+9juada3kEiDejssZIDKPvsapaoLmPVLeFy52LwGOQS3QE9qAIjZTLYrJmQzbyUBXK++B2NXdC/tSUxmJJjEFyzbuFbtu9qt263VjOsJjzNCxdxIcq4I6g+lamjNK9telIzDDwkkanAYZzwfSgDIv9Hv1S2m2rFIJiJsD5ST1I/CpPDuoG1drcShxGziIHhWHrn1rWn1qws76X7Qs0iBVZlwdoPTj1p2raZaLZ21xptxG+5jtCLwwPNAE9tqTx2Lz3byuQA6rcLuXb/dHpX0tXxvc61cS2sFoJJFlEhEsaqQvHqTX2RSYBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYWsurXrx+V5jLArD5f9pu/wCFbtYniIuMFQ+0JlgnVsZ4poCghlRxIiMUOEbJwUHqPWgx7XKuQ27ggj73tUDajG8CeS+ZCMNGx25J/qKts7RIWOGVQAoY4LNQBzOq2+oShEsYwBBLumEg5ZPRT7Vylxp8un+L7uJw72GpQiSN9xwjL147GvTXdjIfNUBsZ4/iPpVe5RIY/tEmwr91kcY6+lMR4/8AFHw+qvZa5p6vG7/K3TB4/irD8May+li0aaViJWLQCPpK/Qr7CvWNeaxvtHlt55UVeRvPIVh7e/SvE7EL/wAJPDFaJ5CRSERbxuQEdePegD1+OW1S7l1O6imf7OAPN25GSOR74rXjvo7rS/tcayyJDlgVT5mX6HqKzvDOuW2qtcKrPK6Koe3OADn0FV9RsL3Tb6UWeoKY0kWUmST/AFY7pjuPagDW0OGCYearB0nfeFJzgfTsannt3W4niuPKjt3OEkDZ356Cs/T44La6mvWkNvJKQ8zKPkb0PsKluNSD3Fqf9GaAyEDb824+1AGDq3hmXTLW/Fi1vb2rIHKhNxLH+6K4nxH4Zt00sXG1vPUqyrGcEE/e3DtXp/iC8t7vTHSJ7mFHbEnl/fiI7Vwdnc6adU1C3kfMNwvlMBlnJxwSKAOa0m1k+3vqFmkt7FIfIAbI8sAcknvWPrnh+HUGivrAuFEjFjjBUjr+Fdtoskuj6gbBp5BaBw8qovMgbocdgO9X00uO11O7i+1wzLeEkIw2qR220AeSLDdQRRsHIJbcrKMHPbPtWpbag8kIa4uDFMrksAv3/bPeusn0tbJ2Z43himk8ogjIKdyM9cVzGr+H42tReWUkkthHLtXGTk/QdqAOkkWLWfDU0MP+jTQKG8xj/rF75Pr6Vyeh3L3N8tlqCv5bNhJtuGjXoCa0tPvMRxwFk8uGQMZJv4m/uY9BUt/qka6u1zcI6xLiO5IAAk9MewoAwbfR57G6aOWed45GYLOfmxzxmugsdHitiizx3PmvhpJM5Qt2GfSuqvvNttFV5IIVikIIVFyoHZqk0vQt+mTt9s8+O4UEujfJE/YFaAPPriAS35a1hlkk80wyLzhf9rjpUlnd3ViC0ySGEyFVhHCsOmSfSu403w3c6XfzSL5izRASS7Gyk5PtWT4rupI9Of7VZxCaC4BbYMYQ9fwoA5aeX/RLtFDMm5Y03cgAnnBrV8C2UYu7mOYRuXT5V9h6H1rD12Tc0iaXDJjhyuc7fp61f02U2tsLMM9pNIRKWbnj39KQHTRRpYG6LRK0v8CqR17VUh0+IrK2q3JGqxfvk7DYei+9LZ2x1PxJbxy7xCzbgVbAkOOADWy/he41O7ImJkulcsJCcLtHRM+1MCu/iKOOWP7VYl3ddqhWGD6fSq19LfT7ndXa3GZNicL7KfesnUtOvtKuxBqAie+eXzsA5CKOhx9K1vDmsWRt76W8V3hlyYymd2/pkCgBusfa9U0yC5uk8uWBRGI0/hTuWHepPAekJbSSqb2OSdo2aMyNxsHJwO1dYtjp40UEyxPIsYO7PzY64b3rgI1nt7qOWYtDbSsUUKADGD0596AOl12DT72xkuLu4ULcSAZP7sAjivpOvkK9u57949Pum8yBDlItgDFh0b6V9e0mAUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWJ4gl8uSMbtoZeSOvWtuuN8bm6e78qAKqLBvV88lssNoH5U0BlXupQpehGKbW+bJTjd7H0qzaX0l1a7FgD7T5iSKdy/h7isTR7GXVVK3qOFCAZ3Y2sO1dbaWyWdxKLfYpddxB5DkelMRGJWnjjkdPMQqckNjP0FZGrq97fW0Mzn7IQHgkU85/ukVqNZyysShaJlOVY89euRVgwwkwsULSKuAwG3ApAeZ65bQ21ndw2lxK86v/AKQxZdsa9d1cQbQ6baHXDGkzXEhQ7GLde/Hc16L8QUtdMgd4oBvvwYZAq7uPU+g9640RIY7axaPyNLQgwyRvne47n1GaYFrwHHLA8OqwCPzN5t/LAIB9d3oRXbataQ3luZ7aDfOjFpA4OZgPQ1zWrTy6Xp9ulkTGk77ZVjiMi57s3vWjpMt7b3/kTXcaRRx854+XHAbPSgCOHUmjt5rF7ja10S4FyRmKPHK4/lWXvnxH9kYNZ5ACEY8sj+IGsyUzyeNbZpRCXVCztKcbvTae9X55tUmtNUtrqNW6NAWYLjPUAjoKALMOqy2qrcozm2SfZLJI+7Jb27isfU4LyPVpb77PaxXQk32yZ2kqf4s1T0zWZUtpdPv5baBYVCJhfmY/3SPT3rG1/U2urVLUuwAJI8wfdQdArUAXrm6lgu5RsDXSqZHQudxz1GfQdcVDq95KotBeNDcwrtaNlYrsX2I6muPg1CV9R/0m6YRY2OpHUdiPWtu/u1jtbGS0Q7kBIMi/L7MKAOqsNXM8Nzeat5b6epMEWw5MbH+I9xUOn6C6Wl5Dp108sZUhkPAI65U+tc3pmrzxabcSpFHcfaXHmIyAbsdfpWtYeIrZbC5RFuRMTkuXGMdl9iKAMRLfyNRa32AgKWMZf5iR711GsaR/atqs+MTHDMCmF2Y7471zV7qDzzk28EdvKeI5pPUdyanTUbyWyWETTJ5jF5dz4V/UL7UAWLHW7iDTri2kn3XH3Fgl5QJ6j8K6bw7NI0NhcwXiW1orZEEaffXuzk9q8/hS5gSOWXYi3D/KpGSO2Se1d/4cmjXQBFaRTRC4d4WkuTkKvqvsaAOym1KGa8L2dzaIcp5rkZ47Yqr4jihv9ROmypEyMfMeTGcgdia5Cfzbd4Y1hkuYFfyFjCfNgd8jtWfeeKZluord7UwPHMVZg+4t7H0oAzru0tFvzdWlykTCRomO4bQAeOKgg06LUrh5pLkBV3b5QTyq+vtVXWvDV5q2pBoIULyOXMWNo59PUCu4uNHs7Pw6ls8QN0g2yhOGkxQBkeGtWb+1h5JiuhLtiVm4EJ6AqK9RtbzTrTTZokkRvLXc4APH948V47pi7dWV0SOCM8g55Udx9auWN1HfawhtdQlkMcpBWP5Mr6MP60AaV29veajLe+VdzWHKBokz5p7cnkUwQpFrFtYhU/0hdsVuuA0S4z85rrLeTSkiuLWSOe0M7CNhKT83Hb0HvXNXtrDY+InYusy243xsnIIxyufT3oAbPDHZlrw3Egs1GyaEt+7LjgE98VRuLhJrrJvCRlUOVARD249Pet157q701RbWlsi3ByUHt6k+1X9F8MvdTCbUbVI2dArGQZOB0x2/GgDm7XwysF4b3UboKjsfnZuo9M9jX1TXjq6BbwAWV2iXWn7gYlPLI3Y17FSYIKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmvElg91qUNwylo7aLeihsb3yeD9BXS1l6vA08iopUArzntzQBxMt7aRWs0ouHsGYYWRlzg9+natHwtcwXmmNNE5dkIYgnKg+qn3qTVtKZZfMgRfJ43JjJJ78elV9Ht57QW0MswxLI2ZETCkZ4GKYjeZw8reUSZCA/wAv8qbNEWblsqzZIIxioJiqMzRvnBw+ev0q7GNzPIGyWUAZoGc9r+nfaY5XWCKT92yeXJnGT7CvOfDWmXF242yKbawmYNIEwN2eEQHoB617DMjSA7co7dz2PqKyLHSobIvLuZvNb51IyH98UXA56a80yxF1bTzKXYEnylJwewPvWBd6hFPrUcYImt5EVZCVyWPvXW6rBDPB5gtCJTL86jGXQcZ+lYVxo7vE1krNA8jEwTR8MQezHtTEcz4liVPETQvDBOoi/ckOQEHoTTra+Uxk3KRxSKmZtuWU4Hy9aZq0pjlj00pIFiItzMRuOV7/AO0KyUVt13BDcxRvysjxcbVP8RBoA5vXZw1zdahF8t2SN8iDBJ6ZwetUbm4adI5JCrQopRsDl3I7itPxraXFsY4o1WSxhiVhMAQzg9ye5rl9Ov7eNjBIsjJLlhGD0PrnsaQylIonni2wiQRDb8zbSrD3712PhwrrFstveW+26i58tjlTH7elchLNbC8e2DsRt+dHOPmPQg+tU7K9ls9Q3u82xBu3KMKB2yfSgDvLbSEksJjBDvg3/JPnpz93FVRa2dqb+aRRu4ZS74BI9O1R2V9ONNe1V5I4ZszJtHHPWsy2hMtzfC4t5JLTyAuT0Rj0wDQBqnUba6gk/tEqUnZUMrEAAegH9a2bdpp/lu7WOKKAGOFmXcAuOK4K6t1mW1WNhEYv3cZccH1yPX0rZh1P+yBcW87kwS/vN8jEkDpkCgDq7JjbW0dvdw+Zbv8AKw6mME/epZL7JltbQzi1g/dyGT7wX+8tYsOuJHODzcxSFCjv1A9xS+IdXtZpx5cbxSzyqMryFx/SmI7vw5qLJb28k0bt5as8eBgrgcAn3rmhZNqkkv2i0+yvcTC4JRshAfUmsQJfB3YvJDkglRJjJ7YHYGuj0rUL1r+dbf7NuREaQS4YN6jNAEPiHSNW0jUEa2nMgkwkMwbBPsPSnPpd/bam9xdT75RbryWyF9ifWtzUddlinWD9zIocGNHXcEPf61majqMky3CGITwbg/m9AhzyoFAHNapqWy3NvHHGhySwK5OfUH0qj4LXyvEFzfXXyYIARf4k7102o+IdK1RPs91aLbvDGRHJHHj8xWbb6dDIBJ9sijWf/VrnBCj39aAPW7ee11LTPP0phMwbBkYZ2DuMGues9Pih8Y/ZpllmjuVAW4jUeUPaovCbXNhatEkYVfMC+UzcnP8AFgdcirscLT+IFEN1tsBOG+VhlT3X2FAHXxeG9Pt57iaSEtK7LlS3ysemcdqnGq2Vu9vbzyqJWk2RqCfm96u2k0dyLiOaKTMTbQT/AB/Q1BJYW1zJHcz26gw8pngr+NAFeee3R5GaV4Vibepc8soPOPavUa8f8XEfZQibN6Eglhyc9Fz6V7BSYBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVbpMyq3bGDx1q1UM4O4YJ6UAU50Vpowc+ufpTGURNncAp65HOfb0qwW4DSHjv7GkJyMSAcjp1oAoTLukQoEOT36Af40vltHcnBLBhyp6CrjDaQpA2bc1GABGyDg9c+hoAqMwM6qY8oTgsTjB9RRcKfLkEJHzcL/hVphsRY2O9yOCe5qOVQhOC2GHKqOhoA5LU9Ke8aK8kmMFxCwUrF8wVR6VhanLPHvto5pS5fzFmmwBIvfHcV6G8YRCdoIwScdT71w/iSNNQuLyCGSWCWO1MnnHBUjuAPWqEQ22lW2o3z3Lyo6lAsMWfli9s+vvXn/xRsobTVGaIZSeMLiNc7R74rbTxJYaRYxy6g4FqCHkEQJLoBwcfXtVbX9X02eGHU9IlU+ZHn5xglfTaehoAzfDzHVbSGyvow8kChlV2/1g9/TiuE8Q6L9nu5zZHywHbYGGAfxruDZDypbzTfNtIoYvNdSMElu3vWb4git59AH203DiRx5pXhY/TigDz6S08mxju8Ce4jBK5XO5j24qCG2kudJKwlGdg3mW7nbtPXr7Vdu5HsIC0Ku8qSjbD03Ds1V43aQF5JCVkkPnw4wyE+/ekMhlil1DSIZp7nLWyhG+fbj8utXdHvI7tHsisrQD5FdH/wBY2O+fSo7iyJ0qQWK+Wm87FC5DEfw+1UoLSS3ignVmEzsYUiQfcf8Az3oA0HguUKJbqr7V/fADOz0b3NPsYT+8nl3NPIPJy3O4euPSprOORLmO6v3W2uiNhwcKx9xUeoWwstXsZbr5ITnEu/5Xz7dqAKqeG7ueffp0pCxHOwZJ/P8ApWhZR3NnbTxXduQ0smzzP+eY9QKvabbX1neQT29+0iySfKUwBt+lbVtor37PNDes11KSGt5RjyyO+f6UAc/bOY5GuC8lwu3YgI9PWqU5MF7FMGZCwJFuASoJ7t61sXkAgR4EmAlSTfKq8kt6jHQVR1MSXE1vAzyKW+VZVxnP+FAES6jfi+AuJka26Ky5ymfSrvm/Y0dobh3nyMsOjD0I9ap3EqWjui/O8WfmAyc+nvTLa9gtblRCkjtvErhuFJxwDQBe1+0wsr7ZIJAEkVo+4I5AFZOk3Ulq0kQDTrINx3r9w10GsxzXlnb3g2sIyVkIbdtz3xWZ4YnaOXUbOT5ZJcFZCBuK+vtQB1+i66ZXSSF1jwyhc9ZMevpV6K8hhvLpoXhMTS7tgO1t57D15rmbfS3t5POkMiwAAx46OfT61vzaRZzQ24sCWnmlXBK/Nu78UxHoNn4hjGltI8sSXioFZWO7a3rgfyrK1TxpDFdTWdk7y3KhcsUyg7kisjUPC+qB0t7OS3hQEFpAvLkdjXKX9uLC8t5ridJdQklZGij4QY7k+tAHZR6vaz5n1FbkW5bc0Ttjd7j3r6Qr5Hlm1DV9PLzI6eScueBuA68V9cUmMKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUFxnPAGAOpNT1g67fpZ6hAGhnlZlUKI1JAJJ5PtxQBo9VbaQSDyO2PehSvKjAIGW+lQo4ZRJEm4ydR3rM8Ra7HolssjQtNKzcIh+YjuSPQUAbRIIU4BXHU1ER97bhmXse9R2k0d1bxzorCKdQ2G6//WqZSFUBdo9s9KAGY3RAbOTxj0NRAbNoyMgYPFTFgwZSCquOGqP5gw44I4B64oAr3YYwsYMeZjCgcVzfiBolNuZIrYRzkxzAthiuOcV0kpMTcruVgOPQ1z/ieymnWD7PHEzrL825c7FPUrTQjxLx88VxI0VnG5hTjjlUHbJHc+lVfD18b7IvrWyd2Ajx93ylHXPpXe3mhSQ6HeLLEPOkc4wMZGeGOO9eYxvbWuu3NrPh0cgnuQR3zTAvWervY6p5BKm0u5flZm8zGD27YFS6rJHqGuTxWEo2yHbcRlv3ZT+8nvXIa9JJb3MKxbvs8UjbpAOMN2A9azLDVI7Vo7qF5g0chCRfdLf59KAOj1Tw3LMbltPUTWzgL+/kxKSO4FcuI7uC7jCgb923aF6r657muisdXN+/nxtPCZRulMhwEI/hx9Kp67Obm8tpUm8uOYGO3EfUAf40hku65a+EEZ8uCc5KA5YH+97U7+zBeXEN/HKkarJ5W1mwAe5x3NQaZcWmpS20W6ZL1JDvR3CjA6jd/Su/t9CRvtMtosMcaKske9d+G74oA5jV7aaLT2ZoPkjkDONuXKj+Imud1VjdSw74Xa3WVfNfGdvoP8a9Yk8+1sZPKRZQw3SQyJ/q898e9clqmn6bq73U0c01tOkJ8xgPkJ7CmI4rULnybpRCQHfgsmdqjtjFbVnfslwbq5VQhAJ2k/MQMEt6VbttIt438yW4tzYLbiRyww6uPSqvnyLp9xIkCmJ5QqBVzuj/ANr/AOtSGKJUldnhfZaqDtdPlD+xNLJbzWd5aLb7C5O5nJDqnfg1Q06ya+1GW3hibYQY0h34X8vWrH2K7spkWR5I7lR5JYcqvtQBFrWqWpulUbVfBZcr8yerN9TWe2redbhWRCd3LKmFOeMg9zVp9OB1C5EeBHja7Ocsx9Sewqvq8KLGjGR1wnlphcRsTwCPpQBp6HbxQysJGkkLjADN296ikMiySCSFGJOcr2X0zXG6bc32n6jHJeRkRRZQuMseO4+tdZpF/PNtu5A6RHJLygfLnocd6ANrS9YnihFk6u0dwwdRL/AR0/Cus8P6TdT3f22e9ULHiWQK3K+gAHY1w9hdwwyyq7xzGNt4kY9Qe3416V4Th0lJlltpZIW1CNSIxy2B1GPSmI2dQ1aSS4bTdPaaWQYPm24+4TzznrXN6p4UlW5mZ/38xYOFJwg/+vXoapFHcQmzWNo/LIaQPypHYj1qlqrrgwNcD7WF8wbUz5i+hX1oA8c1ufUdK1u2ja2eKAPtfYf3bH29a+zK+WfENp5N4ZInzDEu9YmBI3919q+pqTGFFed3HjWTS/inrOk6i2ozaZFptrPBDZ6ZNdlJGeUOzGGNmGQq/eOOOO9cvoPxdmt/CvhwalNpc+s39tcXcs2q6jHpkQjSZkUAlDlzjAUKPukkikB7ZRXlH/C2bu80691PRfDsd1plho0GtXUk+oeS6xyCUmNVEbBnAhfuAcdRxmbXfHt3BoevJr+gtay22mRapFFZ6q4aWF5Cu0yoiNG4KjIXcOeGNAHqNFeXeNPFmr3lvdLo1ksGlWWu2Gnzaj9uaOZn+1wCRUiVDuQ7jGcuuctwR1Ifi/p83ipNMjTTGtX1Q6QuNUQ3pl3FPM+y7c+VvGN2/OPm24oA9RoryeD4uSTaNrmqJpOnvDpljPeNbJqym7jMbbRHcQGMNCW5II3jj3Gbmo+P/Eun3eq2tx4SsvtGm6curThdYJX7Od4Cg+RzLmJxtxt4+/yKAPTKK84v/iXJGNVv7DRhc+H9HMI1C8e68uVN8aSMY4thDhEkUtl17gZxUp+I4Hi++0hrPT44bKZ4phNqSx3pRY95mS2KfPF2BVyT1xQB6FRXm0HxJvU0621DUvD62tlqOmT6nprLfeY8ojj83y5V2ARMyfMMFxwecjlkfj7xPJcRWy+EbD7TNpp1WMHWTtEIOCrHyMiTJXAAYc/eGKAPTKK8i1r426dZxJNaQac0KaZb6nMl9qsdpOyTJ5ixwRlSZZAnOMqMkAHJr1i1nS6tYbiEkxSoJEJGMgjIoAlooooAKKKKACiiigArO1C4Mc5SLY04j3BD6ZPP0rRrzv4la9L4f1jT7hIyY5YmjYquSevX0A60IDpba5kvLbfh7eUEo8ZHJ9x7VQvNKsndLu9SSby12KXfJAz3rH0XW7e/urKGabN+FO9s/J0yOa27pbZmVpAxGdpQdCD3x3pgaNuSLRPsgUKnZj1/+tU0QMi+YyjeP4/Wm2qiK3hhQkRKNoX2qwpCqGGNoGMUgGO7dVAIyBx6etQSEK53uODlvp2AqRwSMo2GIJPtUXzqF3ruwvPGefWgCEzrMGEZViCDgHmqV0sbTZLkvgtGh65/wrQEXyqVYDP3uKqT2x+1wy/uyIwQTjk57UwPMtdubi2vrW01K/e4upZfkECYAz049BXjfiANDr1y05MbCVj83UH/AAr6duNMtkupb6VAJNp+b+7XhXxAtvtOry3sBzcEYCOgAKjuaYjybUtVvr6/jSOSSNVbLKBgPjvVFb1I9V3mZMshlUk/x9vlrrhFC/nXMhVkcbXx1PHRfSuSvBCgECRrLM6lUBGSjfXvSGbGhXUtvZJDqsouEdmYSdQHPIBrfsY7e6it/tQQXLLsQNwFJPDD3rh9Ont0t/sl55plGdoLYQ46j61du5opLWzTTUMTgloSz8sfrQBqSWT6LcXQ2pMPmZwxyEb1U969H8L+IbC00Nr27kle4QYMeMq7Hpk9q4XwtqKXyzWl15YhTb5rsASZOwzXSyaOXsp7q3DLEkwNxHEPkdfQeppgekaOx1+wvURYI2kTA2n5lJHAPtXB+IdH1Hw1aC9Nu0yINs7AhkGT3Het7wmZNPt3is5BbjduQsuS5PVWHtW2dRjl0qdLyCaZZ2KlscMfTFAjyNbb+0AWfcJQmRl8rKO3Ht6VqXmn3AsdPjuSYrWMAQoxwZHJ56dq6/Q7XRdHtUviBJcO/kumzBUnocdh71W1Wb+0VuBK1uFRdyMzYAIOAB/gKAONt7SW0u2vrJisEcpVTnkt3H0q0k8NxBMZUmJXJePbgp/tZ75q/q1tBbjciblVQdhU7C2OT9ay5724W3hYxRwMsR89XbiRT0AHrQBmkxOIpxKQWyWiQ/eUd2q3dRW8tvG7Xca28SZhWQcYP8uamuNFSSy+0RBI7GRUaJwfmX1UetZ+o6LPJqJdwDBJB93bngdGPpSGc74h1D7HbtGbdmZGwzDkOD2FWfDnmyBJ54diKhYQs2Rjtx61p32kX97paxNFJNbOADKkeF257e9SLouppHKdLtJnWEAM8i8YH86AKNvDHep9siaKaKJwkqKMEe5HtXoFxrdqkFobS1jinUKgkjbDBR6e/tXn114cvQttIfMgkmy2+I43E9jjvV3TNElUpcX1xPPtcPsIwRg44NAHpei67ezalKJJYorJhmUAYMeeN5PcmvQLAK9si2MIlcgfv2b7w7kHrmvPNJggsdQgkLJJ5zYaMsMBexPrivUbrTI5bW6ijmxLPD5YKnGBjj6UxHk3iXUrn/hOEgcJDZq6oQzg8+v1r6jrwC18NQaTJEskUd0wPKuC7K+OxNe/0mMx7Xw9aW3iu/8AECSTm9vbWG0kQsPLCRs7KQMZzlznk9ulYNh8PLTStP0630TWNX02eyilt1u4DA8kkUknmFHEkTIcNyCFBHryc9tRSA5JvAenyWWu2899qU51nS49KuppZleQxosqhwxX75898k5HA4Hddf8AAel65Hepdz3qC701NLfynUYiVy4Iyp+bJ69Mdq6yigDjtU8A2uoXkj/2vq1vYyX0WpSafA8Qge4jkSQMSYy+CyKSu/b3AB5qzb+D1tdTNxY65rFrYm7a9bTYXiFu0rMXfJ8vzNrMSxXftJJ4xxXUUUAef3nwusNRtrqHWNb13U/NsZtOikupYTJbwykF9riMFidq8yF8Y+ueg1TwpY6jqOr3k8tysup6YulTBGUBYgZSGXI4b983JyOBx1z0FFAHDXPw00qaSZFv9UhsLryPt1hHJH5F6YVVVMmULDKoobYyhgBnNW7vwNa3+rx3eqarqt/aRXTXkWnXLxNBHIVZflPl+ZtAY4Tft56V11FAHC2fwz0yC3FtNqer3dpDYTabZQXEsZWxhkXawjIQEnaAoaQuQBj1ztxeFrKO/gu1lufMh006UoLLgxEqdx4+98o56e1b9FAHE2/w9t7CytrXRtd1vS0isYNPla1eHdcRwpsjZy8TbXCkjdHsJ/AY7SJPLjVAWYKAMsck/U06igAooooAKKKKACiiigArx745JqEmoacNLulikRFLROuVkBZuD+Vew15Z8UJ9Ri8TQPbm2FpbWazHzBl2kLuAB7U0AzwoILHRrdpYY47q7c+fH1A+meRXWT7fssAEazrG+712+mPeuCk1i400m6ntIJr2VQkKocL065NdPo+qTyPFGIbVllUSOVk7+w/rQI6mHHkKVzg8475qQuMkKgOPU859Kggk4+XIYjO0j7p9KepQgFMZz1PrSGSnlt55APQGmFyC685ByBSheDwCc5b/ABFRyOUy/wApX1c9BQBHKGw6q4JwCWPc9qjkO8RqvyuTnGOBjtmnvJtjZpTlSfuYrGk1+0TWxYFmMrx7iduUT6nsaYFiUI2+N1BQnBI/i9q8Q8aLCvi/WzK7tBGiIrofljzwcjvXsOo6vZNCsCXPlz3HEPlLk5+leY3Vst/POg1IvePJtlLxiMkdNgz1+tMR5v4m0uys4YBbMt1auOdp+/n+Ljp9K4qWwUJJ5JJaGTEa5/1kfcCvQPsDtHqthDA4dW8vCyArgHJx7mok0BbeURsUxJGSRIMNEcdAaBnC6nZ2v9mwNbRFGkZmTf8AwEdRmshfs1zDbx2bFJ0UkpKpOG9BXQSyWtmrzS+dLCHMZiK5w3qtULxrSIPujnDqRICoG5SfSkAywWKGKD5kjujJuUkcN6g12+katqb2clsgK28suQkL5IYH+VcxZWENzdSNckfukDpHjOM+p9a2dGiuTZ30e3y4YiDHPGwDZ/GgDs7xvs/k21pcs93dkzCNlJxx/Eexrf07WdWSAQGySS0ji27nIxu7kHtXCaNqt9Hd2jxb7ieRx5qPHuATpnPYmvV9GtBNokkMsQtZfMIAY447cd80xHEX8kjXkZE0UwmcGWQn5VA7ZHerFuZ7u58oRKC0hO2VR5aAdGzVPULFLq6vIrOykhkib5o1bJb3UfWpbqxvplt7WEnyTEqNIThl5ydwoAsXkMUt+8fmKkHBZM7t0hHUelcrof2a/F5bQiEyW8h4nYZK92+groIpo5PPkty09vAu3c42srL1/CuaC2nmpcpGpkIMb7E5G7+960Aat5FE+iRrbXKSSQORycRoh67ais/OhntEhlEkMmFKNw749D3WuM8RpKUaDTbotsIjaJQQH+tWrW/updNElyciE+Qsin5oh7CkM9QTUJXhFrcolm1tMdoTgup7YqpqOtGRb2OOWdLuDDo0Qwvl/wBz3J9awrPVBHeS3d7buxEYjdZGJMi44IPbNR3OtWN3BE0QMflMVkbnKjsD60xFnUNRis9btruDCxSKss0TfMEbFWfEXiBbXTY4bSeFrPaWkLx5kB65U9xWMl1bbo3U/aLmRTH8vCMp6UtxdpBYWlheQI5Qli2MlB6UAXtK8TwvpVrFPbRy3qS7recNgMp7Eetex+H7xn07EB3uu12IXdn1Ga+eYL2A6hPFb2tuqREhA/Qt6+1eofDLVkitpI3Lyzsm35Pupz0FAHpt40EzKZdwO4eWSuNh7Z9a9IrwLxT4ie6uoYdGKXdzauPPiIIUqRzlvavfaTBBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeT/FvMPiPT5YYzLLLCsTbSCY0DMd23vXrFeRfFuCNvFFvI0zQ5s0jeQZ+RS8mD789qaAz4bixOl/ZLi3V13/ukzzubqW9Ks+FLK30xLe8Vkli5tiu/c8RLdPpWLFHvguZ3uFmMFuqyC3OBkH7ynucda0/DepvDNLb2+iGMPH5izqcmT0ZgelMR6KkqiJsbvkGMjqfepbS5S5jWSJl8oZ3HODkd65WLXLSzgtTrV1Fb3Eil035UkA9Kt2GpxyahFHp9wv2eQmQ7Y/lcH+HPrSsB0cc6OiyRY/eHAbHH1pl1Iqwbrho1QHG5untWJrWsw6Nbm4uNrwNMI/lGPLz1+tczrPjeyRJBe22yUbjCCcoV6hm9zQM6zU7jzr6O3zJ8oA46EnpzXmUNybbxxqd9BNPMsUawywqOrHgEHoRW9Nr0ZE19YtFezy26bohKUyPp/e+lQeHIYrmAgRf6RdHfNvO7y+fuADvTEacyQ2N3d+cXZXtsiVGBeJ8ZKjHesTU1F/cWMum2sUoj2s0jf63OMlWHrVvWp7WHUWRLoxGGJyzuuFMhGAzntisi0jlji0+yF0iMy+e08coz5nqxHb0oALqxgurp2SGMXUSGR7UDYcNxuYjuK5fXPD919jsIlkM7NKUcMw2+3ze1dJZwXSeLNXuRbRGymIUq0nzSEDls9x7U/XF04L/xLlikeNwXgZicE8Zx2IoA8r+xwOklunnMtmzM4Vg4Zs8fhWXLpclykblDDIZMwJsy7NnnP+zXZzaTFaaRc/bIS7y7wrou35geB6kmq9vZ3t9pFvcvG1pKkvlpNLL8x9VNAGDBZSeYpiL+a/7xkCj5sHGQK3r2wYxPJHGzkAOUXGGOOmPUVoReHpo42ltZ7e7aIMTPkkrjnafatOazS+0qGe6vUhgEm8qgwQ5HTjk0WAx9Naf+y0eWaIPKQBHCm1lPYNivUNPsTqNoIL3dJN5GMbdnOPX1rjLLw65TTiJ0lWdjIQFKvsHTd+Neg+GtPfTtJuITN5l3ITKm5vmz6GgDB0jTruwR7vUDCbtIDAmOd7Z+X8vWubmkuF82xR4ftqtuMrZRN391m7g16JdWL3tgElikElsfPIHWQjkj3rzzTLfVLjWjd39rPDb3LFoLRkyZB2ye2KAK17p15ZaXJIXjj84gSQoN3XuPauR1LTpIIZVjh2sNrGQHLsp/l9K91lsxNpn2Uxvb4RSc4JDE9Mj+Ved+M7F9LvLT7Os6SXErRnYvOQOOD1zQB5/fKFSFEMLSY3tJERvOfUeorMsoWQi7eVGYsS2F2gH3XvXdT6Fp0k8aRXUceoRxCSSIrj5j1L+/tWbBonnRR3Vosd1GXMUjq2QBn+IdjQMpxpHcQhSrRrO+1HJ5Y+h9AK5m40q7uPttvFeQNJGxQ8cEDtmu5ufDd5ZyPFBCCEO0yyPuJGOqj2rEvLVUd4lglmh3KWlZNnI6c0gM7SbSGxsI45ZHljYHc8YO9G/wrbuplgudNVZoRIQELMPlGe9U7XzrRriYXCTQO2PJdcMSf8KpyIf3xu4kCH/VlznPP8JoAra9ZpFcTrHKJbyV9iSRnao92rS8HFtMEq3U/lQKuZQjHJbtUd1aS3MuLaxZcDI8w5DED72ag0/R7uLyTHOZ2YF3jU8j2oA7TS9Wtra4ltls3a5lKnesnysCea+tq+TvB/hoNbTm5EkJXEoY9UJPAxX1jQwCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5X8UpGn8X6RYN/x7vAWcAhSxJYDn2xXqleJfGkY8b6a0juqizUR7V/jMj8k9gBTQHOeJLhbfw09ro08UarnawYq7MPvg+v1rP0rxReWekXT669zMSIjEsLDLDP3c/SrWq210gWZ54LjbuSNEIYAEc4+tZMGiXD6INOt5YXvUkE6eY/yMD1T3NMR0K2+na3cao0bSPfzQ+XIbrLKiYypX0Iq7pmoxxLapcnJuYzBBeW33YGQYwR61yGky6jOy3EEgsrlWNuA2dqP7DuKlm8yyisXN0z2itJG8saZzMepAHGaAO/sb6203SEhkkXUryUZl+0HIIz19qwNdurBtbaSdIWjnTyo7aQhdwP8Q+lYtxq1pBaCN1uQiKHlniTcX5wFrJvrg3VzEY0s3URkurg79meMk9/pQB3Nxd/ZdGZLKa2+02yrGu5PvL1IH+1jvVKLxBZf2EYtPleB5E+WVchkZjggHua5O/F5qHh54QksnlPmNRzx6r34qxp6/a9Nkuru6SCK1h8sKAFZ/U+maAOttpdunTeHx5N1ewN5zyzHcJ0xzv/AMKp+H4bvUvEMV0nkiwtl2uFTGT0Cj1FYBewto3nuJpIb7aBaTMeWLDA8yjVbi8i1KGG4hZZIIArOJdsZPfAHegDpvGs5jlurXYiRACdmdyNgHYAdKZHcT3M322zt47iGSFJG3Yyw4AAbrmuSutdP/CPXVpAzF5o/L2spJiAPLMT61bk22mi2D2xhjmkx5c2/lFxycepoAvXsfmNcvOkqXU11lWMuV46KRWhY6SyWMlhqChpLtiyrv3bJPXPXFc5a3UctrZpEpnBZjMZSXZvoegq/p0kdxbRm0crqTkwpKHJOzvn6UAbGn6GbeztrOa2eMqzozxSYA9C3rmrGi6DLDqNpb3c0N27xs0YiT7gJ656ZFWI5/7KsrhrhoXR2ETs0nyAqOGYddxptjrFto32OxtoJgpzczRDLHk/wt2HfFAHRpdW0ervpkW1jBCTKxTax91PStXRpEMkkIi8ueNQTGwydvZt3eq8dpa6lqDXDI0i3Uf3mb5Sv93H86s6lK9haRC1eMTw43AjrH6UAT6rNeRwBNORftpI3c8Ip7+9JpEUgSUTy5YnJDDmMnsD6VzuhajJqVzDNEYopnBDocnKg4ypNdsNtuwZndvMIRVPQUgKixqsjkK0e4c56EjvVPWtLhvLZobpS5c7oygBcN6qfWrd3dW1v5YluYonfIG5xkemPWoZ7vy5bOAkl2b95xljnocfw/WgDg73wsLo3oT93qqyKFdACSAOAfc96woPBV3p8xZZWij+0q8iugyzHtx2r2FYYo55jgPIzbmZBj9ap2wS1CNemNLffiME5xnpkmmBylz4a26mzFJ3QR4+Q7Qo7n61ydxYXN7rstvxJBEuPs5wFMX99vRvevZbm3ARI4zlSc7Ccb89QTXPXmnQW8F20+1kuF8vfs+cD+7kdhQB5/HbxRx2i3dnFG8UjGNQgO+Md/b8a5fWT5drPcyW6SWk8haCTYCIuemK9euEtDZW8cVuDNKhRC3AcDjlu1Q3eh6ZqYtNOubb91ZR75oUOEFAHkOl6amrW4d7W4jAHAjbK46lv/rVuWGiu13bvYxEwBWSSVhsYkjgH2rpbDwnYrq0l5p97dvaSuW8pT/q8cbcdhXaTKh1lCsMarBHyx+70/zzQBxPhrRUu7UbroSqriFmD4YSA9B9K+gq8xsfsUupSWttbQ5YfaJMHiNu2D3r06kwRxXxF8eR+DJdLVrBr1bhzJdFZdn2W1V0SScjB3BTKnHGcnniruvePfDug6lcWGp3s0d1bQLczrHZzyiGJiwEjsiEKnynLEgDvjIrG8SeAbvxN4i1u71DW7qxsLuwXS4YLEQvvgIJl8wSwttJdiPkI4Vec9M7SfAviFdB8SW+r3enS6hqnh230hZY5HKmaJLhC75QEA+ch4BP3uOBlDOw1TxroOl6oNPuryQ3QRJHEFrLOsKucI0ropWME9C5GaxPA3xFsdcEVnqUvkavLfXlmiJaTLAxhmlCoJSChk8qMMV3Z6nAHFQaV4a8TeHde1C60X+xrm31SO0+0NdzSxvbSQxLCxRVQ+YpVAQCyYOaZb+BNQXw/wCH9Pmntd1jr11qc7I7YMMsl0wCnb9/E6dcDIPJ4yAb+nePvDepTyRWeoM+2KWdZGtpUjmSM4kaKRlCyhe+wtVex8daRrF3o39k6iy299OYozcaXcqt5+6dwIZWCrwEJLfMONvBIrmNK8A+IF07QdK1KXSVsvD1ncW1ncW8khku2eBoEMiFAIwEclgGfLYPGK3/APhEb/yfh6vnWufDzKbr5m+fFo8P7v5efmYHnHGfpQBd8P8AxC8MeIJIV0vUXZZ4HuYZJrWaCOWNMbyjyIqttyMgEkd8VY0Dxroev6iLHS7i5e4aA3UYlsp4VlhDKvmI7oquuWXBUkHPFccnw5v28GeFdGvLu3T+zNIutOu5YC7HMtv5W6IbQWwcnnBpvw6m13V/Gdpe6npa2dlpuitYCVYLqESyNJEchbiGJgMRE4UMF4G454ANbxX4zvLLxxDoFjJHZxR2X226up9IurxSC+AoMRVUGFcl2YjOBjOafovjk3Gr6hHcEXel22k6fqEVxYWE7yzm4MgLCFd77fkUhcEqCck4yNHV/Dd5eeJtU1GKS3EF1oh01FZjuEm92yeMbcMOc568VxsXw98UWNjINL1O0t7ptJ0nT2MVxJEZPsxfzlEgjJjDB8K4BPsKAOzf4heGk0k6i97cJbi8/s9kaxnEy3G3cIjDs8wMRyAV5yPUVHp/xG8MX99DaW97c+fJcC0xLYXESxzkkCKRmjAjc44VyCeMDkVy+gfD3WrS7e5vJLNC+v2+q+X/AGhcXjLFHbCIoZpl3u2RxnjHpwo1bvwVqM1rexrNZ7pvE9traks3EMcsLsp+X7+ImwOnI59ADfg8beH59cGkxXzNdmdrVW+zyiFplGWiE23yzIADlA27g8cVRtfiR4avonbTrq5uG+zzXEQ+w3CrOIhl1jYx4dh/dXLe1c5ovw6vNL1m1UwQXWnW2pSX8dzNrd8Su6R5Biz/ANSHBfG7dg8sVySKu6X4E1G30zwVaT3FpnRftIumRmO4SwyxjZlRnBcE5xxmgC7ofxN0W/8ADOk6reRalaTahAkq2g066lkJMau/lgRZlRQwzIoK9DnkV2OmX1tqenW19YyiW0uY1likAI3KwyDg8jg968uHgvxMfC/hnS7jTtCnn0O3+xxXUOtXlnMVESxrIksUQaMkKd0eGB4+bivR/DFnfad4d02z1a+OoahBbpHPdEYMzgYLfjQBp0UUUAFFFFABXkPxh+0zeIbW2Tb5LWqsnIB8wO/X1GO1evV4n8ZwI/GdpcRTzJdppw8tQNyLh5MsR+lNAef6tALPUZ4YVLYhWYeXJzNIDzg+3pUNvqlzcWst8ZA97C5O3y8gKOoXsGqG9mkaaJ7ezUmRM/N8oVj3UdcmqFpqY05ruNw1s8sw+0Qk5Ebngc+9MRsz3sclnZ3cj3d7bSSiSeJAAQ59fpRNMkM0EMflXWmNJuNvu8pgT/FWXbzHZc2ChWs0JM5Z8MpPTa3cmss26w6wyPFNHCFyVb94duOGBoA6HUZprEiJLyGKQqSCqEboSf4R0zVXU4o50QWt0Li64liimGHkiHU5HT6Vl6lqbTPaxwmYmzG8ApkeX6Mava3d27rY3Ub+bO6eYgTARR3UntQADW7mK1WTSm+yw+eEQhuRn72Qe1Z93Pq1nqcjXd1BJZxOJIUhiDoQeoAHUmtK2tUl1BTCkjwLAbpbNcFVPoWqrdyebJaSacvlRzYDxthWBHJ49BQBfvJXvbS5V5IEO4M8kgwYT2Xb/Wsu9TUGiiudREb2sSgRcEB/U7vWqV/5l5dmUylFDYkONolXsAO/1q9qGqvcx2kRhMdjEMSb+jnoAB6j1pDH6bNDq1p/ZiBUjlJkeYtnHqM/T1rQnllggsrWwSN4rdjFLM7A7VP3TjtWJf28mlxr0hgMZkQW67lkB7nHQ1Hpy2tvqNqHMrxTja6HlZSRwPwoEbeniOytfMiuNjnehgRcZ/2/YVraBYTQ2M8yanEq7DKjyR4dQRzx6VkXFrDLLcWDxTeXHFn7QjgFj2B9qvQ373nh4200RafyRD5qYJBB/iPYYpga/iHVDqOh6fDNsUHbKJYxgSOvBCj1PvWpp2oafYNaSwxtcymFpZGlkwYAffpXB3n2dbJVYqS6/MQ2PL7LgU6x1G6j00RPCEnaFoXZwCskZ6cdvrQB6jrXiO2j0Qzi6aP5dyW4O3fnjAYdB3zTLPxPdPd23m20UcEcQ2TO28ztjhQf615/o+sxfZ5NLu42ktZgIli4YuxHAz/CK63S47i00a2kglSe6sHHmgAEbfT3wPSgDXvbg6TNb3V3JL/aShSyg4jwx4UGuh0/Vv7ZgnbzGt0RwqO/D+YOuOxFcTfazaajohu5LxUsPtDF/kLFsHjGelXbPUbO9XyoIhHZo6MzTZ+cdto7H1oA7OXQdPaaO5m077TdJIH3SOevcis4uLaS81PTlF26qStw/VueYvwq6sgvYJGhuZSGjIEisPl7cVSjtM6XHbgSRRrLvRQPvgdfxNAGvZ3U+y3gitPJgckh927YTzgjvUmsKot1V2SVuvksMZA70yyjsYbdpUuWiEzDeQ+cMP4faq+sW8jo5gmUXjyKinkgITyCKQFuKWLUZIlDkrDyXH3VPse9Gu3VtZadLcXUyrDGuTJ6nPHFQNGkCyxWMuJY02lSQFU+pFYl5e+bNp9lq8EcrucHyULqD/ePagC7DLNEIJbmRpLN8SqsaggZHAquJoLu/wBRs5ARI+w/uwQ2z3Ipl5qF1FBcNaRjyQgUtOmMjPp/Ks23u4dL1tozLck3WBI7LnZn6dKYG5fta2twreaIriTEahVz5pHbj6VcaVpZoS8cNuoXeyyNliem3b6e9VtVvbbTxY/aJFSKR/Ljkxlt/Yk0zSpre9u5tQRID5Y8nezcsvc47UASXF3HFO3m2ZeTzB/qRw2Om31r0+vMre1gs5rdLZiQJc5lbLKD3U16bSYIKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxf43SWkfiGzE6z/aJLQLE0QPZ3PP09K9orxb4xyvD4ztPMuUtbaTT1Tz5BuWN/MfDEU0B5HeQ3xvLOW4RRNMy+W5BA4PAb0NWNUtbS7uTMkJYRqZbtXbG5ge/uK17K7uZUubh1YNbxSJA0hzHM2PvD+lYkdtDPapKpkMpg3yQM2Nkg6n3HemIrWnlC4khVIx5jgRb2wrOR1T2HvVP7cItRjs2kdZ7csI3z+6Gf4WPenXagWwMg8/BVnm3AhRnt6H6UyK8jS4WKOOGSSQHz5GJ8vZ6D/bpARGd5LaKQ3BjJuCoQLtVM9WX1GPWtCYWdv5zWbxXdpGAoU4+Y9yR3IoFuuoS7rKcLaRRFFaRSfKUc8jvmoZVtRbCSa0UyzKqQOp2/UlaAL2lwyQ6YjC7IkSRQERMmZGPC59K1PFmk2w3zoWNzJhWSPGFJHIPpgVk6HeWVrMLpxLKrMY8uSFUjpwOla2o3FpeQyXUUrNcMpNvHHwjt0Ib3pgctc2jOkBgkWWQoIoVdSrLtPpV6eXzo2iKjzk+WViwB346LWg9zbrpSxWcWdSlABuBLjyyOq+2KivNOmtLG3vYJIZbt22k7BzGeuM9SfWkBi3Fy8tiJ5YZGiIKykfKGcdCPWnyWlwkMbGIYdRMnlkEpnjP1qxIk0dlepHAYrZT5NvCW3EHqePeoI90k8E1mjLEsflTiP5mjc9Rg0DG63eXK6yLU7ZAsYCtnLbQOc4609VNvqa2tgJVhGJZMnHmLjn6mnWt2ZNR36hNFCsCFVlMfXPG3jvUnh6b7Fqk096sf2AMQu5d/ltjg+uDQBVvRp92ZZrJGEYxvU5bcO4HpUnh5ZTc3Ut4IWluItkFuG4x0XrUM0rPDcEEWltIx2uD0Oen40qWzPfW1wLmBUiYb965dmHQD6UAaOlz30Rv5UjhF04+zFXjAdfoP611GiXQt45JxMbF4GSHM/3WA6j8fWucvvOt9Ye6BheXyTmU9j3OKiaOW6gaNbl57eMGTyh3Yjnj0FMR0i+KNOVbqR4fNRpQm2NMpb98D1zWnDr+mWc0M8ohtZxg5ALoVb1HriuSs5THas+nODDLtJJjwFIGMYPrSXlnc2rQSlY7e4kTaoKZUufXPcjpQB6Fb+Iv7JabT2cT20qi5jlUhAinogNal1G1zpD7J5JJ4mYKYyQ6lun+99a89tGaO3ZDEzAgSb3ADHb1UDpithNSGqaXFfB5JHWTfiJyPLHQr9cUAdp4b1ON7OS2idbu4gb5gigdOufeprvWYtPaMJewwxyxs0UsylmDA5OfauN0iyax+2SGKK00qWMiOE3ILSM3csOadfypbrYpPPi2IaKOOWMNvwOCO+PegDbutXsbKCLWPsrSs8TbmiJ3EnrkfrTD41toLnTo7USPb4DzMBuYBhxn/Gs2/QRzxPYxvBDEnzwg5jdyOTjv9Kx47670yW5N1arcO8alpQypiIn7mB6daAOr8XzzXVtDHHIn2ZZVldycBQOcYHWse68RyahqVkNMjKWi/NLKcKJFHfJqgksWrw3C2FvLIQQojnfCcdgOtUNZuhZxQ2zWxtbq3Uq0ca7oh3APfAoA6LW9bjvZfsptLgq0ZkaEOoC89QexrJstYgs9Sv7+3iljvFQRETfdHbHpVK1e5uJJtQih8yVYx5uw/u3bsw9PpWct7czC7gXzJIXDOGaPLiQjnI9u1AHok9/NqFily9zDbxxuq2ZjGS0mOp9QD1r3WvlGwv7Zxplj8880akKiNjy5PUj1NfV1JjCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV438Z5YYfEtsZxHJuslCRMMlyHfP14Ir2SvBP2gDM/ia3jjiicJYxyKz/wAP72QNj3IwKaA4i41SCZJbbSo4kiyiNPISByct8vaqt/Fcf21MjIskSR+YjAgbk749ajs7p7e5eCW0SDT7gFGhc/MCRwapaV56zvb30cUrwTeWt2742RnqMd6Yhtvp0Muk6ld+XJ9nDmMgNknvn2xTYLNpNGS6WNfMilUAkYyp6ke9Ta5cvYWPkgkQsGaESRbQDnAPHXirryyrb2s0RjYYVnbJKqQOAfY0AU4JJbW8uZICUuUwJIpF+QsemPbHWn2s9vcQS27267oiWLwkiSV++zParum291qccj24T+0kfzJZCx+dfQAfpVa5trm2ilSSykS6WXz38ttp8vPNADLeJ7ezkaZ3hhibzWhmADA9snvUthcQxSXQYR+fjfHKV+SJuuRT5NNn1OFINNWSZx++eeZshsnoasaFA8GnKl8qmWGZz9mQ4YL/AHTnqDQBBBaWyfYrxpWlzGRKHU5J6kgDqT2pv2yexLabHDbTbMTRvMCrbGOcDPcelbFlthMivbM9ulwu3axLQkjPPsKzdVsZYrpTeXcQ1LcJ4Zwd6umewoAiVY7m41OGUiOSRdyXIfb0HCgdjUt1pt/p2gwT3UaNdKMxmNSBtI++/qaybJr+SdVmjVoDK6tKB8wB5346VfutWuLj7GmqTXUsio2wIPLDKD8pYdKAKOmQx6gJ4L6/xbzBQ528h+2B/WpLP7Ovl3WltLLKmYLjz4/3ci9AxzVZre4u5zdRgY+8Cn8bDouK02bzluLa8eO0uLiI3DxsSqqR/CtADLu3sLS3VpgRKzLPFMEzHIM4YAeoqrq1pNDc3CCEyFmChww8xt3fHYYq4Y/tDwi3Qw/ZYFkeYvuiQk8gD3q7eWtsdKH2bUIZbyWUTFycEgdSO/4UAY1xp1rE7WkVwztkuUDYcADkE0zUAkdxYtbXkayTD982SBGO6jHfFaKoxX7bPIv2jzd0jRENhPf0p/8AZagX04jjly4LSuRtkQjO9T2xQBmi3QQR/wBhzzzPBJ5jPMOGA6Dn0Nb/AIlvJtSVAyQvcokck7sAEUj+tQ3GmQzSR6nZX1ulq8W2UDqF9dv9aylntkiuxG3mLAuN7DCsT6D+I0AaEtnqE0Rubk/Zvk3LbB+JV6ZB/pWupj0uzi2kyWxTBdBkRuOfmrAsHWa2sJgHuIrdG+R2z5cnUY9T7VZivpbn+2IbmOR7MwrJJKnyumT0YdM0Abs+sWVynmSW9qLGRQRcc/Kw7H05rLiF0qy3E8SWwkPlqJZtzBDyGQ9s1iWn726+zQzI9ouUUSfKA2MjPrU7awpWW81KCK4EbBEgLYZdvGfTHtQBr22vRxaUtuITFP5uQivw/YsGPf2rLjeCbVYo4pJPtMJZ5Nxxu9Ax6ECquoHzvsu5LVVEoEUSZJXIzk/zp7Tpp1nb3U7C+RrgxzInDFTxg+1AEi393p2pPfWk6wyICsikbkYk/eI9MVoPfJDqFrdTSyGWUFEIAaKVPQn3rB1COVL9JNJimngeXGTwvl45Bz1xWfK0hC7I5ZTHmTyjwH54A9KAOlttVuImuraUx28tyGVY4wWCxk9vSorCazv7kfYw0VtaBTJGk5zM3Qlj1xWXFJFJeWskMFw0043GDdtCN7ntV8vbx6msdusaSwp5jsANkrd1+ooA29EFiNSW5iijV2mLSqjHCkfdVT796+rK+PdN1C3invY7dhNHORLFEqcK4659/avsKkxhRXP2XiP7V451Tw59l2/YbKC8+0eZnf5rSLt244x5fXJznoKU+L9ITXotHme9t72aVoIftGn3EMUzqCxVJnQRucKSNrHOOM0gN+iuJX4o+E2kREv7xzJI8MRTTLphNIhw0cZEeJHB/hXJxzjFXF8ZaVctpF1aarCLC8junEb2cpkk8kfPg8eUUIbcrqSegwQaAOqorltE8feHdbEv9l3V1OUtDfKv2C4VpoBwXiBQGXkgYTcckDqQKv8Ah7xRpXiC4vLfTpbkXNnsM9vdWk1rLGHBKkpKitg4ODjHB9KANqiuI+I/j6y8LaTqq2rtPrNram4WFbSaeOMnOzzmjGIwSDjcy57Vqaj428P6drDaZd3zJdI8cUpW3leKF5PuLLKqlIy2RgOwJyPUUAdHRXLxePfDsusnS472Y3Yu2sSTZzCJbgZ/dGXZsDHBwC3PbNOs/HWgXt1Nb2lxdzSRpNIClhcFZhEcSeS2zbMQRjEZY54AoA6aisXw94o0rxBcXlvp0tyLmz2Ge3urSa1ljDglSUlRWwcHBxjg+lbVABRRRQAUUUUAFFFFABRRRQAV8+ftBxef4406D7TJAZNPXBT1EkhFfQdeD/HmF5fFtm0aIPKs4pPNLYYYkl4A7j1poDy9rqOGI3E90bq+tvklwo2PJ2J9wKnRNOurS41C7mSZnUFDDlXQd1x061Ti+ypqaSWM0IYfvLiCRP3fuT6n2rS16whgusTPaiAoBvgy2ZD0DAdOtMRlSXMVwYPMilSJyQkkzdMD5do9TWjK08OnQ20d4ILeRvvBQVk7kFu/0q9oWlvcmIzbLu7t5Cio0nyRnHBI7EVPFpFhJBMhcwwRyJPKGyyLIDzj0DGgCt4VuprNZr6UPaxXKnagAViV9uwIqee9i16OW9jCYiG1otxCkdgzVoMmnf2w02oxyzNICYoISCjJt6f7JFZMkFmwSOzinto5gZIUGdq4PR/p60AXNL+1Wfh9hbood2ZmkY5KhegVfSsG4e4FnI0Lkx3swjM033pD6gdR6VPqL3L3U8drIssvlrLKIiQGcH+Ht+FbttBNema4CpNeCHzEdSBsI7AdM0Ac9dD7LfvBqFvdRagditbRSlRIg7g+pFM1e/sn1iyuo7eaKxhXDRSPjp0CnqeasatEt9d/bhGbOdoVkuJJpdwwDgke59KpXaSSRRTQmCcu2Vw+7MY7ex9jQAtre6ldmR1sIUDqXRUOfLAPOR9KJtQZ75rG23SWVxAZBcSNlN5/u9/wouX08D7fDBJB8wWaLcdwB4J+tQ2JRAb1WZPszeVAjAbQW6c+vrQBZsUW4sY4JQ+nSW8u4XchwrMBwo9u9bEWiSTxTpFLFOLldjSzA7JW6kqT92s928i4/svUXEJliM77m3xbhypJ9/aug0iEnTLFLOGWdHlLS7n3BQf+ea/3aAOU1O2urSJLLT763WbzgmS4LMPRu3FaqRJqMM1v4fsIBqVuwDPLw5A+9sWulv8AwzCq/wBqxxRxtOpDQNHkhh2UHqTWJC7xa067JrPUoUWQvwWUNxkjsBQA2TRrdRbqlvbQ2sqny9pO2V/41fPNYe06k0tj/aKWVgmVhglXAZR16dvrXpGqpG0Nrf3EisIk2p9mcYkbPUoehJ71xmpwxs8iwWpMzHYzsRnOcjI7UAV4bOG31G3s7WZp7xoghGNqhf7xHTAFVLtILLWGgjRLiyaQxCeX/Vq/c10ejW8tvpty2oXmzUUYyiCOPLZHv3GO1c/qyBbyCXU4pwl2jL5AGUBP3WI7GgCpYpd2F/EYbdUhdyqPuwHIPBAqxqMtzbR6vaBvsttd52qGDtkclif6VUu5o4ryzDRee9oBHIEBG09uD/OpodNf7QLy1DleWkTG8oc8hfWgCrB9nuxC9vc+YyKjJ5Y2iYj+9nvmmxvcvfNeXNhEs770MKjcoA6kjswq7emO3hSWe2byQrRjyAA2Cc/dHcVWR3l1FltmmnaPbMTGmxgnfI7nHWkMgtbd47aSxRftBvyQJV4ZQBkjnkUafara27Q3c0RMXz7QpO0dgD7VNNqFrPdSX8Us8l75v7mJVwqDGMsexpNFiY3bPeyyI8Od0SMGEgb+63TNACaMS9tLcWy3F5bq5RWD7VT8PrUwiCzWdtOJYbnYQTEeJGbp+NarQRaSkaImIwxVVY7ZZy3QemKqvL9jTzhC8aqjb45V/wBUmegI/ipiMqdr7T9QSSaITG8QoI24MBU4BNM3x2l7HFeorOuMTIcsHb0rfWdLu70+ae2a5aOH5yz7TIh6fQ1z97aPBKs1t9y5ut6RqNxRl6An0pDJbhBb3TPIvkNbSbQA3MjHqTj2r7Yr4/iu76K9dbqyttlwSqEAEo3c5r7AoYHB3mi+JLD4i6n4g0Wz0e+tb6wt7Ty7vUJbZ0aJpGJ+WCQEHzB3HSsGLwP4suvFGn6hrF5bXEdrq7X/AJp1e6YCH59sKWuwQqVDAb+ScE5GcV61RSA8+0XwXqNjF4LWWa0J0XULy7uNrsdyTR3CqE+XkgzLnOOh68Zzk+HuqrdQyfaLHYl1rc5Ad/u3jsYh93qARu9O2a9SooA811DwT4g+xaH/AGRqVpZahp3hyfShcZY7bh/s+1l+X7v7lueoyCAe03w98I6xovirU9X1dohHdWNvaon9q3OoSbo3lZmMkyrgHzAQqgKOcDufRKKAPNPGng/xBer4uttBXSXg8Ronmz3tzJG9uywrEVVFjYMCEBzuXBY8HvW1n4dXk+vaxLBBBe2GqXiXkn2jW762WIhY1ZTbRfu5v9XkEsp5AOQoz6pRQB59J4K1FtPaATWm8+J11rO9seSLgSbfu/fwOnTPfvWLb+BvF9v9vOkXtj4faS1uUVbPUbm4t5p5CCji3lXbb4+YkxluWr1uigDzv4e+EdY0XxVqer6u0QjurG3tUT+1bnUJN0byszGSZVwD5gIVQFHOB3PolFFABRRRQAUUUUAFFFFABRRRQAV4X8dYlfxdZySSyokVgCYk/wCW+XkG3PYjrXuleI/HKNZvE9lHFdyR3ZtFMdumP3w8x85z6U0B5KtpdLEJn+zuIVPlQ+Xkqc/x+9X9WjS4tLT7TM0E924aSZP4nI4UDtTrnVp5BdJePa2j2pTMeAHf1ZiO/tWU9ze3eqCw039/keeCTwW74B6GmI6C1sY7fw/bi6iuoDNIVuZSMHrgFyP510Vj5dwl1b/arZ0iRd0hkG2RR/CfXFcKLy6lEMFxcNDDKSXRnPyle3vzU8MqLdyteWB8ktvCwSYWRvU+3tQB0M01g8D2HmpFcPGzJcy4RSc9BjsBT7SxjM98J5zMjyRlGtSQIxj5jz/Car+Tol3NbF7VDcTxuubjICSYxtVR0HvWn4ftDbaU6XbBr9SFFurHJUDCIfagDHsLZF1y4037cEu8NdQPEAEVQfutnjJpZLtdRv8Ay0tkBu5Nhjzt3sOrIR/KtQGOO2S81SW3a5kJV7VVA2gcFS3rWbrAe0s0kgWOO3sJlVNqDKRv7jvQBBqmnafY+HJZLZWd5bvy9rHKJ75HA5qrcaEbW1jTTrlPtSoTcIgADgnPA65+laOsrbQaSulWEsccfy3TSsuUck8gj1otJLM+InlWaNZjBgIyncFxyfoe1AGW0/8AZlnDJbW0l5bXQKyZjxIpPGCT2Haqi2C2tnLasZ0tsiWIyqMFie/qa6+RohDZmEO0W7ZPb7vM8lTyrZ+tYM08Nzq0S2l+J4omLy3AX93bHoc570ATal4d/tLUGiGZbUxxlF3bTBJt+8T3X2rV8N3Nzo8Fney2Mkrunl7LVtznBx8vt3q3o1rqWbw2ky32JleONlAQxEfM6nvW/p9jZWd5YWrMHm8wvFbLkNtPf8DQBIlveapqMtyuS9sVktnnXIhz1j2/3q4DVIrSPVb3VtcuBaG4f7OUXOXcHqD6H0r1uwtEWeeS1YJku8gV/lMn+0PWuP1/T7O9T+0buNIDC4Ro2T93JIehwen1oAw9cWWKW2/soRXvlAJLOTkxtjjco7D1rFg+1aeWtUht7z7QxZ/Mk+83XIPbHpXRNYX2kQXbyLNNdiUITwqiPGSR2IrmtbuY9cvRHAsUFvHGfJmClCnqxx1oAyr6+vdPhjvLaR7mSV/s88FwDmIMeqf41Jf2909nHJukkhS4CtE5xKwA+8M9RVDRpHZVMf8ApYZzCFkPJRf41J6HNWrhmubR4rKbLMm1izEsqg/Nyf6UgI28u4ufMd5GvpA2xZvkP1Yf3QO9V9NtF02Nb1ruWIedtkxIVK546dlqlbSWrW8M9wJvt6kpLwW8yPPyj2Fat5H9nuLq1lki8tUE8jOMh8jhSPagZZvtIW2ultxDNc2kimZpIZvljB5Jz70ulpbR6pHHaTRi1nQs0iliQg/hOe5rMtJDBpMLySObfBlaUdAP7p/pVa2so5riyT7V5UUjedgOSVB6L+NAi9Kjm1vbjTnYTkl41I+SdRwRt9vWlE0lh4fKSZhllPmDKgxqD1UZ/i9q3tMWS6ureIb7OSBy0sm0OqL6D/CmXspu57FJDC1i0xRGZQcsOd23tTAz01K5gsYZYLe4ufmW3BkXmJm6PjqcVJNfvbxS2r3MX7ksJJbnnMnqR6Vm6jqTOlxHDGHnZf3bRORu2tWr4W0C51qaN77To4LGcne1w253GOAB3OaAJYJpbxIJLN7VbjaIZpDGdhY919AayBHNYT3exGimDFHdRlU3dXyf6V18Fium6T5l9AJRDIy2iwjiQDpvB7jtWJc3EflpZLKypdKTi6QExOegwPU0AZN5ALWZZ2u/PulKbZEyUcdz7GvtSviti0EhEsMcMtmdpjU/ugT6+ufSvtSkxhRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8d+NGlpqHiC0KvJ9o+yhAinaG+ZyPm7Ec817FXjXxnjtY/Fem3N2l46GBEKwglGAeQ4f0HNNAeY6LBc3E8QhsI2iML+ZK+1lkAPJYnnd71kpNbKblbZ7l5p8MpKHCc43Bx2A7V6L4et1fU7kyRra20SZl3dJUxwAo6DFRWVtbiaVdKtbiy09nbeJlC844HP8JpiOEvbO4lNyb6/Dzq2+CToJIj2C4/WqKWl2IY08mU3UitFHIpYkZPUdulesLa6dFb+SkiXmqXNuEt1ADFNp5wfQVX1GxSS/I+1tDCWWFZYx86YGW4/uk96AOZ0qYosM9yXuXhxGgVNrtIp4BNdTdWcn26XXjbvDPCvnOkT5bb0ySOD9Kt2WlwafpMcc/liK5c4dvmSRv9kDkE1ZGkE6PLb2k4t2lYPahWKopU8ofXNAHKtb3NjPB/x73llfFroeYMeV3+b6+lZkF9HcaOizW7W9vJdb5DcvhJUJ6fhXfXMZbSbg6jDkAhnhI7dCF9jXASywQeHJLS5hc2dzMYUicAFOeAAe1AFmRjPq89qVthpVun+jrHja5PAJamWOn3aT6jNrIt45NotoGc7XY+o9QBV+G3t3tpdKeOWGFUj2WioGbep4yw6LXYT6FZ6hb28+ov8AYrvZshMhA2sD1A70AcTeWk6SwvaGKSSWLyJVCbSzD2Hc+9WNEvNZsra6s73SrNY5F3BXQbXPZTj0PWvQYorF9OV79TFGsm5bwpsaRum/Ap9tojPNDcalcRTxqMAqu3IJ+U5PegDHtob6Hw1bXs9ujanGvFvartQN2Kjrj1qTUVuoobSW4eIanERO2cKNo+8MjnpXTSW7wSPMJRKVwI1VfmjHfJrm/E2j3Gr61YXSyQRQWyt5yAZkkJ6DPoKANTT44UDzQlWguiJElfghW7YPvXET6a/npb685uvLuy0TJISjjPCt712aLbXjJbW10JIoVVnOOCegB9vpXP6JFPJfyrM8Ye0mYshUERr13D1oAqeIoL7Vby5X7bFbaOjKkABy3mDsT+lcLd2dzaTKjo0QaZ/PnQnCFex9QewFd34auLGZLx57VkdpmeKS6JUOM/eRPrW5qVkb23nspXZfOG5pPL4k9gexoA8XvrAXUbXrzNFC/wAwixypzwfYetVLe5gtt6Da1zMxSdyvCHPDL2K+tdhqGhXcVvdW8dhNIJhtCDjbjpurDlt7bS7draS4iLQwrJMPL3pE2eme+e9AGfJHJMlw6wIsTyhNirtYf7a4/hNah8KO1qSkkhu0wwaU/eXOSo9ai0iS6stXF5qEDPbBRDAifKsm7+Ie3tW0pm09J94bz7WQlNjHcd3YelAHL3OmQXSyRtHLb3e/dtDfuTjvnoBUurF7CdIWFuZJrdfKKYCo69cHvxXS6lpnnWF5bXEawloFe2Z2xukX5mD9q4PxHezE24iGIoUWYoyfMX/ix6A0AdJqN/8AYbpZrVjLPOyNIANqbNv6+5rm727kXVARaxGOYN5O58AjuR9KpahfxanfPcQpPa2UMW4BmwWb3HpWaI1k1yBZI/MQspRI2Jw/p7UhnpXhPwxC4gW98yQsuYiAApJ6EH+ldMZ7qwW3bMUqiQRlwCRgdcehqzZF5IoLC5glgmihJ3xgEIezKfUelX9PuLZXtreB5HnwIyzLkM2eXx2J9aYjP1OWK9aza7tmaTY8myH7rEeuOhrjdSsNoS5lgmurWRhvlhX5om7fgO9dBqdrcWGqSwaJs2y3hVYd5YOxHzEmrgtb2MWEFvby2f7wpcQ5zvU/eK+ooA4No8SrLdqoJYq0hUk7uxr7Hr5zt/DcFrqtxKEebZC0cTK+VIPRSD3r6MpMYUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvHPi5Z/afHGmmYym3NosflxyFfMJd8g9hgY5969jryX4pRRP41sJ/P8uW2tFkbIJAQu43ADqcg00BnN9kjMjaYsu+NBbExHd5gxzz0+WtXUo1uHRYpkkgaFE8uQAiVjxkn2FctatPHKtvpyXdpaTTNO7uAVkHc57A+lbX9nrNPiY7rGKFRCy9PMzkYx2+tMRU1CBZYtVsYbO2sL+xHlR3Sg8QnncD2J6Viokpvnt7Ga1kkeJQBKfnKkc7fcVoteahaR6jJuu3u/PWGJWj3xqB1J/vKf0q/pci3l2Z72yt0uCN1m5i2RrjhlZvf0oA0NLsnu9LvrSVVilZCLeZl2sHxgN6Aj2os9PSFEs5r7zLuKJQiOcudo+aTPrW5azvc+ZGbf7KiYIBIcHPofSquvy21rd20qMJJJB9nbyiu4ZP8qAOd8XR3MuyYK8lmCkc9xtIJXuMfrmuDkBTVGImiuLKKYOY7g/M7ZwMH0x0Ar2HxXbSzadIUnETYIUDkMAOQ31rxmTSpby0tdStY1l8tgCQ2BG44wF9PegDr/C0Mz6sQyRiRZC6xONjyqT94+oFejmKGTel2kUgVg670GF9ga4/wFGralcvcxv5ohTHnHOzHUK3pntW9fSJ5sk9vIbmW0Rpmt24MnHA5oA15ktrmVoJQANmBxjZnuvaqbLIbI2NzEs4UhIxIfvgc72x0NYllqrXkdi9+DiaHKFcAq5PK4/2RVqSaxF+91ub7ZBGYkLPzInqB3oAvpFHctc3EUh8y4Ai82PooX26cetPWGRLYMj/AGgFAuZMAsQevHekZWi06N4GEKLhxgYUg9QR60C32ytcrIVRmUhH/hHfA7E0gObsdXtLvU3gmE9tqFpLuwIdse3oQPUfWsHQ9QdPEmuXEMKSWagx741Pygcng9TmptHmkvtS1+yguj5vniRY5Rncq9lPpXJeDNanOt3VrIyxLLue4YkgqxOPkpgejy2sdwfIcNlYd8Mka7WtsjPen6RPcW2lIdZAS7LkDa2RKv8AePvj0rO1Y20mmxWTXkwnjYb5S2XYenHXNaExWKGaS9a3ljjVUhiCjEIxzubtQByHi3VpbSW6DeabBdrR/MRv9T7rXPedp2rXiLpSLMs0WCC2IweuT757Vq6roUsxisoVmu7iSJmFx5oKBWPQj0FUtH0GPRlsfLEM5nnaKNIvmAkH8RI6CgDS0TT4dW8qMXkyhE8pcr828f3R0+lb6+HneOyubiJ2uw/78SvhiF+63HFW7CPT7TSQk0hiMrsrpj5gx4JHpitR/wC0Entf7O8ie2A8u5nuASdijgAdyT3oAxNTEl7BPY3McqPOpMcwgARVH9T614t4vM8+sW6C1kthHKqP5PJdewxXv0dvDHBJbTLIsM+6Q7nJYydQF9h6V5hc2Gozal9q1NYmvrdgAkRCiWPn5iPUDvQBwGq6Lbyy3s1tO0dozR7ZH4LnP3fzrpPBtqv/AAkNp9qgh+yxO7PIq53tjjP09ah1O0ksGgZ2AjVwkUbYdEYnOTj2rqPh+qRzXV3c+SbolyhA27FPX5e4NAHo0d5b/ZBII1+zBQzybdqsT2BNR3ttDbSxmxfY8h5k7QLnkg/0rMt7tfsEUd6jvbzHAUgYiYcg/wC7ThCb+Nopi1tHdEeQY85aTuee1ADry38vxDbCyjPlAFt20EMf72fWta3n/wBOxKvytGW8wjKJzypPYmn2ml21pa20NnJJIEJjcO2ee/XoaZZTR3wmVBIDC+SFXC9eFz3FAGdqtnPHqss9pI0SzKISAflYHvg9Mete1V5hqemi+iUSsxhUEMTwxJ9PavT6TBBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFed/Ea1tzq0c9zBM6yQRwmSF8MoDuSMfjXolcr4xeDe0UkpSR40OFOGIDN0PamgOIuY30m5AYxmzSHy7WOduW7sfwqbwjY2gkNyiBY7g7IEEpeNfVh35pfEU015p8D2Nq0geRoFe4Us4yMMQO4I71y9vbQ6PaGW8kntGiiVVWOQlUw3y5QcgH1piOy1COW/fUtJeCS3tomUyXQfy3RccFPUVlatNJYW9tMkDuYZkjjtQ2YTGeN2e5PWnXgW71tru5jla8aBQUjlISZMdh6YrNn0qG5vZZrKZbiK5ZAZIpSqwlONoUnnHegDRl1240zUNRXUvOisrcZiYRgKWPSND1Ymub17xDcX9xJC2jeXeSN5lvGoCyx4GQ4Pc+1aGs295DYeTa2xvbi2HlxXAbc5bqSEPAPvWAI7q41ASrcNDqKx+X5U9t5qocfeD+vtQBup4rk1PTltItUtzIYVe4aaMbonX7ygd2P6VA8tumnmS2BuLG2lR4GX/AFsjk5bcO4HUCsHUbews7aTT57q2t9XULcrOLXazt3A+vvU+ivHdWlrfWUl3dX6s25ZECMB/eJ6A+lAHX6Qqsb+e3uCLlslJZiNsK9QxTsD0qrd3d7NLJqMbJJdQLG0UCfeZc/Mxz/DVbSz/AGjDqMMhjeWSPLzK25VC9t38RPpVPUZheXzPoU7rawW225AQqyY44+npQBpPdW90i3EiDTZZmNwLdsF3XOCqn3qC21JtQ1W0aVFWxtypcxp8ykHIXPp61y1xqEMOm6bLqJbyoWdBOxDFlb+I+hHpUN1q1zDFm01V1gmjQ7W5Ewz1Bxx9KAPZ4r2SaCKZolmhkDNlWztP8Ix3pim8Vp5byKJSUwzoSdvt7Gqnhy4kbRrNQHMssRIJwoH/ANerc6uoliDvGgGSwOWz6n+8KAPHdav5LTXv7QsUUSFvLtpEclXA+8c9Pzqhpkc8viubzZFe3bDgSkR7i3cY9PSrvjoF9FAhbyi08hHlrwg6DH1qndCTSvDtp/altBLcPIGUr/rTjpk9uaAO9/4ltgJPsbItpGGgaJmzLcN1ypPSubGsT6ppt4k1pfR2xZiY8DYAf4j61gw3kUn26bV4JmnYCZNqHy1l6YPPHFbdjqdp/Z5v9RjjneJGVIrYlYmUdQRnJJPFAGl4XWVLW3a9eWxtbkoscxfmXngH2PpXU21hb2etG52pBEY2iFvHwztnlsetUvCOjXHkprGqTIsNyiNBaScpbkdNo7GuzZohE0r+T5iHzMEgEfWgCILHFGrXKokDgBTKOc+9PureSaIKkjRkkKZEwCy+gqSRVcqyMjFvnkQkEE+3tVG6ubiIXOI5SoQtGCeM46/SkBj+IdVkRJLXS1kaW2XY07L8gJHXPrXne27vJ7a6mjnW5CGNLp1IBUH5gw9D611OoXuzRbFpZI57W4VlvuCjbhzlR1/GuPk1XUJJrm4uZ5VGPIWMfvIljxwSB7d6YGLqLIZp/JKuVmzsc4VMD7w9RUvhud5PFdr9onkMSZD3AGSNw+Xj0qr4cubePVvO1aESWx582M7pJQeAMU3V9YhgVxZxNb3CS5/eJsynYMR1oA9lymn26hI8Wt0670kOXXb047ZrpJVQKknLTSnKgAFozjsOw968l8K6p/ammpLeGeJoDh97ZRsnueuBXrNtLG8UXlzI7EbGkX0P92gCpeP+8aOWMMg2+ZgYdz6j1+tS6Np7WSSwxyhgzlohjBRDzg+pq59kD/K4aSVEON55NWV4WGRWDKTy3TZjqKQEari4jVYnILEeYR93j09676uIU5kKFiqyH93k+ldvQwCiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5LxVbK2rR3MoiCxwr5bsMlW3N19sGutrnPEzRLdxPPjYiAlm+6MkgZpoDmNS0Qa5bxxi7vtPWOcStLE2PNPYD0U+lZQgVLhZLiAXYtHWFpIhl2Ynow7oPetWNNSWK+h0+GSzmhXcp3CQOzHg4PTitTw0JZNOaa8tFs7vcySuOC+OrfQ0xHMzWN3d3yR6jJbxXEB3bYhgkD7pVv5iq99Ar6vfXNlmI27LGqyJtKyFfmKdvrW1rOn2N3fXnmwKt2Y1SzuWBChj1QEdT3zVjVtOms9IRbLUPsccaKk8jfOuP4uT3PSgDz+VvtEt2L64FneaIy3YQN+8uU/226HOTgCq2t3AutRt2uJYrO1kj+1WMdsrGQHryOmTU/iGNL+4uJRPbwo3MUs0A+VYxk/P0YGsjRhf3VxY3qafPA01q62qRt5ke8H7y+5FAGffSX15pmnyNPbPKzyTvKxVpVZOx9vaovD5/tjVbpIZLs3NkFvRdxKVE4bqCg9O1R66kK6rLHZ2Sw28eLieydSp4+8xY+p610GhXcxjkvENtazrB5pji+WMoegDdSMflQB1ugW5ksLEtZx74ndpBGcFXPIynqRXCajBqdtrurR2zzXBMJlMIwETnlSfXFeqWi/ILpVt4byaFZA7PvWQAc/hjvXlHjW+F9rzX8N3CbRoxHNbhjFKqjk8d89KAK9tZ29joi7bd5tHv8AIRSys6SHhnHsDWPr5id4bS0drlRbBPPjbb5e09x6mn38VgunWkNtL5V3cCQpZBigiU8gHNNiP277GhtY0hwoeWMkLM3pj0HrQB6p4L1UXFvaWDo5a3TDNuBbpwSO1bt7skt5Zi5/dKWKuSpQnjn1BrzbQtQTSdYvH4liltwI3hUqisp6EnkkVv8Ai/VbjUbSKDTrpXjlVJJ2ztZlPbHegDkvFOp3tzPpcUdraxvvKmP/AJZhP75B6fWsjWo7PULxI7SeWZtm+W5bO0leg5qpcRXEviG8QxSOY43UBscjHBPoK1rBwdPFp9jIL24ZyrEo8g5Gf8BQBmJJDZfYmvYzNKWE1vChLM577x6egrpYtA1KA3V48EEiTxCaOJPvRMTnhR29a0fD3hTU5jbX2q/u7lgGeSOMKxHZOfb0r0K2tU09mktEjQA7ZAP4M9c5oA5W8uNQbbDcWqnzVX7OySHY745DDsBWcY7y4ELXTxb4pDC3nZRsNxlvUeld7Np8V1FICpHyEROpyVJ/iX3rnNEtUvgTPJNPJYzmKS5nO5/bOOv9KANy1u44LRLLPnXMKLlSuCFBx8x9fStZ7dX06SPcysV2nb1APTBqtpoSdme2iby0PlyM67SzD+IHuKt+YTF5iI5ikOOcYBHc0gPP/EmjSyP5jzB/LZY9xXHlD3rGttBj07w3fywzGXzrkrGr9Sp4yD6Vd1DVd3iDUFt5ftl556sttIdse3oy/h1rP1i5XX/Eiw2JdNPhKi6AzsK/3fpn0pgc7aW8tnL/AGfPbKsJJRZGj+bOMg7vbtT4vCAvJysSXU07RKVlncBVAPOfeuxg0n7VYSTX3mJPbSBoobh/khAPGMe1U7yeDUdOmnhj33EuIVuEyOQehXsPegDEivrXQfEEz3KGW0aLyZraJeZHxwwFekaXcW91p0E9qRBKjhkRl4+Uc4HevI5dSGia/aXtzHK77Nrxj5wqdM+pFdh4Tup9S8TxXd8nm+SS1qsb4DREcgeoHpQB6Za30eoRB7e4UxSDKkjByOoqzbEiN0ZTGSdpydy8+/vSQ4Ozy4tihcBVUAANT4WWQo/luIVcx/KMbsdzSAeGCKfNIOP3YbsD713Nea+IZo9M0O5vXjX92pf942AT2B969KoYIKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArjfHoEVvezl8H7IoG4bgpDkhgPxrsq53xFEJLwKsixytEPvcggE8Y9KaAh01FEEE2eWjXDIeJOO/ela3WW4tpmkmjeF2AAOBJn+9606BVAXgM0Y5K/Lj2q0i7l3NlwvO4j7o9KAKuo6aLqECNxBdE7ldRkAj2osreR7T7Lqi28m8NvVVyjr7j1q7AIkG5XIRh8ufT61IhRQNhAV+h7UgMTUdCsbu0+yNDH5IQxxKVB2AjoK57+yPJbZEJ28iLyk2LtWFeh8o+tdozBtzY+7LtBAplwoRC673dfu7Rnr7UwPLvFHhy3h02GCea4MgX7OCRvZlJzvbHftVG10F4bhrq5twQq/Z2gc7iNo4CDvuHUV3Gq3lxBqHkLG6LOgCXMSZZmzygHpjvRbubETWlyI2igzPC7HJA6kFvamI46eU3Fg+malbS20Fwm2yAkw0Y/wCeZI6dK53xZp9hLf293c2aJF5MfkTbj5jleGAXuB61b8RXyGfTbue4lh02e4MoMMZVVbPVm6kGjW5LO5v49VMX2m4gm8qRonwtupH38H+GgDjDDjWbaW/uIZbRLmR4bhI9zygjAj9sVPF9nSwsrq4I+yJdETQs/wA02DwFx0FQwRTQG+msp4ZJI9xNwpzG0Q5zg9M1oQaZBrGjX1/YhYCdsoSVtpjyPuj1Gec0AKGMM8t8GAnaZp4YpG+UxEYKbOxpW1gf2BqFxYQfZJIZFiRXYMTjngeoqjqZfU49Ntprpl1aKM4nVAhZAcFT/jUGqzCynfTLW2t/scR86URHLqTx8zHr+FAGYplk1LLRsJr2AtHKJM7h3LHtXXeBtJTWtVjutSurhI7RxG8apiOQr0IIrnprBbJGu7rYiTBSrwoSEiPBQ+h969G8DXEdjYwpnDSeYFgd/lTH3fqTQB6DbpHsx5jsJOIwx5z7elVkuCWWWWMyTNJ5YG3Cgf7R71W0Z0uVifcmxRwqtubePvDmp7S9lW6uhM0BtlOYmBw3PY+9AE8waFZWVpfMQEq5Hyj6j0rkIpInaBbSaRILiWWee4B2g49Px4p/iXX1kiOnWF0CsWTPNEhYY/5559TWPpOpaPDZ3RLzIbJcooI2gk8Rt7mgD0aOWGFVjcfI4BTD/fGOAfesnW9Yj0m3PlRK0XlO4cvgqQOF296565la6097uWCOKeNkaOInzJICegYDjBqleTXV3e6fHeLZXLK7SzICUQf7IJ/ix2oAxPCmoX2qeKZtUvYo1a5tSkdqsW3ee5+vvWBYwarqeowX0l7JGst0IGCHlVB6ce1d/d3P9k61Z6fDamzsLi3leK4kkDPEcfd9q4rwzFqGn6oLXSH8gvEbkeeM7yp+bcTxyOlAHr0FmGhZ448SyfKN77yw/wBo1xPiPTJ7PVZ/sjPFsxcdMcd4wB1rW8P+K/tFzi8kjdJYmkhSNNvlbf4D6mti/wBPXUbDfaTJHcXa+ajsSxUd1b0zQB4/4h083X2K8SEW0cjfJk/dfPAc/wB0+ldJpsCwRWF3bL5N5Jx9ljk2hJc87c/wmuhfRprjyDc/ZbTcCJVbnzCo4KZ6fSsKOGaHX7Y3j27+aCsVwckBx2A6CgD0vSbi4uyJ4/vj925VhsHqMetSanq9tosMCzPIRM2yMFflVv8AaauVstSewYukE50/yzJNBCMsXBwGQdwTWd47urS/W3gmN2/2gqj4mAjjPUEjse1AG/4hW28QeF5rW7kdpELMwjJyHHY+or2evPNMij+wx7QChUDYCDggY+Y969DpMEFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVga3Du1WCZQoZYwCT3GTgZ+tb9Y2uJ+/jfcAFAJA5PU9BQBSf5R5hJO3hu/zep+lWop87myMLjIBzVJ1mYzPGqsTgrtfgjvn3q0DEicswH8RVcE/40wJZmZSTtXbyR33f4Vj6teyLOtpZgPcfKWtQCDjH3s+laD3CRSQxSfM0nMTY4JHQGs+0iil+0CW4mZ2m3+YzYP+6p67fagRrxyO6qVUHA/ebj0qJcNEWVsKTn5e3tUcF0FEg8nYy5ygGevTB71KuEiyuFGMu2fut7CgZlXTT2vm3MrFkQlxtx8ox3PYV5H4w8RS6oJVty8NvCSsZiGTLIehf/ZNd34t12O4nu9KiklghCgysYiwLAZxketef2ZaCNL24Lf2mjJcEW53iSEnCqFPAx3piLFpM0kWn2+o6nMbcxtIqpGEj3YxtHsDWfpkrqsVhPdRiWQvPPbxID9rXPBJ9e2K3L64XVNNvHh+zxvp8375Vfe6A8llX+97Vi6fcz6lrMEGon7NvBcqUB82PHyKWH3TnsKAK/iiCIaPdTWlmlv9pWNGhjbAjQn7rr7VDNEdNtHtI7b7V5qCOO6aYJnIzlB3C+td7HYra6LHeeIEguLiNcO6KCZgDwjDpwK891+N5yIIV8ozS7xub/Up6AdloAo6dbRz6dc3V7BJPfSu0AYyZ/dr0I+tQx2TNplxpoSKJJkRvtrDk5OQgFW4bqSGSNILR7O63orzgrJmMH+72yO9XtE0htVm1K5iePYl4JFnMu1HXuFHp9KAGCyuFmS0uoS8KworLvxGEB5cDufWtyTxALi4vLey0pntrfywokj2A84MmfSs3VtYtri5kurlI4tNA8pPKyxkPdSp7HsayNQjvL6/XTGW8klYpIgjn2hIOuMDqBQB0t3rxtnZ7OW2Dxs6hY5AzMx6qPf3q/4bvG1vWIJL4QyMqlmHKFOPu4HUj1Nc2NLW6vpZbWyt0bISMHBdT/E6n1rudFnN07mDNvaWygpcmAKWI6gn+IUAX/EFhcHS4rHTljhtJ23PcBMNF7n1rlNc8NWmjLCZdRdbS4AmEiQbhJKvTzD2Ga72OW4k1G1R+Iyxcxu3RSOGXHb2NcT438Viy1eHSLezeVI5QJmmiJjkjbkn2AoAz7u8uLK++0PaiVbq3I22jjLSD+MepBqa1tbO1gZNQvbibUpCs+6RAXR9vYdCa56w828tjqkitHHDckW8Cg7nhHdB6ZqHWNWM99oYSVGgEhEcYX54l7t9frQBemuZnj1OCHymCyBrWeVNxlcj58N0Bp+hSz3Xm2kunzXTRRl3u1PyOO+O+4elQTOq6nZKJpPs8khjwh+XjksO26r3grUXtfGscVlNLcWFwr7knATcx7otAFHTJ7eRvJGm3Fr9nkeSGdMuGz1GOxxXRT3Opw2sN1p+beJbYDzFO5sA54X+8feuyGj2899JIFa1kEWPucA9zjoWqprWkQP5Eb3TxujrcxuQEDBeoY+9AFCJm1WzZjYyfZ7Qh1hZhukyMn6c1lafqUUt1dw2tsioFV2jc/6luwAPv6U3Ub29t9ck8t7eKyuZBHb2bAs49ZDjrzWJ4pOvaXqRbysQmMmUBSymP6+vf2oAe2sXllC1/qTuuqK5WBQe2cbgvoPSsqeUW+pwXESQXNjcfvH3IRGsue/frVe0jFxaPcmULMDlVnjOAM9z1B711OmaZb25t0F3NGtvuWN0ZSrs47g9AexNAHVQeKPJjiXUrR0lb5ZGt1LBY+zHHava68WhspFntUsZN1tHEI3t5WALt6Bu9e00mCOZ8aeNdM8ISaUuqJcv/aFwsCmBAwiBZVMsmSMRqXQEjJG4cVe1TxPoGk3i2mq65pdldNtxDc3ccbndnb8rEHna2PXB9K4jxr4M17xd4j10/aNPsNLk0v8AsmA3dmboyLJ88skeyZDGdwjX5geYwcY65lp4W8Sano/i6417SI11jU/C1vpse6WJzJcqlyJFDbjgFmibJIHI/unCGenal4h0XS762stT1fTrO9uf9Rb3FykckvOPlViC3PHFY/g7x1pPiRRB9rsLbVzPcxf2b9rR59sM8kW/Zw2CI93TjPU4zXMaZo2t6L4i1ia58NHXINYhsQJftEAW3MUSxvHKJGztDKZAUD5LHjNRaf4M1WDQPDcKWK299b+JbzULmRHj3JDI92FkyD8xKSRDAJOMAjg4APQ7TxJod5eXlpaazpk91ZqWuYYrpGeADgl1ByoHfOKpW/i3SNQ1C0ttG1jQr7zJfKmVNSQyITGzqERQ29iFJ2kr8oY5OMV5vonhDxANK8M6TNoQsH8Pafd28t4J4WS/aSFogse1t2HZhKxkVMFR1610cHhbUILT4XwwWKRrorhr5EZFEP8AockZPB+b94wHy5656c0AdhpHifQNaumttH1zS9QuFjErRWt3HK4Q4wxCknHI59xS6V4m0HWL2W00nW9MvruEEyQWt3HK6AEAkqpJGCQDn1FeW2fgPWIfA3g7TktotNvLLRL2zu5xJGBbSy220MSp+b5+SVz0yal+GGtweIPG+mtpmnw29ppPh9rKV7a8t7qJZGlhKoGgdwBiNyAxDEAnaO4B1nibx7BpXjC18OWraM19JB9pmOo6oLQIpbAVAEdncjc2MAYGc8060+IekLrs2mazfaRpxWzs7qG4bUUMV01x5vyxFgu8Dyxhh94MDgUa3omoXPi7WL2C33W1x4fNjG+9Rum8yQ7cE5HDDk8c9a4ax8La/YWN/ZT+Fpb86j4V0/RxKs9tsgmjimWRZN0gbYC6ElA2dvAOBQB6pqfifRtPuXsptY0mHU8YS1ub1ImZ9u4KQcsMjB6HjnBrK03xvaS6rqNtqLWFpaWOm2moyagL0PbkT+YOHKqNg8vhzjcGHArI0Dwlf6aPFyzQLLNd2Nta21yWTdceXaLGec5A3g9cetcpB4G1qKyxe6LeTbNH0SBPsV5BHPHcWpkZ2jLkoWQlOH+Vs9TQB7LpOq6frNkt5pF/aX9oxIWe1mWVCR1AZSRVyuV+HVprFro92dfiMdzNeSyx+ZHAk7RHG0z+R+7MvByV4Ix3rqqACiiigAooooAKKKKACsXXFjNxEzFwy44TqRk9T6VtVkayzCQYwcqBjHI5PIoAoQxegXdhsnacEfhVhQfJ3r87+WcMoxk+lQCTZNtU5APIzg47nFSI6qEC7gDk4U5GPU0wOc1bVoorEvqMNxbx2+GWUHDBz0UDrms+810W11ply1qztK58zqyQqRgux7VT8VaxcadrAWRY9QNt+8MRAXeG4DOOuBWVZa1qEmt6jb2FrLGjRjzbxzvgbAz5adgM0xHZz6kmlieV703VtcSBY2RcqikcKMetXLnUSLBZIoQ8MqsrgEZQgfrXB2t9JHqaCZVu4jH5loc4Qvn5ty9gtbunahDNPqVpJMiu7i5hZx+7EfQ7T6ZoAz9UntLqxeWWScNMyW06CQJuf+HGOR6GuavIp0vEt5E8nZMUheMqTE69N/ouenrXo2oWCW0089lZ2qzTMpaVyFUkf1Paku9KcSTXKwrJPPgSxIijGP4ie5oA8jvbLXNH1t7hovMvJnaS5miTHm+wA4ya6Tw5oN3b3Mi3EP2e1mAmgjY+Y7SHnluxHpXT2mkadpVnNayTy3Ec84uArOS0bHoM+madd6ja2rNbxyvG05dmZsjbxguM9PagDnPGMFpeQAID59rKpCPMFQknGSB3z2rl7kWEkN7BZi7tbyLEV3LIuUkJPBQ9sVueIodHuILbSbxY4XXFxbO0gDzSY5MhHAx1qTwdbSa5bSSRTwwOJlBjZN6uFH+sDe9AGRbaBaXNmZr+6igvAPsyJZgq8v8AtkntW7YaLHD4ea3nsjbKitLFGG+4qHoe5Lda25LCW2vWjhCCSKIltygrLKT8pJ/pSeJJJtK0kbLY/bpNoyo3B5WGGCk8gUAeX2WqWs07NbMtlbxhnaWa23nB6E9sVqSRtfQRXBhsraaJRM08U2BNngHHZSO1Zr2doLS9mW7unt4cQ3ySKRFG2c4GOSK0rfbdzTecbdbeKZS0RTmO125GMdj+lAGXBGJ9XinhWMxDL+WX2rNHn5vL969X8IwJ/Z4E2SgkLIinOBnIryrQ9OXUPFtqZjG1qs3m2u4kNFF7exNe129n9lV5UkEZDAMWbIYD+VAHMas8fh5ryRpGlmv5cQyFs7c9QvuK4e+ikutTlS4vblpkmQR+SwPmKB8+4dx2xXbeLLpZZVQRxBraRWhu3U4Ep6KB3BFcpF5Q1WR41dYY5C8k6ERpED94knrzQBkMbu9bVH0+LfaJcJCIwCjR56qD/Dn2qhqt2x8Szxwxx281mESAvHljv4O71A9a19SluH0W8vNFlmt7SaXZPLCMqjA/fGepb1qabRYrnVLCC8vIDJcyK4iX7zgDgMf1xQBFquiSWIfTo1e4vMrd24UYUMv39p+natDw9az2d5YNMkaOsxZ3ChniD8jjqM11Gt6FNql3bmyuGiaHIdYWDeUCMAYPTNZNzbww6fZyTl7S+ZvshmVSZHZW+VXPZSO9AHoyyxMpkhdJGz95DnB71jeLNK/tS3iKySzQCQGSKPgcc/NVjw9M9yt3EbcQm2m2xAch1P3mB781seUwYqDuLngrwfxpAeR6hqCxeKC+llorqbHlSTjbHGV6gZ57dK7bUbNda0VLjUbuRrcRCeTyRsVvoOvWqfjHRIbiezldVxEzy+ZsLSK5/un/ABq34Ujvm0GA3qGALkIgwzOueN1MDirrRFOqNdQMbqzmRUeBsK2P7+O+O9ctqOptYeI7g2cMbadIgtp4JRkuB0Ef065r0XWrZ7XVYBf2sP2WUNIskfysHH8APv3rhLzTQmpQXvkvIbt8lCwzAp7j1/CgDT0/WJpTFbzTGOOLbJ/pJ2v5WORFjqfWvp2vkm6uFl1eGea686bTyRFGsR2ynpjP8PFfW1JgFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVieIUBZH3FTGu7cBkgc9q26xtaOLkFmIQxbSQOmSe9AFKEhSAdgXGQe5p07xBWBXAI2+5J9T/Sq8ckYHCBUCiME8sf/wBVUtYFybW5MG1WSJnB+8XZfu4pgcV8Ro7OLxBpjywtDLjf9sRvnRBwcDo3pg1nadrKNK8OmiUyag7QwWlwdtuAv3pCRyGJ5rpvEEJ1fS9Iuljt7ueNVeaCZ8JLk8jI9D2riV3WMk0spsF3Xbos0qsBGAOFTHHfGTTEXmvHivJLYX0CvpzLvtZl+byjw7qfTnvWf4ZitU1F7K9a6vbSEtHbIzARqjtlQ2OSaf4g+yy6zZT26OXjg+ybdu5pZO+/P3kp+jW9xe6u51FYEs2kFtLx5TOy/dcEdMdMUAeou0dwqW8qRPCiAzRF+Y2Xpt9asSzCAqYwNszH5mOGJx/WsrTrq3tY7mGRoGkiYtk8MB3BPrWPrniG3bWVW0Imt4UwyzHZEeM5D92oAoa5dJolhcXJhu5LyEZRZGBwCegx1Ge9cPdPe/avtd7JI5uUElxakmT5f4VA7LnrWxqOrxzQ2gW21CHSUlLvKZd5JPKoh789TVK20+5vbye10jP26SNmeIyeYVDnl2bsMdB2oA53URd+ItSECeW+qvGYZbe3X90iduntXs/g610/RtL06F7iIXUkS27hCSocDoB2OKx/Cnw7OkfY5riQZt5d/mQzEPtxyp455rt72KKy0y9uLaJnfmR9sIdt2OCBSA5+ye4vddvYXJlm08/LIj7RIjf3u24e1Z2sWkjX7NdzGK1t1zDLJlhKp6sWH3SD2roPCkNvHo8U8Epnm2vOzRnduJ6hvcdK5PULoXM01zbXapax5Y2kkm4TseDGU7fWmBh61J9qkg02W4jcTI08FywMfmMp6MF4K+hNWrTQI7qIXNwY4GmCp5EdxtjcD178+9XdIMeoRW9vbmeyEMvmJbiLm2tx1QP3BNaOmafbFL3VrqF980+2MhshdnQ4FAE3hnR7Q3atDYRwR26YCkktuz0z3Fds6JsEYRG+Qnbng++Ky7GAC1nmRSrEhvvZP/1qsPbSfb4bgyKkcKbc5yXB5IpAcx4tgkglMVqzbSyyuhGVc9FA/GsTUIIn8QS2FxG2Xt1kukZdkXm4/vdMD0r0PUrE3dr5dqyQ3Ay8bMOB/hXCXduk9rLGkkt9FBdb5ftCnbIzcFEPdfrTAwTEl1Mskd8sqIhlW3KgR/JxjaOCM1qaJp8t1rr30kMUNpaRrL9pABLyMMEIPasrK26R2NjYxTXb3TRNalduyAck8dAP1rUs1s9P8QJJBO0FnMQ4tZG2O59cHooPNAHc2zJbMZyIld+TJ2bjoff2qtJaWdyiJ5cc/nvuLLJnBHPFMj1CGK++WUtJdN+6DD903Yk/4irMWnot9PNbRLbgwmNc9Sc/kPagDKEVza31vdW5IkUmNYySwCZ5GO7V07M/mOkUO6QfOctg89j6VFaxLb2sEZd3kgU4bgHd/jVlHCCMqh+Y9Dz253UgIpEhmQo6hW9Aecd8VFJBJsbBBGRtw2Dsz0NWQiSJnYwCHqepX2IqG5WKCNoZRhHBcDnj3JoA4j4jaZNd2MN1aTq509yRFvwrNnpjvXLpCk3zTwq8xOViUgnPdlP8P0rvPGEW7Q5Zo2VLTBkmkC7TgD+Z6V5VoMt1bWI+xXK20zvny5B93uNzd+KYHXat4astY0hJQZYZkTcwjbCy+7H1FfQVeI+DtZu7jTHXWEYMrlvMijG1vQg98+le3UmAUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWNrO17tI2P8GRjvyevtWzWHrR3XqoeU8sMw6EDJ70AZ0ZQRllk3qR5YDcgfSsW81G0hjaW9cQlUdg6scZxjBHc+1WPEFot/pTW7StaRs6osqZDAH6fzrir2W5srxY5ZLa3tIpkwkjhnlVRyG9PX3qhGn4Qv4tT0q1ktbZkUsVKKnlncDywzwOOaxNS0m1XU9Ygjie4t/IUSafLNsRNzf63d0znnArK8K6u1zreqXlu0rWkt60aRMCY1OPvKo5IrrNXjiIia8mN01nGJPsaKN8xH8R+nYUAcYkcuqagmxbmG5uI0hMkwwIihwHU98it3WLW2PnaPGEgRD/pOzLylcf61D0XJrA1fU7m6vzHAIp5lZHMshwSG4Me0dwPSun8I6HavLZX7wS213KJVNo77lljHGBn7oJ7GgDOuLd7zQYbVFkuFkmUzsjYlVF4DA9/euX17UrnStWvrD93qkjxeXFEWwhjA6sO2PXrW94kvp7vxPBpvh2V1WNCXuYDtRT3QL0I7Vd8I+D1kBurqHzWUnFxOu0hifmG09cUAcfoug6t4gt7BJbmV7ZU862ihfaq44C57V61plkugGWVooRql1GMujAyMRgbfcCmyalaaVcS6ZFHGzD5cqwEcXHy7mHTdTNYur5prKw2KdbCh98EAeOCNuO/P40Ab13q66Rp0lxrDGK7kO2GFmB83H93FR6frgv9TubGVFtZmiDyKX+ZQw6qD1rlraw3PbW+pSTXV8kcqRzNGfu54XHr7ior/wAGXeq69/aL3otrwFYl2c+XEB81AHXnZ4e8MGB50M53JFKFCK5PTgdxXl1veR6lf3gtYDfWVxcpaNIyFQpA+8hHPJqTxnq+oaXfTWYmkl0lgohiEe/GON4b+HJ4Oa77wx4cFrbWl5dPFDcRqXt4rdcJEGHO8fxGgCDRNFvrTTrfT3uNsW4+YYuoGeIx3I963xYwW1okEMUUayEhUXkbuuarahrEOniSeaC4Mca/623TcxHqBVuO6tLoRyA+W6J5gEnBAI+9/jSAniiEMCltwQ5DNnPXrmiOHOxDIWt9pG0gHJ9c1DHJDbmJonYwEEsMHYSe+Pes291Y2d8kDRsYZgXEqIWEZzwuPWgDVhCNGQokMaZwc4xjt9K53Vnt7W/hbUbmVHOWt0iXajDupHQ4610yyK6pjnoCHGDk+tcX8RPENlpFxbWjLJNdtGzRRCMEZPH3j92gDm47S2/4TORpiwaazJyybVJH3Wz3NaLXSRSWcd/DaapcSHy7m4HQLjguex7YrkodUu76PbM8lzpyOlw0kX+tjYHBVs/w1Y002mp22oWOlFrW0kmDrOzHdKT95iPTsBTA6TSmMOo3yiOZYYZkS1GzefLP3hGfT1rsDd3EtzBDDaO+SQSTwgHQ5/pXEaWfISaJRfQShFA/eKGRQeNqe/eup0qTVLm3+0lFiSRzGoYcrgffPsaAOhiBU8rjByQBnafU1Z+aRy2drsDsUd/XNV4UYCNiQZCAJHU4DGnIX3STMp2lgqqRhgR3PtSAe67gjFyACG2Lx+FM2l/N3oBGR0zuD/4U9w2N67XjfGxjwWPcEU7BDkOdy4OGHQH0NAGZqEcb2M0M2CgXOwDuemR0NeV674fuXZbeTyI9TSUJCg/5bRHkkgdx0zXsAEcUjmUEiQcHsW+tVLyzgJEwXdcofvv95VPYGmBgWX2Wy00rNDHGE/5YxtwpAxkHt+NeuV4n4yF2LjS7XSodttcylJ42Ujd6ZP1r2ykwCiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5TxTfCz1NVdhIkkKr5Kj5l+Y5fPpjjmurryT4uX7xeIoLOPzgJbRGYqfl4kbAPsT1poDdF+BqAidYtjodh3dhyDt715T4wt2l8SNcwK62lwzSXUbDAmIHG0/4Vv8Ahe51G/t7ryfLuH0tmSMyJkyuRkordhisDXr+3v7vTbrT4XuryQCPy4ZcRWUmcFQnfHc0xGl4OmAsbe5hmQTGGUPAw/eqyn7wx7dRTbrxMs13aStFP/ak9s6+dbRjZt6AvnoM1zUFpd6bdXI05JftlhM0spD7W8xxjcc8Yx2rS0/T9VS5htoGd9Qnt83UaJ+7gRj6nuetAEaWsmi29lcTIs9xJI0cmx9/lPjOQfU9qj03VbzUrjabe9uoZZd8kQkCvDjjaD65rqo/Bs9ldvHBDJqlwyb4TqD7owR0wo7571oaXpel+Fora+1W583U7l2IFuMlpm6qq/3RQBXk05NItJY4mlhurrYm24iyltGOSAR0PvUekX1tf6ZqUGkRy3FrDCsat52DvY4f5jzge1P1DV7mS5M0tm0l9HbOJbWJt0ZJPyjHQtimaGtwYZdReAAxQQ7rePaNm4/MSOhPbFAEETnQ7KWxgs4RcQzx/O8e7z1PcZ6geprpNctoY47mS0WGG6YKsd6u6STJHzKU/u+lcdJLJq9+01gWur+ZZGht2fI+9g+Yf4VArqJ9WvFj0Wea3SxhidobpkKsCAMBgf7p96AOjsNNlggS9gaR7liGdAwXIxwBn86r+H9DvYQ9/rFy4vriUmRIwNm0ngH8KzP+EuttJ1N01SZHgO028SLukYnoygdjXaidX2jkBwCvTFIDiJ7R7bS72zW5jnh8wwqsqAbstkqPWun0O6gm0tWthhUPkvHxmNhwQawtfkin+1S28he0B/fMkW5oZVPDc/lxVXwrrijV9chka3jWN41WBIiMlhyxPdj3NAHZExtb/vTH9nYFZOcAj3qqE+zYhhSIwrEShC7gB9f6VZnCBAjRh1IwwTBBHrXOXt5HowjjllJjmbKLHwOOgGfX0oA6FpIniVmQoAmVOOPpWHqGqWcFvJdyDAQhZFC/NG398+gxXnOqatea4bmO8vL62tZAV+yQnYYgpyCfrWdDd3t5ZStcJLNaQhYbiaH94cfwtt78daYHqgvYbq5ivbe5hlgbBgYPgyJ/E3PTmvLvEVzfalrd5qurZsdJtbgRxQyjc2R1Ix69c02OMafK8Nm4uRCyJLJfsVEgI+UJ7VY1iFodPsrKxuZ/7Tkl2tHcDdAwY5b5j2A6UANuLS6la8NlFF9o1ErPHdJJmIKvQD09wazItQtLSTT9Pl02eOOISzfabWcNt4yWYdMZ6CjUJnGtXBt713tokNusbJ5MQI+8AB1HvWRqE27VIbKyaVbElEkjkXy5iH/hQDqM+vagDu/Dlu+oa8l64eZ5okWa8lTH7sjgR+px1r0Z2eER+R5W9WARXY/6sdSffFVNEsY9PsbKCUI8ka7UOeF46DsDV8lzIIi2JwCwYrxtHXPvQBY3EsyBgVJwBnselSNIwjaV2VCcDAOcAcVHCTuPkkO5wwLA81IkETkKxIQMWMbDv/hSARyEhDbCxXrjg49hUSu832mPDxquHGABjPY/Wpwyh5I2VlOQuVOTz39qXylCbSG5zkjgnHTJ70AIrMWderjAxjGawvFF5f2EAOlCE3MsgjCyKWOO5A/rUc+oPD4hazkd1LQgI8j/ALtz3wezYqvoNqXuJXsLiWS12/uruV9z7u+Af4aYG1pSTiAC+uWupSm8naAFPcL7V3dcNbYQRrG/nhh/rM4IHcn8e1dzSYIKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxL4x6Rdaz8QNMto2T7G2n/AL9ZWZFYb343DjPTAr22vP8Axxaw3niRVuxJcQxWay/ZvU73wy/7X9KaA8guzLpp09reW6IdgimGQJCSOOcdeOCadpVpql9G1vawpHC5aR1iQBzLu4Xf1wRXeS+CtNuZ7ae8a68iLBt4InwsQzkgjp1611sNnFGCYBFBLKQTtGTx0+tMRjL4atdU2rqMrmOZR5tumFO/HGSPvEVo6dayaHAIdPjfUJCczSXBAdY+3PfHpWwiJI6EeW2xsNzzG3+JpuqJetBcC2eMIUK7SvzjPXBpAcfFcajNr4m1Sa3sVuUKWlqqnexX1b0PU1mzarC+oxNcCNdRkjeC3lH+rLD73I4Rj2z1rd0zRdPksXhtGv4txJV5GLPHj721jyM1hS6RZW+s3H2qWO4gVPMeNG/cs3RRJ/dbHemBFf3MkOuWS29nNbrPb+VGYGEjO45JIHQe9beieH7jWRHf6u72unlWT+y9uADn77Hrz6VbsbyxhaDUAlu0LsqRuqbniUjGNw4610EkEsdxcTZ+0SzKqmHds+X0HoaVwOJ1edfD9150t7YxRRXG64jaArmAjARSBzjrWVN9ma2mnv5LW+eeZZpYIDl1tc/IcDgH1zR4tv8AU9O1me9lt7e7sraD7PMbjEe+Jm6/RfXuabPbpBc4s73Tr7TZP3jRlPLmdcfLGGHVQeaYEGqW1jb6kPEt0jxg77MhEZtykYBx2IB69KvfDi4vPD1smj6rbvHYszz294z71dW+7z6+1UmvX1iG9nkupiI4/IgtVT5LoAfOin/PSm3t8x0LTXWzuHtrcYEUb8LnjaoHUg9aAM7xTrE9tb6gz+ddBnzLIFKxuScLtA7jvVnRFt762iuLeRkurKRY9Q8rKueMjAPUe9dFbW0Nx4msoYtrNa2pNw5DBFU8qBngnP61o6jbjSGmMEKM8i7ry72BXRRyHx0YetADtC1RLO8bSJQ4UKZ0mj+cYPY56H2rnfG5ubm6lurYTxXVk63EdvNgxzBOwI6E9aNSv7aSz1GZ0nR0SOWK8hfYLlD1YD0FX9T8rUWtruwh8y5ltPLERjxKjY+VznjBoA4fTHvrm7uPs+z+z72UXMk88W8xHui89qv3kg2TJoO37Q9pKHVDxJtOCB74rIu7aS9nuLCyhNn9mR47iOaMrG8ndlfPBFTacI4LWAXV9DJePkhypQpxjCsOCPWgC3eG9g0vTJ41ie3+xsUuL2MElsfd5/izxWS7zT2UcupxCadYEFuhbfHOc5Y4HQgcV0eqyvNe2VsvkyxRBRPMqmURgjkc8c+vaqOo6LFDZLPAnlfZZPKtCz4dtzc7cdc0AYsstzIn2Q2NtdPHKJ5OqIY2/wCWZPUEVr+HdKMviuSWZ2huLXy3uYC/mkp0TafarEtokpuZrWeO30xV+zys4zKrjqxA688V1Xh+0u7Hw+IiA+pgFy7AeZIvbj0AoA6CJobhJFhUMpbbhTweepqSRg7NGS+/dwg4YkcZH+zVZGkfzIxEjRkZZB8oQgf/AK6dAJ/PLC33oECrMhA3kn7p9hSAvrvQMFc7w3BBwDxxUiRLIsYlMomU7mVWxk/XuKhjbP2hctGVOFYDO38O9RIZWkdl83zkHlMRjD99w9KANEtDGJJUc5A8tgF/zmoYHEReOfzFAfgE7s56c1k6tbPfmFEnkgMMgclc4P8Asmrsl0iTyQPLELhgTFETg47keooAoW+myyvJ/aamaaeZpGCcRhB93Hvj0rTEQs7NViThExGi8cf0p0kjC0U2swZEIUrjkt3+lSSCQhxFFtOQdpboKAK8EjyNEzoIZfvTDII6dM+td1XGHy5XjMgVnPz4z1x3rs6GMKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXM+IIov7ZWbGJjCqbl+8VDMcfTrXTUUAcdE6CGSRSPLVsOMcY78VYt0RwHUo42nym9vT2rqaKdwOXWdLFzJNEwMmN3lpnzG6fp61LPJKsyREBlxkuxwMf3fc10dFIDyjxNNLe39vpMWoXlm4Zrtmg4eT+7GG6FfWsi/u5LDQ7lIrC2t7icAz20cnmtIgPzsD3IHPtXt1FO4Hhuo+JPs9/pkekuz2F5APspiTCqV7uuOe+QK7PwnrcGpW5sr2ZjqKgyGLYVYJnAau/oouBxlzoZ1PS7q01QxTk5EMzD5uuV3juAe1cHrNu+hXGmHXLdb+e2YBX8sJBIXOGfI6EDsa9voouB4rDHM3iYNpQuJo4HaVlkTy4nRuAYj03e1XNaeDR0OrMrQ+XH5FpGn8TP1XA/iz1NevUUXEeRfCzyit5bw3BuEVAZPMJfEpOWXce4rtL+zM19Zn7PFNC4ZZWc9FxwMehNdTRRcZ88QWl6mtalYRvdWVrHI0cdzLt2q7HiJP9jHQV1fhS3nTWriK4Y3HlxeTK56IyH5Tnua9coouKx5H4g8Krd2GpR3d3OI7nIjiQ/K2edx9DUOh+EbXT3hCwsJkh2QzuoeIf3mC+/rXsVFFwseV6za3ltEZIYYJYkgZJY0TDuSOo9q5TSre/JhEdtbmzlhCiRGx5LD+Lnv8ASvf6KLgeK2OnomvSTGBoVNuoa3Dj5z/E5Pf1rZZs4f7NKJFYRpLjLEd2/wB2vUaKLhY82QqHZAACv3JSMmQfT0pmmXPm2xaN5DbvvO2T5RnoAPTmvTKKLgefMjuUNzgcAuVJyG7EHvVEyyxSgWUsZgZiZi+d0fbA9zXp9FFwseeNKDIoiYSFBglvlYccZ9arwMLzVATCjSLEB833427r7V6XRRcLHA2xj85JA2UJIBwfnbuCPb1qaaOSaJAJ3tz5m5igzkDopruKKLhY5JhuQkxqD228fgPautoopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marinkovich MP. Inherited epidermolysis bullosa. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright &copy; 2012 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15642=[""].join("\n");
var outline_f15_17_15642=null;
var title_f15_17_15643="Drug and toxin associated odors";
var content_f15_17_15643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-associated odors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Odor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetone (fruity)",
"       </td>",
"       <td>",
"        Ethanol, isopropyl alcohol, chloroform, salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bitter almonds",
"       </td>",
"       <td>",
"        Cyanide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Garlic",
"       </td>",
"       <td>",
"        Arsenic, organophosphates, phosphorus, thallium, selenium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mothballs",
"       </td>",
"       <td>",
"        Naphthalene, paradichlorobenzene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kerosene (petroleum distillate)",
"       </td>",
"       <td>",
"        Organophosphates, parathion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Freshly mown hay",
"       </td>",
"       <td>",
"        Phosgene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotten eggs",
"       </td>",
"       <td>",
"        Hydrogen sulfide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wintergreen",
"       </td>",
"       <td>",
"        Methyl salicylate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15643=[""].join("\n");
var outline_f15_17_15643=null;
var title_f15_17_15644="Changes in pregnancy and heart transplant concerns";
var content_f15_17_15644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal physiologic changes during pregnancy and associated concerns in the heart transplant recipient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physiologic changes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated concern in the pregnant heart transplant recipient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased blood volume",
"       </td>",
"       <td>",
"        Hemodilution may affect serum drug levels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased heart rate",
"       </td>",
"       <td>",
"        Exacerbation is possible due to cyclosporine. The denervated heart does not respond to the autonomatic nervous system.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased cardiac output",
"       </td>",
"       <td>",
"        In a denervated heart, the cardiac output increases result primarily from volume changes and circulating catecholamines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased stroke volume",
"       </td>",
"       <td>",
"        Rejection may create systolic/diastolic dysfunction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricular enlargement/tricuspid regurgitation",
"       </td>",
"       <td>",
"        In patients requiring serial endomyocardial biopsies there is the potential for worsened tricuspid regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium retention",
"       </td>",
"       <td>",
"        Increased edema; exacerbation of edema by prednisone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased T-lymphocytes and T-helper cells",
"       </td>",
"       <td>",
"        Increased risk of infection; decreased risk of rejection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased glucose tolerance",
"       </td>",
"       <td>",
"        Increased risk of diabetogenesis for patients on prednisone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased gastrointestinal motility and tone",
"       </td>",
"       <td>",
"        Exacerbation of gastrointestinal symptoms with use of immunosuppressants. Exacerbation of reflux due to ulcerogenic effects of chronic steroids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased risk of urinary tract infections",
"       </td>",
"       <td>",
"        Risk increased secondary to immunosuppressive drugs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperemic/edematous gums",
"       </td>",
"       <td>",
"        Worsened with immunosuppressive agents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased risk of cholelithiasis",
"       </td>",
"       <td>",
"        Exacerbated with use of azathioprine.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15644=[""].join("\n");
var outline_f15_17_15644=null;
var title_f15_17_15645="Surgical treatment VAIN";
var content_f15_17_15645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surgical treatment of vaginal intraepithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients treated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurred after first treatment, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Surgical technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow- up range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gallup",
"       </td>",
"       <td>",
"        1975&nbsp;",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        LE, PV, TV&nbsp; PV, TV",
"       </td>",
"       <td>",
"        1-12 yrs&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lee",
"       </td>",
"       <td>",
"        1976",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        LE, PV, TV",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oliver",
"       </td>",
"       <td>",
"        1979",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        LE, PV, TV",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hernandez-Linares",
"       </td>",
"       <td>",
"        1980",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        LE, PV, TV",
"       </td>",
"       <td>",
"        &gt;5 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choo",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        LE, PV, TV",
"       </td>",
"       <td>",
"        8 mo-18 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Woodman",
"       </td>",
"       <td>",
"        1984",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        LE",
"       </td>",
"       <td>",
"        7 mo-6 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benedet",
"       </td>",
"       <td>",
"        1984",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        LE, PV, TV",
"       </td>",
"       <td>",
"        &gt;5 yrs&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lenehan",
"       </td>",
"       <td>",
"        1986",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        LE, PV, TV",
"       </td>",
"       <td>",
"        5-112 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ireland",
"       </td>",
"       <td>",
"        1988",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        PV, TV",
"       </td>",
"       <td>",
"        3 mo-11 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Curtis",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        PC",
"       </td>",
"       <td>",
"        9-99 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hoffman",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        PV",
"       </td>",
"       <td>",
"        6-73 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Julian",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        PLV",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Sillman",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1997",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        43",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        21",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        BX, LE, PV, TV",
"       </td>",
"       <td>",
"        &gt; 5 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        CS &gt;5 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cheng",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        LE",
"       </td>",
"       <td>",
"        1-124 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dodge",
"       </td>",
"       <td>",
"        2001",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        PV",
"       </td>",
"       <td>",
"        &gt;7 mo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LE: local excision; PV: partial vaginectomy; TV: total vaginectomy; PC: partial colpectomy; PLV: partial laser vaginectomy; BX: excisional biopsy; CS: chemosurgery (with 5-FU pretreatment).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15645=[""].join("\n");
var outline_f15_17_15645=null;
var title_f15_17_15646="Interventional Rx LBP";
var content_f15_17_15646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interventional therapies for low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Net benefit*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Graded recommendation&sect;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemonucleolysis",
"       </td>",
"       <td>",
"        Sciatica or prolapsed lumbar disc with radiculopathy",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        Chemonucleolysis with chymopapain superior to placebo injection, but inferior to surgery; not widely available US.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural steroid injection",
"       </td>",
"       <td>",
"        Sciatica or prolapsed lumbar disc with radiculopathy",
"       </td>",
"       <td>",
"        Moderate (short-term only)",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        Some higher-quality trials found no benefits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intradiscal corticosteroid injection",
"       </td>",
"       <td>",
"        Sciatica or prolapsed lumbar disc with radiculopathy",
"       </td>",
"       <td>",
"        No effect (versus chemonucleolysis)",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local injections",
"       </td>",
"       <td>",
"        Sciatica or prolapsed lumbar disc with radiculopathy",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiofrequency denervation",
"       </td>",
"       <td>",
"        Sciatica or prolapsed lumbar disc with radiculopathy",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facet joint (intra-articular) injection",
"       </td>",
"       <td>",
"        Presumed facet joint pain",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medial branch block (therapeutic)",
"       </td>",
"       <td>",
"        Presumed facet joint pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiofrequency denervation",
"       </td>",
"       <td>",
"        Presumed facet joint pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intradiscal corticosteroid injection",
"       </td>",
"       <td>",
"        Presumed discogenic low back pain",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intradiscal electrothermal therapy",
"       </td>",
"       <td>",
"        Presumed discogenic low back pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intradiscal anti-TNF injections",
"       </td>",
"       <td>",
"        Presumed discogenic&nbsp;low back pain",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intradiscal methylene blue injection",
"       </td>",
"       <td>",
"        Presumed discogenic low back pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous intradiscal radiofrequency thermocoagulation",
"       </td>",
"       <td>",
"        Presumed discogniec low back pain",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiofrequency denervation",
"       </td>",
"       <td>",
"        Presumed discogniec low back pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural steroid injection",
"       </td>",
"       <td>",
"        Spinal stenosis",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural steroid injection",
"       </td>",
"       <td>",
"        Non-specific low back pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Botulinum toxin injection",
"       </td>",
"       <td>",
"        Non-specific low back pain",
"       </td>",
"       <td>",
"        Moderate (short-term only)",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local injections",
"       </td>",
"       <td>",
"        Non-specific low back pain",
"       </td>",
"       <td>",
"        Unable to determine",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Interventions varied substantially between trials.",
"        </p>",
"        <p>",
"         No higher-quality trials, all trials had small sample sizes.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolotherapy",
"       </td>",
"       <td>",
"        Non-specific low back pain",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5-10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1-2 points on the Roland Morris Disability Questionnaire (RDQ), 10-20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2-0.5. Moderate benefit defined as 10-20 points on a VAS for pain, 2-5 points on the RDQ, 10-20 points on the ODI, or a SMD of 0.5-0.8. Large benefit defined as &gt;20 points on a 100 point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.",
"     <br>",
"      &sect; Grading:",
"      <br>",
"       <strong>",
"        1A",
"       </strong>",
"       - Strong recommendation. High quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.",
"       <br>",
"        <strong>",
"         1B",
"        </strong>",
"        - Strong recommendation. Moderate quality evidence. Strong recommendation, likely to apply to most patients.",
"        <br>",
"         <strong>",
"          1C",
"         </strong>",
"         - Strong recommendation. Low quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.",
"         <br>",
"          <strong>",
"           2A",
"          </strong>",
"          - Weak recommendation. High quality evidence. Weak recommendation, best action may differ depending on circumstances or patients or societal values.",
"          <br>",
"           <strong>",
"            2B",
"           </strong>",
"           - Weak recommendation. Moderate quality evidence. Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.",
"           <br>",
"            <strong>",
"             2C",
"            </strong>",
"            - Weak recommendation. Low quality evidence. Very weak recommendation; other alternatives may be equally reasonable.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15646=[""].join("\n");
var outline_f15_17_15646=null;
var title_f15_17_15647="Gram stain abscess 1A answer";
var content_f15_17_15647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptococcus pyogenes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of an aspirate from a neck abscess (x1000) shows Gram positive cocci in long chains. Streptococcus pyogenes (group A streptococcus) grew from this specimen on blood agar and tested negative by catalase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_17_15647=[""].join("\n");
var outline_f15_17_15647=null;
